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ABSTRACT 
Stem cell homing and migration is regulated through chemokine SDF-1 and its receptor 
CXCR4. In vitro studies in mice have demonstrated endogenous mobilisation of 
mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs) by administering 
growth factors and AMD3100, which is an antagonist of CXCR4. The hypothesis of my 
study was that antagonism of the CXCR4-SDF1 axis would mobilise stem and progenitor 
cells into the circulation, and by increasing the available pool of cells in early fracture 
healing, improve bone formation.  
Peripheral blood MSCs and EPCs were isolated from rats treated with VEGF and AMD3100. 
Non-mobilised controls did not yield any viable MSC CFUs, whereas mobilised were 
significantly higher at 2.9±1.8 CFUs/ml blood (p=0.029). The MSCs were CD29 and CD90 
positive and CD34 negative, however unlike bone marrow MSCs, they had a mixed CD45 
expression. These cells were only able to differentiate down osteogenic lines in vitro. 
Mobilised EPCs had the typical ‘cobblestone’ morphology, were CD45 and CD34 negative, 
with low to variable expression of endothelial markers CD31 and VEGFR2, and MSC 
marker CD29. These cells had variable in vitro tube forming ability and could differentiate 
down adipogenic and not osteogenic lines.  
In order to evaluate the potential of endogenous mobilisation on fracture healing, a rat 
femoral osteotomy model stabilised with an external skeletal fixator was used. Several 
modifications were made to improve the reliability of the model and are reported in my 
thesis. The influence of gap size on interfragmentary strain and subsequent healing using this 
system was evaluated to identify the optimised situation to measure the effect of endogenous 
mobilisation. Mechanical analysis of the construct stiffness and the interfragmentary strain 
showed the gap size did not have an influence on the construct stiffness. However, increased 
gap size significantly reduced day 0 interfragmentary strain (p=0.013), with 1.0mm gap 
having significantly higher interfragmentary strain than the 2.0mm gap (p=0.029).  
To evaluate the effect of interfragmentary strain on healing, a femoral osteotomy in 12-14 
week old female Wistar rats was stabilised with an osteotomy gap of 1.0mm, 1.5mm and 
2.0mm. After five weeks, the 1.0mm gap had the largest callus (0.069um3) and bone volume 
per microCT slice (0.035um3). As the gap size increased, the bone volume per slice 
decreased, however significance was not found (p=0.082). Histomorphometry also showed 
the bone formation deceased as the gap increased. There was an increase in cartilage 
formation associated with the decrease in bone in the 1.5mm gap, whereas the 2.0mm gap 
had an increase in fibrous tissue associated with a decrease in cartilage and bone, indicating 
	 4	
that the 2.0mm gap was tending towards fibrous non-union. The 1.5mm gap provided a 
suitable compromise to test endogenous mobilisation, and although the interfragmentary gap 
strain reduced as the gap enlarged, there was a reduction in osteotomy healing as the gap size 
increased.  
VEGF (V), IGF-1 (I) or GCSF (G) combined with AMD3100, or AMD3100 alone (A) were 
subsequently investigated using the rodent fracture model with a 1.5mm gap. At 5 weeks, 
groups V, I and A had increased bone formation compared to control animals, however, 
group A had a significant increase in bone volume (p=0.01) and group I a significant 
increase in % bone within the callus (p=0.035). Group G on the other hand, showed a 
decrease in bone volume. Irrespective of whether there was an increased or decreased bone 
content, all treated groups had an increase in trabecular thickness, or more accurately, thicker 
segments of woven bone, compared with the controls. Histomorphometric analysis showed 
decreased cartilage tissue was associated with increased bone in groups with improved 
healing, and was associated with increased fibrous tissue in poorly performing groups.  
Overall therefore, AMD3100 given alone significantly increased fracture healing over and 
above the control level. In conclusion, disruption of SDF1-CXCR4 axis can mobilise stem 
and progenitor cells, and can boost impaired fracture healing in a rat femoral osteotomy 
model.  
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IMPACT STATEMENT 
Clinical translation 
Around 10% of fractures seen by the NHS do not successfully heal, with a significant 
economic cost to the NHS and social cost to the individual. Fracture healing can be enhanced 
by administration of stem cells, however, typically they require processing or expanding in a 
laboratory prior to re-implantation. The question I asked in my thesis was whether it would 
be possible to mobilise stem cells endogenously within the body to enhance fracture healing? 
If successful, this methodology avoids the potential problems associated with cell isolation, 
culture and re-delivery to the patient. My study identified that endogenous mobilisation of 
stem and progenitor cells into the circulating blood steam can boost bone formation in a 
compromised healing scenario, akin to a non- or delayed-union. This is the first time this has 
been demonstrated and offers a non-invasive means to improve fracture healing. Notably, the 
most effective mobilising agent, AMD3100, is already licensed for another clinical purpose. 
Through presentation at international research meetings and proposed publications in high 
impact journals, this work will be disseminated internationally. The next step will be to 
develop a clinical trial, which if successful could have a positive economic impact on the 
NHS, as it would reduce the financial burden associated with revision fracture surgery.  
Endogenous mobilisation is a low cost, low risk means to boost healing and could potentially 
be given as a prophylaxis to patients with fractures at risk of delayed healing or non-union. 
These patients may include those with fragility fractures, comminuted tibial fractures, or 
when treating established non-unions. This approach could have promise for other conditions 
that may benefit from stem cell treatment, such as liver cirrhosis patients, musculoskeletal 
disease including osteoarthritis, myocardial infarction, and neurological 
degeneration/damage. Veterinary clinical patients, who can also have problems of fracture 
union, may also benefit from this approach, as well as being informative as a ‘one medicine’ 
model.  
Development of a robust research model & understanding of fundamental bone biology 
Rodents are becoming the preferred model for the understanding of fracture healing and 
evaluation of regenerative strategies. I re-developed a highly adaptable and reliable femoral 
fixator model, which would be of interest to other researchers. Further, its biomechanics 
have been evaluated, and over a defined range day 0 interfragmentary strain theory does not 
accurately predict the course of healing. This should be considered by researchers working in 
the field of fracture mechanobiology and for groups using a critical size defect model in their 
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research. This work will be disseminated through international conference meetings and 
publications in international peer reviewed journals.  
A non-invasive stem/progenitor cell isolation technique 
My thesis also expanded on fundamental and applied stem cell biology, specifically aspects 
of stem and progenitor cell mobilisation. If optimised, this approach could have both 
national and international impact for researchers, as a simple and cost effective means to 
isolate adult stem cells that avoids the morbidity associated with bone marrow aspirate or 
adipose tissue extraction. 
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a scattering of CD45-CD34+ cells and CD45+CD34+ cells. 
105 
3.11 Flow cytometry histogram fluorescence counts for VEGF-AMD PBMSC CD29 
and CD90 expression. a) Red plot shows cells stained with FITC conjugated 
isotype control. Green plot shows cells stained with FITC conjugated CD29 
antibody. b) Red plot shows cells stained with APC conjugated isotype control. 
Green plot shows cells stained with APC conjugated CD90 antibody. In both plots, 
the right shift in fluorescence indicates positive expression of CD29 and CD90 
markers on the PBMSCs. 
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3.12 Flow cytometry histogram fluorescence counts for VEGF-AMD PBMSC VEGFR2 
and CD31 expression. a) Red plot shows cells stained with FITC conjugated 
isotype control. Green plot shows cells stained with FITC conjugated VEGFR2 
antibody. b) Red plot shows cells stained with FITC conjugated isotype control. 
Green plot shows cells stained with FITC conjugated CD31 antibody. In both plots 
there is no right shift in fluorescence, indicating no expression of VEGFR2 or 
CD31 in PBMSCs. 
106 
3.13 a) Light microscopy images of osteogenic differentiation (x10 magnification), after 
21 days of osteogenic supplementation of VEGF-AMD PBMSCs (n=5). Wells 
were stained with Alizarin red and there were no stained mineral deposits in the 
control wells and significant staining in the supplemented group. b) Light 
microscopy images of adipogenic differentiation (x40 magnification above the 
horizontal dividing line, x10 below), post staining with Oil Red O of VEGF-AMD 
PBMSCs (n=5). There were no visible stained lipid droplets in the control group, 
and only 1/5 showed any signs of adipogenesis, which was less evident than seen 
with the bone marrow MSCs from chapter 2. The panels from top to bottom 
represent cultures from different individual rats. 
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3.14 a) Boxplot showing the number of MNC x10^6 per ml of blood taken after red 
blood cell lysis protocol (* p=0.035). b) Boxplot showing a significant (** 
p=0.036) increase in EPC CFUs per ml of blood in the VEGF-AMD group. 
108 
3.15 Light microscopy images showing P0 VEGF-AMD PBEPC CFUs on fibronectin 
coated flasks in the presence of endothelial media, at x4 magnification. a) An early 
outgrowth style colony showing mostly spindle shaped cells at day 7. b) Late 
outgrowth style colony showing cobblestone shaped cells at day 15. 
109 
3.16 Light microscopy images showing P0 VEGF-AMD PBEPC CFUs at day 18, with 
classical cobblestone cells and some elongated cobblestone cells. a) At x4 
magnification. b) At x10 magnification. 
110 
3.17 Light microscopy images taken at x10 magnification. a) P3 VEGF-AMD PBEPCs 
at day 30. b) HUVECs P5 at day 7. These two cultures had a similar cell 
morphology and were unlike the fibroblastic MSCs. 
110 
3.18 Light microscopy images of VEGF-AMD PBEPCs in culture. a) Dense P3 PBEPC 
colonies with cobblestone appearance, with some elongated EPCs between, shown 
at x4 magnification. b) P2 cells at day 19, at x10 magnification, displaying a 
swirling pattern. These cells were more elongated than other seen. 
111 
3.19 Light microscopy images of P0 VEGF-AMD PBEPC culture showing an isolated, 
circumscribed, rare colony morphology, seen in some cultures with a morphology 
distinct from the typical early- or late-outgrowth cells, day 10. a) At x4 
magnification. b) At x10 magnification. 
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3.20 Flow cytometry fluorescence histograms and scatterplots for VEGF-AMD 
PBEPCs. a) Red plot shows cells stained with PE conjugated isotype control. 
Green plot shows cells stained with PE conjugated CD34 antibody. b) Red plot 
shows cells stained with APC conjugated isotype control. Green plot shows cells 
stained with APC conjugated CD45 antibody. c) Fluorescence scatterplot of CD34-
PE vs CD45-APC fluorescence for PBEPCs. d) Red plot shows cells stained with 
FITC conjugated isotype control. Green plot shows cells stained with FITC 
conjugated CD29 antibody. In plots a and b, there is no right shift in fluorescence, 
indicating no expression of CD34 and CD45 in PBEPCs. In plot c, the vast 
majority of cells represent a CD34-CD45- population, with a scattering of 
CD34+CD45- cells. In plot d there is a clear right shift in fluorescence indicating 
high expression of CD29. 
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3.21 Flow cytometry fluorescence histograms for VEGF-AMD PBEPCs. a) Red plot 
shows cells stained with APC conjugated isotype control. Green plot shows cells 
stained with APC conjugated CD90 antibody.  b) Red plot shows cells stained with 
FITC conjugated isotype control. Green plot shows cells stained with FITC 
conjugated CD31 antibody. c) Red plot shows cells stained with FITC conjugated 
isotype control. Green plot shows cells stained with FITC conjugated VEGF2 
antibody. In plot a, there is a right shift in fluorescence, indicating expression of 
CD90. In plots b and c, there is no right shift in fluorescence, indicating no 
expression of endoethelial markers CD31 and VEGFR2 (n=2). 
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3.22 Flow cytometry fluorescence histograms for VEGF-AMD PBEPCs. a) Red plot 
shows cells stained with APC conjugated isotype control. Green plot shows cells 
stained with APC conjugated CD90 antibody. b) Red plot shows cells stained with 
FITC conjugated isotype control. Green plot shows cells stained with FITC 
conjugated CD31 antibody. c) Red plot shows cells stained with FITC conjugated 
isotype control. Green plot shows cells stained with FITC conjugated VEGF2 
antibody. In plots a and c there is a no right shift in fluorescence, indicating no 
expression of CD90 or endothelial marker VEGR2. In plot b there is a right shift in 
fluorescence, indicating expression of endoethelial marker CD31 (n=2). 
114 
3.23 a) Light microscopy images showing the results of osteogenic media 
supplementation (x10 magnification), on VEGF-AMD PBEPCs after 21 days of 
supplementation. There was no visible red staining post Alizarin Red, indicating no 
calcium deposition and therefore no osteoblastic differentiation. b) Light 
microscopy images showing the results of adipogenic media supplementation on 
VEGF-AMD PBEPCs (x40 magnification above the horizontal dividing line, x10 
below). Post being fixed and stained with Oil Red O, multiple red lipid droplets 
were evident in the supplemented media compared with the standard media. In the 
middle panel, the control group also shows some positive staining indicative of 
lipid deposition without adipogenic stimulation. The panels from top to bottom 
represent cultures from different individual rats. 
116 
3.24 PBEPCs plated on Geltrex, treated with growth factor depleted media (low serum) 
or full growth factor enriched media, 18±2 hours hours post plating (x40 
magnification). In the top and bottom panels, there is evidence of a capillary like 
network forming, with cellular connections and luminal type spaces emerging. 
However, the middle two panels do not show such advanced structural 
arrangements. Results are summarised in table 3.3. The panels from top to bottom 
represent cultures from different individual rats.   
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3.25 Light microscopy images of P1 VEGF-AMD PBMSC culture that failed to 
establish after passage, and multiple ‘late-outgrowth’ style PBEPC CFUs 
developed after 16 days. a) Senescent cells at day 16 after passage. b) Late 
outgrowth style PBEPC colony that appeared, shown at x4 magnification. c) 
Further late outgrowth PBEPC colonies developed over the following five days, (at 
x10 magnification) and figures d) and e) at x4 magnification. f) By day 30, several 
very large, dense tightly packed colonies were present (x4 magnification). 
118 
3.26 Flow cytometry fluorescence histograms and scatterplots for P2 PBMSC late 
outgrowth EPC like cells. a) Red plot shows cells stained with FITC conjugated 
isotype control. Green plot shows cells stained with FITC conjugated CD29 
antibody. b) Fluorescent scatterplot showing PE conjugated CD34 against APC 
conjugated CD45 showing a predominantly CD34- CD45- negative population 
with a smaller secondary population of CD34- CD45+ cells. c) Red plot shows 
cells stained with APC conjugated isotype control. Green plot shows cells stained 
with APC conjugated CD90 antibody. d) Red plot shows cells stained with FITC 
conjugated isotype control. Green plot shows cells stained with FITC conjugated 
CD31 antibody. e) Red plot shows cells stained with FITC conjugated isotype 
control. Green plot shows cells stained with FITC conjugated VEGFR2 antibody. 
120 
3.27 Light microscopy images post differentiation and plating on Geltrex of P2 VEGF-
AMD PBEPC-like cells, that developed in a PBMSC failed culture. a) The results 
of osteogenic media supplementation (x4 magnification), after 21 days of 
supplementation, showing significant staining in the supplemented culture 
indicative of calcium deposition from osteoblast differentiation. b) The results of 
adipogenic media supplementation (x40 magnification). Post being fixed and 
stained with Oil Red O, no red droplets indicative of lipid deposition was seen, 
indicating no adipogenic lineage differentiation. c) Microvascular type network 
formation at 20 hours after plating on Geltrex when supplemented with full growth 
factor EPC media (x40 magnification). 
121 
4.1 a) Schematic showing the basic components of a linear type 1a external skeletal 
fixator placed on a stylised canine femur. b) Radiograph showing the revised 
Stanmore micro-Fixator at day 0 on a rat femur. 
134 
4.2 a) Photograph showing the first generation fixator; aluminum block and stainless 
steel bars. b) The evolved version of the original fixator, with square titanium 
blocks and carbon fiber bars. 
135 
4.3 a) Radiograph showing failure of the fixator at three weeks, with complete pin 
extraction from the bone proximally. b) Radiograph at three weeks, showing the 
bone without the fixator. The red arrow shows a large osteolytic hole where the pin 
tract was. Blue arrow suggests the formation of a ring-sequestrum around the other 
pin tract. 
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4.4 Photograph showing the previous drill and pin guide apparatus. This apparatus 
allowed for the table-top to be moved intra-operatively using precision XY axis 
adjustment dials, allowing the hand driven chuck to be positioned correctly. 
136 
4.5 a) Photograph showing the revised miniaturised drill and guide-block, which sits 
directly on the craniolateral femoral surface. i) Shows the lateral surface with the 
concavity on the underside. ii) Shows the top surface with recesses to accept insert-
sleeves and micro-ratchet recesses. iii) Shows medial surface. b) Photograph 
showing the titanium pin sleeve (i) and the drill sleeve (ii). The guide-block 
universally accepts either of the two sleeves (iii). 
136 
4.6 a) Photograph showing different aspects of the revised fixator. i) Shows the cranial 
surface of the fixator, which reveals the M2 stainless steel grub screws to secure 
the proximal and distal blocks. The distal screws can be loosened to allow sliding 
and distraction of the osteotomy. ii) Shows the lateral surface of the fixator; 
notably, the pin-holes are eccentric such that the bulk of the block can be 
positioned caudal to the pins, as most of the rubbing occurred on the cranial 
surface. iii) Shows the caudal surface of the fixator, which has the four M2 
stainless steel grub screws that secure each individual pin. b) Photograph showing 
the various degrees of axial distraction available. 
137 
4.7 Photographs showing the original blunt trochar tipped pins (a, and c) and the 
revised sharp cutting trochar tipped pins (b and c). 
138 
4.8 a) Radiograph showing osteolysis and lucency around the proximal pins. b) 
Radiograph showing a distal femoral fragment with marked remodeling around the 
distal pin tracts. The upper pin tract has a sclerotic region with a surrounding lucent 
zone suggestive of a ring sequestrum.    
139 
4.9 a) (i) Photograph of the 3:2 proximal pin fixator next to the standard 2:2 fixator. (ii) 
Radiograph taken five weeks post surgery using the 3:2 fixator system with 
1.25mm diameter pins. b) Photograph showing the 1.25mm sharp trochar pin (i) 
next to the 1.4mm sharp trochar pin (ii). c) Radiograph taken five weeks post-
operatively showing no evidence of pin loosening with the 1.4mm fixator pins.   
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4.10 Photographs showing the temporal sequence of placement of the Stanmore micro 
fixator to achieve a 1mm osteotomy. a) Skin incision exposes boundary of the 
biceps femoris to tensor fascia lata. b) Placement of drill and pin guide jig, retained 
with micro-ratchet forceps. c) Proximal drill sleeve and drill bit, with spiral push 
drill. d) Proximal stabilising pin in place and distal fixator pin placed, with sleeves 
remaining. e) Checking the full trochar has penetrated the trans cortex. f) Four 
fixator pins placed – short pins proximal and distal, long pins centrally. g) Fixator 
pin tracts made and skin placed over pins. h) Fixator positioned along pins and 
spaced by precision spacer from bone. i) Cutting the mid-diaphyseal osteotomy 
with a diamond tipped handsaw. j) Setting the desired osteotomy distance using the 
precision titanium spacer. k) Checking the osteotomy size. l) Surgical incision 
closed with intradermal continuous suture.   
144 
4.11 Photographs showing the new tools developed for the procedure. a) The temporary 
stabilising pin, placed after the first drill hole is made, to prevent jig-guide 
movement. b) The precision spacer temporarily placed within the osteotomy gap. c) 
The pin working length spacer, which accommodates the skin and sat between the 
inner aspect of the connecting block and the outer aspect of the bone. 
145 
4.12 a) Photograph showing the cranial surface of the scanning fixator. The ‘nut’ 
component associated with the bolt threads can be rotated to pass in between the 
existing fixator pins, and then be rotated back to allow it to compress against the 
pins as the M2 stainless steel hex bolts are tightened. b) Photograph showing the 
scanning fixator in place below the titanium fixator. Note the ovoid hole on the 
right hand size, which accommodated for the differing gap sizes between the 
proximal and distal pin pair. 
145 
5.1 Photographs showing the set-up for the biomechanical analysis to determine the 
IFS and stiffness of the fixator construct. a) Lateral aspect of the femur with the 
fixator and microdisplacement sensor in place b) The load was applied from the 
femoral head to the femoral condyles to simulate physiological loading along the 
mechanical axis. In the orthogonal projection, a LORD micro displacement sensor 
was attached to provide a highly accurate measure of displacement at the level of 
the osoteotmy.  c) Zoomed out image of the test apparatus. 
149 
5.2 A typical load displacement (deformation) graph. The gradient of the linear portion 
of the curve provided the construct stiffness. 
150 
5.3 Plain radiographs showing a) 1mm osteotomy day 0. b) Non-union. c) Partial-
union. d) Union. Images b-d were taken at five weeks post 2.0mm osteotomy. 
151 
5.4 Radiographic and computed tomographic images showing microCT analysis of the 
60% osteotomy gap window for a) 1.0mm osteotomy. b) 1.5mm osteotomy. c) 
2.0mm osteotomy. A representative transverse slice is shown from the most 
proximal, mid and distal region of analysis. 
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5.5 Photographs showing the post-mortem processing after limb removal at five weeks. 
a) Bone embedded ready for removal of fixator pins and blocks. b) Block being cut 
in the microtome. 
153 
5.6 Histology images of the osteotomy gap. a) Shows a 1.5mm gap non-union. b) 
1.5mm gap partial union. Both images are shown at x1 magnification with a central 
region for detailed histomorphometric analysis at x2.5. 
154 
5.7 Histology images. a) Examples of 1x area analysis of a central sagittal slice. Total 
callus area was measured between the innermost margins of the fixator pin holes on 
all samples to provide a consistent landmark. This was possible as the surgical 
fixator guide gave a consistent distance between the two innermost pins and the 
edge of the osteotomy. The blue outline delineates a central region of cartilaginous 
tissue. b) 2.5x image, with a grid width equal to the original gap size, in this case 
1mm. Intersection points were then scored for the tissue formed. 
155 
5.8 a) Photograph of the four femurs biomechanically tested showing the position of 
the fixator (numbered femur 1-4 from left to right). b) Line graph showing the 
mean IFS as the gap increased for each femur. c) Line graphs showing the mean 
stiffness (N/mm) as the gap size increased for each femur. Notably, all trends were 
consistent despite the variations in fixator position and femoral length, with the 
higher IFS being measured on femur 1 and lowest on femur 3. This could relate to 
individual bone variations, or the positioning of the fixator / osteotomy on the 
bone, from proximal to distal, potentially influencing the bending forces. 
157 
5.9 a) Boxplot plot showing the percentage IFS was significantly affected by gap size. 
(*p=0.029). b) Line graph of mean±SD construct stiffness (N/mm), which was 
unaffected by gap size (p=0.779). 
158 
5.10 Boxplot showing a sequential reduction in overall callus size (TV per slice). b) 
Boxplot showing a similar reduction in mineralised callus (BV per slice) as the 
osteotomy gap increased in size. 
160 
5.11 a) Boxplot showing a significant decrease in tissue surface (TS) per slice in the 
2.0mm compared with the 1.0mm osteotomy. b) Boxplot showing a reduction in 
trabecular thickness between the 1.0 and 1.5mm osteotomies (* = p<0.05). 
161 
5.12 Bar chart showing bone volume (BV um^3) per slice overlaid with a line graph of 
IFS (%), vs gap size showing the relationship between the reducing IFS and 
reducing bone formation within the osteotomy gap. All values are the mean±SD. 
162 
5.13 Shows the histomorphometric assessment of tissue formation between the two 
innermost pins at x1 magnification. a) Bar chart showing histomorphometric 
assessment of the actual area composition, measured in square pixels. Values are 
mean±SEM. b) Bar chart showing the calculated percentage area composition of 
the tissue in between the two innermost fixator pin tract holes. Values are the 
mean±SEM. c) Boxplot showing the area of combined fibrous and cartilage in the 
callus region as total area measured in square pixels at x1 magnification. 
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5.14 Histomorphometric analysis of tissues formed within the osteotomy gap from line-
intercept analysis, at x2.5 magnification. a) Boxplot showing percentage bone 
formed within the osteotomy gaps. b) Boxplot showing percentage cartilage formed 
within the osteotomy gaps. c) Boxplot showing percentage fibrous tissue formed 
within the osteotomy gaps. d) Bar chart showing mean±SEM of all tissues formed 
within the different gap sizes. As the osteotomy gap increased in size, there was a 
reduction in bone. The percentage cartilage present remained similar, increasing 
slightly in the mid sized gap, however the increasing gap size was related to 
progressive increase in fibrous tissue. 
165 
5.15 Representative imaging including microCT and histology. a) 1.0mm gap with 
complete union. b) 1.5mm gap with partial union. c) 2.0mm gap with non-union 
(atrophic). 
166 
5.16 Histology images of an atrophic non-union seen in a 1.5mm osteotomy gap. Images 
are shown at x10 and x40 magnification. MC = marrow cavity, CoB = cortical 
bone. 
167 
5.17 Histology images of delayed healing in a 1.5mm osteotomy gap. Images are shown 
at x10 and x20 magnification. CoB = cortical bone. WB = woven bone, Ca = 
cartilage. 
167 
5.18 Histology images of healed 1.0mm osteotomy gap. Images are shown at x10 and 
x40 magnification. WB = woven bone. 
168 
6.1 Diagram depicting the sequence of events for endogenous mobilisation of stem 
cells into the peripheral circulation after osteotomy surgery. 
180 
6.2 Boxplots comparing microCT measures of the control untreated group (1.5 
Control) and the AMD3100 without additional growth factors (PBS-AMD). a) The 
bone volume (BV um^3) was significantly increased in the AMD3100 group (* 
p=0.01) b) Trabecular thickness was also significantly increased (Tb.Th um) (* 
p=0.003). 
183 
6.3 Boxplots comparing microCT measures of the control untreated group (1.5 
Control) and the VEGF-AMD treated group. a) VEGF-AMD increased bone 
volume (BV um^3). b) Trabecular thickness (Tb.Th um) was also increased, but 
significance was not shown. 
184 
6.4 Boxplots comparing microCT measures of the control untreated group (1.5 
Control) and the GCSF-AMD group. a) The bone volume (BV um^3) was reduced 
in the GCSF-AMD group. b) Trabecular thickness was increased 
(0.069±0.03um^3), as seen in other treatment groups (* p=0.048). c) Total porosity 
was significantly reduced to 36.9±7.3% (* p=0.048). 
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6.5 Boxplots comparing microCT measures of the control untreated group (1.5 
Control) and the IGF1-AMD group.  a) The bone volume (BV um^3) was 
increased in the AMD3100 group. b) Trabecular thickness was significantly 
increased (Tb.Th um) (* p=0.01). c) Total porosity (%) was significantly reduced 
(* p=0.035). 
186 
6.6 The mean±SEM tissue volume (TV) and bone volume (BV) within the osteotomy 
measured using microCT. * represents significant (p<0.05) differences compared 
with 1.5mm control. **,***,****,*****,****** indicate significant differences 
(p<0.05) between paired groups. 
187 
6.7 The mean±SEM trabecular thickness (Tb.Th) and separation distance (Tb.Sp) of 
bone formed within the osteotomy measured using microCT. * represents 
significant (p<0.05) differences compared with 1.5mm control. ** and *** indicate 
significant differences (p<0.05) between different groups. 
188 
6.8 The mean±SEM trabecular number (Tb.N) and percentage total porosity of bone 
formed within the osteotomy measured using microCT. * represents significant 
(p<0.05) differences compared with 1.5mm control. ** and *** indicate significant 
differences (p<0.05) between different groups. 
189 
6.9 The mean±SEM tissue surface area (TS) and mean bone surface area (BS) of tissue 
formed within the osteotomy measured using microCT. * and ** indicate 
significant differences (p<0.05) between different groups. 
189 
6.10 MicroCT 3D reconstructions of mid femoral regions, with a mid-sagittal reveal 
(top row). The bottom row shows a 3D reconstruction of the central 60% of the 
original osteotomy region (180 slices) within the osteotomy that was analysed for 
quantitative morphometry. All groups other than GCSF-AMD showed increased 
mineralised callus formation when compared with the untreated control osteotomy 
group. 
190 
6.11 Boxplot showing the absolute measured area (square pixels) between the two 
innermost fixator pin tract holes, measured at 1x magnification. * represents 
significance p<0.05. 
191 
6.12 Mean±SEM absolute measured area (square pixels) of different tissue types, 
between the two innermost fixator pin tract holes, measured at 1x magnification. * 
represents significance p<0.05. 
191 
6.13 Boxplot showing the % bone formed within the osteotomy from 2.5x magnification 
histomorphometry 
192 
6.14 Boxplot showing the % cartilage formed within the osteotomy from 2.5x 
magnification histomorphometry 
193 
6.15 Boxplot showing the % fibrous tissue formed within the osteotomy from 2.5x 
magnification histomorphometry 
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6.16 Boxplot showing the % vascular tissue formed within the osteotomy from 2.5x 
magnification histomorphometry. 
194 
6.17 Mean±SEM percentage tissue formed within the osteotomy from 2.5x 
magnification Histomorphometry. 
194 
6.18 Histology images taken from a mid-sagittal 5um slice stained with H and E, from a 
1.5 Control example, at x1, x2.5 and x20 magnification from top to bottom. A 
microCT reconstruction with a mid-sagittal reveal of the same sample is also 
shown. CoB = cortical bone. 
196 
6.19 Histology images taken from a mid-sagittal 5um slice stained with H and E, from a 
PBS-AMD example, at x1, x2.5 and x10 magnification, from top to bottom. A 
microCT reconstruction with a mid-sagittal reveal of the same sample is also 
shown. 
197 
6.20 Histology images taken from a mid-sagittal 5um slice stained with H and E, from a 
VEGF-AMD example, at x1, x2.5 and x5 magnification, from top to bottom. A 
microCT reconstruction with a mid-sagittal reveal of the same sample is also 
shown. 
198 
6.21 Histology images taken from a mid-sagittal 5um slice stained with H and E, from a 
GCSF-AMD example (GCSF-AMD 3), at x1, x2.5 and x5 magnification, from top 
to bottom. A microCT reconstruction with a mid-sagittal reveal of the same sample 
is also shown. 
199 
6.22 Histology images taken from a mid-sagittal 5um slice stained with H and E, from 
GCSF-AMD 5, at x5, x10 and x20 magnification from top to bottom, showing the 
marked cellularity and lack of hypertrophic chondrocytes. 
200 
6.23 Histology images taken from a mid-sagittal 5um slice stained with H and E, from a 
IGF1-AMD example (IGF1-AMD 5), at x1, x2.5 and x10 magnification, from top 
to bottom. A microCT reconstruction with a mid-sagittal reveal of the same sample 
is also shown. 
201 
7.1 Light microscope images taken at x10 magnification of MSC culture of AMD3100 
mobilised P0 cells at 20 days. a) Typical conformation of the high numbers of 
plastic adherent cells seen after culture of blood. These cells did not produce 
typical CFU-Fs in ¾ cultures. b) Only one culture developed a more typical CFU-F 
P0 MSC morphology. 
223 
7.2 Light microscope images of PBEPC culture of AMD3100 mobilised P0 cells at 20 
days. a) Circumscribed colony of cobblestone shaped cells, at x5 magnification. b) 
More advanced CFU at x20 magnification. c) PBEPCs forming luminal type 
structures at x20 magnification.    
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7.3 Boxplot showing the PBEPC CFUs/ml blood cultured, compared between rats that 
were not pre-treated with mobilising agents, those that had four days of VEGF 
followed by a single dose of AMD3100, and those that only had a single dose of 
AMD3100.   
224 
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ABBREVIATIONS
2D – two dimensional 
3D – three dimensional  
acLDL – acetylated low density lipoprotein 
ALP – alkaline phosphatase 
AO - arbeitgemeninschaft fur osteosynthsesfragen 
APC - allophycocyanin 
BM – bone marrow 
BMP – bone morphogenic protein 
BS – bone surface 
BSA – Bovine Serum Albumin 
BV – Bone Volume 
BV/TV – percentage bone volume 
Ca – cartilage 
CACs – circulating angiogenic cell 
Cbfa1- core-binding factor subunit alpha-1 
CBG – cancellous bone graft 
CD – cluster of differentiation 
CFU – colony forming unit 
CFU-F – colony forming unit - fibroblastic 
CoB – cortical bone 
COL 1- collagen type I 
CXCR4 - C-X-C chemokine receptor type 4 
	 30	
DiI – 1,1’-Dioctadecyl-3,3,3’,3-tetramethylindocarbocyanine perchlorate 
DMEM- Dulbecco's Modified Eagle Medium 
DXA – dual-energy x-ray absorptiometry 
ECFC - endothelial colony forming cells 
ECM – extracellular matrix 
EDTA - ethylenediaminetetraacetic acid 
eEPCs – early endothelial progenitor cell 
EGM-2 MV – endothelial growth media 2 microvascular 
EOCs – early outgrowth cells 
EPC – endothelial progenitor cell 
FCS – fetal calf serum 
FGF - fibroblast growth factors 
FITC - fluorescein 
flk – fetal liver kinase 
GABA - gamma-aminobutyric acid 
GAG - glycosaminoglycans 
GCSF – granulocyte colony stimulating factor 
GDF – growth differentiation factor 
GF – growth factor 
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1.1 Background 
The NHS sees around 850,000 fractures each year with a non-union rate of 10%. Treatment 
can be difficult and usually requires surgery with a cost of up to £80,000 per patient, not to 
mention the associated morbidity (Mills & Simpson 2013). Stem and progenitor cells clearly 
have an important role in fracture healing and have been the focus of intense research to 
avoid and treat union problems. Currently however, stem cell therapy requires isolation of 
cells from the body, selection and expansion ex vivo and then a further operative procedure 
to deliver them back to the body. Even minimally manipulated bone marrow aspirate carries 
donor site morbidity and potential complications. An alternative method to improve fracture 
healing may be to boost the physiological migration of stem cells to the fracture site through 
a process known as ‘mobilisation’. The main purpose of this work was to investigate the 
potential to mobilise stem and progenitor cells by manipulating the SDF1-CXCR4 
chemokine receptor interaction, to augment fracture healing. The aim of my PhD was to 
investigate the hypothesis that antagonism of the CXCR4-SDF1 axis could mobilise stem 
and progenitor cells into the circulation of rats and by increasing pool of cells available after 
fracture, improve healing. 
 
My introduction gives an overview of the structure and function of bone, the mechanisms of 
fracture healing and the factors that influence it. I follow with failure of fracture healing and 
approaches to management, with an emphasis on stem cell therapy. Finally, I will describe 
the migration and mobilisation of stem/progenitor cells.  
1.2 Bone 
1.2.1 Role of the skeleton in the body 
The functions of the skeleton are directly attributable to the structure and function of bone, 
which is a dynamic and biologically active tissue. Bone as a ‘hard tissue’ is able to provide 
protection to more delicate organs, such as the brain or the heart, but also provides 
mechanical leverage permitting movement. As a quintessential composite material, the 
combination of apatite mineral with a collagen matrix allows bone to have tensile strength 
equivalent to cast iron and yet be three times lighter and ten times more flexible (Buckwalter 
et al. 1996). Bone as a significantly mineralised tissue has further roles in ion homeostasis 
and acid base balance. As a home to the marrow, it is the source of many progenitor and 
stem cells, allowing continuous recapitulation of other tissues and the fostering of healing 
(Rodan 1992).  
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1.2.2 Anatomic structure of bone 
Bones are morphologically grouped as long bones or flat bones. Long bones consist of three 
distinct regions, the largest of which is the compact diaphysis which transitions to an 
intermediate metaphyseal region and terminates in the epiphysis, each with a distinct gross 
and histological appearance (Figure 1.1).  Grossly, on a macroscopic level, a longitudinal 
section of a long bone has location dependent, macroscopic architectural arrangements of 
bone structure. Generally, in the adult skeleton there are two predominating morphological 
varieties of bone: a hard dense form of bone known as cortical/compact bone, and a sponge-
like arrangement of bone known as trabecular/cancellous bone (Figure 1.1). These two forms 
of bone have the same matrix and mineral content, however cortical bone is more dense, 
with 10% porosity, compared with cancellous bone having a 50-90% porosity (Buckwalter et 
al. 1996). Cortical bone forms the diaphysis of long bones, with an internal ‘medullary canal’ 
which contains fat and stem cell niches. The cortical bone continues from the diaphysis as an 
outer shell over the metaphyseal and epiphyseal regions, which are comprised of cancellous 
bone. In skeletally immature animals, a cartilaginous plate known as a ‘growth plate’ or 
physis physically separates these two regions. In the skeletally mature adult, the physis is 
absent and the cancellous bone of the epiphysis is connected to the cancellous bone of the 
diaphysis by a fine line of compact bone called the ‘physeal scar’.  
Flat bones are structured as a sandwich of two layers of compact bone separated by 
intervening cancellous bone, and include the majority of bones in the skull, sternum, scapula 
and pelvis. Overall, the skeleton is considered 80% cortical and 20% cancellous by mass 
(Buckwalter et al. 1996). 
1.2.3 Microscopic structure of bone 
Cortical and cancellous bone are built from two microscopic building blocks; flat lamellae 
which consist of organised parallel layers of collagen and mineral, or woven bone in which 
the collagen and deposited mineral are haphazardly organised. Woven bone is associated 
with the immature skeleton and is also seen in the adult when bone is being formed rapidly, 
such as in response to injury. Lamellae in cortical bone are arranged as circular osteons with 
a central canal containing a vascular supply, whereas lamellae in cancellous bone are 
arranged in rods or plates called trabeculae, without any such canal. Martin and Burr (1989) 
described four organisations of microscopic cortical bone structure: 
1. Woven cortical bone; has a disorganised arrangement that lacks a clear structural 
unit, underlying the rapidity of its deposition. It has disorganised type I collagen and 
can become highly mineralised. Being the only type of bone that can form de novo, 
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it is found in the embryonic skeleton and in fracture healing; in both scenarios it is 
subsequently remodelled into an organised bone structure. It is also found in 
entheses, skull sutures, ear ossicles and in the growth plate. Otherwise, it is rarely 
seen over the age of five years in humans, unless new bone formation occurs 
(Buckwalter et al. 1996).  
2. Plexiform cortical bone; is a rapidly deposited mechanically strong arrangement of 
bone, typified by fast growing large animals such as sheep and cows, and rarely seen 
in humans. In this type of bone, vascular plexii are seen between lamellar and non-
lamellar bone (Martin & Burr 1989). The parallel and perpendicular deposition gives 
a pattern akin to a brick wall. Plexiform bone is stiffer than other types, however this 
structure is more prone to crack propagation.  
3. Primary osteonal cortical bone; has lamellae arranged concentrically surrounding a 
blood vessel, creating an osteon (Figure 1.1). They are formed from cartilage 
mineralisation (endochondral ossification) and have smaller vascular channels than 
the more common secondary osteonal bone.  
4. Secondary osteonal cortical bone; develops from remodelling of existing bone. 
Osteoclasts within a tunnel known as a ‘cutting cone’ resorb bone at the leading 
edge and osteoblasts replace it at the trailing edge. A central canal develops due to 
incomplete filling by the osteoblasts known as a ‘Haversian canal’, which contain 
blood vessels, lymphatics and sometimes nerves. Secondary osteons or Haversian 
systems are larger than primary osteons. These systems are connected together by 
perpendicular Volkmann’s canals. The remodelling processes involved in this type 
of bone provides some of its characteristic features such as cement lines, which are 
non-collagenous lines where bone resorption ended and bone formation began; and 
interstitial lamella, which are remnants of remodelled osteons, not seen in primary 
osteonal bone (Hillier & Bell 2007). 
1.2.4 Species considerations 
When considering animal models for orthopaedic research, and indeed ‘one medicine’ 
collaborations between human and veterinary researchers, it is essential to understand 
species similarities and differences. Human bone has circumferential lamellae at the 
endosteal and periosteal surfaces sandwiching Haversian bone in the middle. Both ‘complete’ 
and ‘active’ remodelling Haversian systems will be seen. The cortical bone of the rat on the 
other hand, is almost exclusively comprised of primary osteonal bone, with a scattering of 
Haversian systems at the endosteal surface. The cat and the dog both exhibit dense 
Haversian bone however, and the young dog shows evidence of prior osteonal banding and 
plexiform bone. For large animals, the pig has primary plexiform with some Haversian bone, 
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whereas the goat and sheep demonstrate plexiform with a scattering of Haversian bone. 
Finally, the horse exhibits dense Haversian bone with remnants of primary and plexiform 
bone (Hillier & Bell 2007). In terms of composition, density and bone quality, there is also 
significant interspecies variation, and the rat has been shown to be the least and the dog most 
like human bone (Aerssens et al. 1998). However, when contemplating animal models for 
research, these differences are important, but are not the only considerations. 
  
Figure 1.1: Bone from macroscopic to microscopic a) Photograph of a sagittal transection of a 
preserved bone showing cortical/compact and cancellous bone structure. b) Higher magnification 
image of the cancellous region showing the rod and plate structure of trabecular bone. c) Histograph 
stained with Martius Scarlet Blue, showing collagen in red and bone in blue separated by osteoid. d) 
Scanning electron microscope image of osteoblasts and osteoclasts within bone. e) Diagram showing 
the levels of cortical bone structural arrangement. f) Ground histology section showing the concentric 
arrangement of lamellae making up Haversian systems (RVC library image). g) Diagram showing the 
arrangement of lamellae and osteocytes.  
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1.2.5 Cells in bone 
Bone is a highly vascularised tissue composed of a calcified extracellular matrix ‘osteoid’, 
associated with several differentiated cell types derived from mesenchymal and 
haematopoietic stem cell lines (Buckwalter et al. 1996). Bone marrow derived mesenchymal 
stem cells are considered by some to be the true ‘skeletal stem cell’ due to their in vivo 
ability to form all the component tissues of bone (bone, cartilage and fat) in transplantation 
models, without the need for exogenous growth factor cues (Owen & Friedenstein 1988; 
Bianco et al. 2013) 
Osteoblasts are derived from mesenchymal stem cells from the bone marrow, bone canals, 
endosteum and periosteum. These cuboidal cells form layers and deposit non-mineralised 
extracellular bone matrix ‘osteoid’ from their basal surface, which subsequently becomes 
mineralised (Rodan 1992; Buckwalter et al. 1996). As osteoid is deposited, some osteoblasts 
become trapped within the matrix and subsequently become osteocytes (Figure 1.1 & 1.2a) 
Osteocytes are proposed to communicate through cytoplasmic extensions, within canaliculi, 
and have a role in mineral ion homeostasis and detection of mechanical stimuli (Klein-
Nulend et al. 2012). Osteoblasts express parathyroid hormone receptors and have an 
important role in signaling to osteoclasts. Osteoclasts are derived from haematopoietic stem 
cells and are likely closely related to the monocyte/macrophage lineage. Osteoclasts are 
large multinucleate cells (Figure 1.2b) that have tartrate resistant acid phosphatase and 
calcitonin receptors (Rodan 1992). They have a complex folded basal cytoplasmic surface 
(referred to as the ruffled boarder) from which the mineral component of bone is resorbed. 
Initially, they bind to the surface of the bone and create a sealed space, and then through 
endosomal membrane coalescence, the brush border develops and efficiently pumps protons 
into an extracellular sealed region. This creates an acidic pH4 environment which dissolves 
the calcium and phosphate ions, and together with matrix metalloproteinases able to operate 
a low pH (Cathepsin K), the organic matrix is also resorbed (Buckwalter et al. 1996). The 
resultant resorption pit under the central potion of the osteoclasts is known as a Howship’s 
lacunae.  
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Figure 1.2: a) Histology slide, H and E, from a rat femoral diaphysis, sagittal slice. b) Histology slide, 
H and E, from a rabbit femoral diaphysis transverse section (RVC library image). CoB = Cortical 
bone. 
 
1.2.6 Composition of bone 
Cells constitute less than 10% of bone and the remainder is bone matrix; a composite 
material consisting of 65% inorganic, 20% organic and 10% water by wet weight. The 
organic component gives bone its form and is a dense fibrous tissue, not dissimilar to 
tendons, ligaments and joint capsule. Collagen makes up 90% of the organic matrix, with the 
majority being type I with its large diameter fibrils giving excellent resistance to tensile 
forces, in addition to small amounts of collagen V and XII. The remaining 10% of the 
organic matrix that is not collagen consists of glycoproteins and bone-specific proteoglycans, 
such as growth factors including BMPs, TGFb, IGF1 (Buckwalter et al. 1996).  
Without the inorganic component, bone could not perform many of its key functions. The 
mineral phase of bone is not pure hydroxyapatite (Ca10[PO4]6[OH]2) crystals, but contains 
carbonate groups and hence bone crystals should be considered apatite. Around 99% of body 
calcium, 85% of phosphorus, and 40-60% magnesium and sodium are in phase with bone 
mineral (Buckwalter et al. 1996). Alone, this material would be highly brittle and prone to 
shattering but in composite with the organic osteoid, it forms a lightweight mechanically 
strong material.  
1.3 Fracture healing 
1.3.1 Bone healing – a remarkable process 
Bone can heal without scar formation. Post-natal bone healing recapitulates ontological 
events from embryogenesis and hence bone is able to truly regenerate itself (Einhorn & 
Gerstenfeld 2014). Fracture healing involves an anabolic phase of de novo recruitment and 
differentiation of stem/progenitors to form skeletal and vascular tissues (Figure 1.3). A 
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prolonged catabolic state follows, whereby primary bone is remodelled into secondary bone 
(Einhorn & Gerstenfeld 2014). The majority of fracture healing is considered ‘indirect 
healing’ (also termed ‘secondary bone healing’ or ‘callus healing’) whereas under certain 
surgically engineered situations, bone can be tricked into remodelling, and will directly fuse 
across a fracture line in a process known as ‘direct’ or primary bone healing.  
1.3.2 Indirect bone healing 
Indirect bone healing is the most common form, and is the body’s natural means to re-unite 
fractured bone. Conservatively managed fractures and those given relative stability with 
surgical stabilisation permitting some micromotion, such as intramedullary nails, external 
fixators, or non-compressed internal fixation, heal through indirect union (McKibbin 1978; 
Marsell & Einhorn 2011). A bridge of tissue forms rapidly, called a ‘fracture callus’, to 
restore mechanical stability and reduce fracture movement. Indirect bone healing has been 
described as a sequence of distinct phases (McKibbin 1978), but it should be remembered 
that these processes will not be entirely linear nor simultaneous in any one fracture (Figure 
1.3).  
Inflammatory phase 
Tissue damage associated with trauma will trigger a necessary inflammatory response and 
the clotting cascade. The resulting coagulated haematoma of fibrin and platelets fills 
potential space between the fracture ends, providing a scaffold for fracture callus and a 
source of pro-inflammatory cytokines (Gerstenfeld et al. 2003). Invading inflammatory cells 
attracted to the haematoma, create a suitable cytokine milieu to drive fracture healing. 
Factors such as Fibroblast Growth Factor (FGF), Transforming Growth Factor (TGFβ), and 
Vascular Endothelial Growth Factor (VEGF), increase in concentration (Simpson et al. 
2006), and IL-1, -6 and TNFα are thought to be the main inciting cytokines signalling the 
move from inflammation towards repair and revascularisation (Marsell & Einhorn 2011). 
These factors are produced by macrophages, mesenchymal stem cells and other 
inflammatory cells, with peak levels seen at 24 hours (AI-Aql et al. 2008). The initial acute 
inflammatory response peaks at 24 hours and is usually abating by seven days, although key 
individual inflammatory mediators continue to have influence throughout fracture healing 
(Cho et al. 2002).  
Critical to de novo tissue formation is the recruitment and differentiation of stem and 
progenitor cells to the site of the fracture. New blood vessel formation requires local 
sprouting in addition to recruitment of circulating and bone marrow resident endothelial 
progenitor cells (EPCs) (Alev et al. 2011). Mesenchymal stem cell (MSC) recruitment has 
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been shown to occur as soon as 24 hours after fracture (Dimitriou et al. 2005), and a range of 
sources are proposed including bone marrow, periosteum, peripheral blood and nearby soft-
tissues (Kumagai et al. 2008; Knight & Hankenson 2013). Bone marrow and periosteal 
MSCs certainly contribute, as bone marrow removal or periosteal stripping delays fracture 
healing (Ozaki et al. 2000). Elegant chimeric labelling studies have shown that GFP bone 
marrow cells become incorporated into the fracture, particularly in the central callus region 
populated by osteoblasts (Taguchi et al. 2005). Transgenic lineage studies have shown a role 
for bone marrow MSCs differentiating into osteoblasts and osteocytes, and a contribution of 
periosteal cells to the fracture callus (Colnot 2009). Periosteal cells can differentiate down 
chondrogenic and osteogenic pathways, in contrast to the osteogenic limited marrow cells 
(Colnot 2009), indicating a role of periosteal stem cells in cartilage formation during bone 
healing. Although only recently an area of focus (Kuznetsov et al. 2001; Zvaifler et al. 2000), 
there has been an awareness of peripheral blood circulating skeletal progenitors since the 
nineteenth century, when they were first described by Paget (Chesney & Bucala 1997). 
Clinical evidence from fracture patients corroborates a potential role of circulating 
skeletal/mesenchymal stem cells (Alm et al. 2010) and EPCs (Ma et al. 2012) in fracture 
healing. Experimental parabiotic mouse studies also support physiological mobilisation of 
progenitors via the circulation to a fracture site (Kumagai et al. 2008). These cells have been 
identified circulating in small numbers of around 1 per 106-8 blood mononuclear cells in mice, 
rabbits, guinea pigs and humans (Khosla & Eghbali-Fatourechi 2006).   
 
Figure 1.3: Diagram of the phases of Indirect fracture healing; from inflammatory through to 
endochondral bone formation and remodeling. The images denote the cells recruited and present at the 
different stages. The time scales shown are based upon a mouse femoral fracture model stabilised with 
intramedullary pin. (PMN = polymorphonuclear leukocyte). Image from Einhorn & Gerstenfeld 
(2014). 
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Once recruited, stem and progenitor cell differentiation will be driven by the mechanical 
environment and signalling from growth factors and other molecules. BMP2, 6 and 9 have 
all been shown to drive MSCs down an osteoblastic lineage (Cheng et al. 2003). The 
mechanical environment at the fracture site also influences the differentiation of recruited 
stem cells, with experiments showing chondrocyte (Angele et al. 2003) and osteoblast 
(Mauney et al. 2004) differentiation being influenced by the amount of mechanical strain 
they are exposed to. Undifferentiated stem cells demonstrate sensitivity to their local matrix 
mechanical environment and stiffer environments drive osteogenic differentiation whilst 
softer environments favour neuro or myogenic pathways. Mechanical influence subsequently 
dominates over growth factor driven differentiation after several weeks of exposure to a 
particular mechanical environment (Engler et al. 2006). 
Indirect fracture healing has two mechanisms of bone formation 
After the initial trauma, indirect bone healing develops through two anatomically associated 
processes (Figure 1.4); intramembranous and endochondral ossification, with the 
endochondral pathway tending to dominate in indirect healing, whereas, only intra-
membranous ossification is seen in direct fracture healing.   
Intramembranous ossification forms bone along periosteal and endosteal surfaces associated 
with the fracture, and can develop along the bone diaphysis. In this situation, bone matrix is 
produced by periosteal derived osteoprogenitors depositing bone directly onto a scaffold of 
fibrous tissue. Seen as early as three days after trauma, a variably wide cuff of hard callus 
tissue forms to bridge the cortical fracture ends. In the areas between and aside, fracture 
haematoma becomes reorganised as fibrovascular granulation tissue, rich in collagen fibres 
and matrix. In endochondral ossification the granulation tissue becomes progressively 
replaced by fibrous tissue, fibrocartilage and hyaline cartilage. Endochondral ossification 
occurs in between the fracture ends, outside of the periosteum and within the granulation 
tissue that has formed (Brighton & Hunt 1991).  
Endochondral ossification is the predominant pre-natal bone forming pathway. It remains 
present until skeletal maturity, facilitating physeal growth of the long bones, and involves 
cellular proliferation, differentiation, matrix synthesis and increased cellular volume (Breur 
et al. 1991). A sequential replacement of tissue belies endochondral ossification, with an 
initial formation of soft cartilaginous callus that is replaced by hard bony callus. Its 
recapitulation of embryonic bone formation is corroborated by the int/wingless signal 
transduction pathway (Wnt pathway) being critical in both embryology, fracture healing and 
oncogenesis. This pathway is intimately involved in regulation of the differentiation of 
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MSCs down osteoblastic lineages and regulates osteoblast driven bone formation (Chen & 
Alman 2009).  
For cartilage formation in fracture healing, MSCs differentiate to chondrocytes that 
proliferate and hypertrophy in regions adjacent to the woven bone of the hard callus. The 
hypertrophic chondrocytes deposit a cartilage matrix (type II collagen with aggrecan) to 
form a soft-callus, which starts to provide some mechanical stability. Animal studies have 
shown maximal levels of procollagen type II and soft callus formation around 7-9 days after 
fracture (Dimitriou et al. 2005). Whilst the soft callus forms, intramembranous ossification 
lays down bone without a cartilage intermediate from the periosteal and endosteal surfaces 
of the fracture, creating a hard callus. Both processes depend upon MSC recruitment and 
differentiation (Marsell & Einhorn 2011), in addition to the TGFβ superfamily of growth 
factors. TGFβ2, -β3 and GDF5 drive chondrogenic differentiation and are crucial to 
endochondral ossification, whereas BMP5 and 6 drive intramembranous ossification (Cho et 
al. 2002; Marsell & Einhorn 2009).  
 
Figure 1.4: Diagram adapted from Brighton & Hunt (1991), showing the regionalised associations of 
intramembranous ossification (periosteal callus) and endochondral ossification (external and 
interfragmentary callus) in indirect fracture healing. 
 
Over time, the soft callus cartilage matrix starts to calcify. Calcification is driven by relative 
hypoxia inducing the chondrocytes to accumulate calcium granules within their 
mitochondria. These get transported into the extracellular matrix where the calcium can 
precipitate with phosphate to form mineral deposits, creating a nidus for apatite formation 
(Ketenjian & Arsenis 1975). The changes in the soft callus are regulated by a range of 
growth factors and signalling molecules including receptor activator of nuclear factor kappa 
B ligand (RANKL), osteoprotegerin (OPG) and macrophage stimulating factor (M-CSF). 
These factors stimulate woven bone formation by signalling to osteoblasts and osteoclasts. 
Additionally, TNFα has roles in inducing chondrocyte apoptosis and osteogenic MSC 
differentiation	(Gerstenfeld et al. 2003; Barnes et al. 1999). 
In order to remodel and form bone, the cartilage in the fracture requires vascularisation to 
facilitate migration of osteoblasts and to provide the increased oxygen tension they require. 
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This process requires the coordination of new blood vessel formation and a sequence of 
chondrocyte apoptosis, matrix degradation and angiogenesis (AI-Aql et al. 2008). 
Vascularisation is controlled by at least two signalling pathways; the angiopoietin and VEGF 
pathways. Angiopoietins peak early in healing and hence are thought to have a role in 
budding of adjacent blood vessels from the periosteum (Keramaris et al. 2008). Both 
osteoblasts and chondrocytes expressed VEGF, a key mediator of de novo vascular network 
formation (vascularisation) and induction of existing vessels to bud new ones (angiogenesis), 
through signalling to MSCs and EPCs (Kanczler & Oreffo 2008).  Experimental studies have 
shown the critical role VEGF plays in fracture healing, as blocking VEGF with soluble 
receptors decreases angiogenesis, bone formation and callus mineralisation, whereas 
exogenous VEGF enhances vascularisation, ossification and callus formation in mouse 
femoral and rabbit radial defects (Street et al. 2002). VEGF can act indirectly through its 
receptors on endothelial cells to influence the development of a new vascular network, 
allowing bone orientated stem and progenitors to migrate into the fracture callus and 
differentiate into osteoblasts (Stegen et al. 2015). VEGF can also stimulate endothelial cells 
to produce cytokines that promote differentiation of progenitors down an osteoblastic lineage 
(Bouletreau et al. 2002). 
Osteoblasts subesquently invade the calcified and vascularised cartilage and synthesise 
osteoid onto calcified cartilage septa. Apatite crystals form giving ‘mixed spicules’ which 
are woven bone with calcified cartilage cores, akin to embryonic bone formation 
(Buckwalter et al. 1996).      
Remodelling phase 
The hard callus creating a bridge between the fracture ends provides temporary restoration of 
mechanical stability, but is not the same as normal bone. The final phase in bone healing 
involves a second process of resorption and bone formation, this time, replacing the woven 
bone in hard callus with lamellar bone organised as osteons, to develop a cortex and re-
cannulise the medullary canal (Gerstenfeld et al. 2003). During remodelling, callus including 
calcified cartilage is resorbed by osteoclasts (chondroclasts), and osteoblasts simultaneously 
deposit lamellar bone. Although it starts within four weeks of trauma, the process can take 
months to years to be fully complete. Remodelling is associated with a reduction in the 
expression of the TGFβ family of growth factors, whereas IL1 and TNFα predominate, 
although BMP2 also has a role (Marsell & Einhorn 2009; AI-Aql et al. 2008; Mountziaris & 
Mikos 2008).  
Physiochemical processes may also influence remodelling. In the 1960s it was identified that 
the application of strain to compact bone created an electrical potential difference. The 
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convex surface became a cathode and activated osteoclasts to reduce the profile of the bone, 
whereas the concave surface became an anode, activating osteoblasts to infill the defect. This 
piezoelectric effect was generated by collagen in a crystalline matrix, and it was postulated 
that this might be the means by which cells detect and remodel bone according to the stresses 
applied. This theory has since lost its popularity as other mechanisms, such as fluid shear 
stress gained traction (Ahn & Grodzinsky 2009). 
1.3.3 Direct Fracture healing  
Discovered by chance and as a by-product of the evolution of rigid internal fixation for 
fracture repair, direct fracture healing is actually a perturbation of bone remodelling. First 
noted by Lane as ‘per primum intentionem’ and Robert Danis as ‘soudure autogen’, or 
internal welding, this type of fracture healing occurs without any callus formation. Rigid 
plate and screw fixation with fracture compression is necessary to create the correct 
biomechanical environment (Rahn et al. 1971; Perren 1979). Mechanically, direct union 
requires the relative displacement of fracture ends versus initial fracture gap width, known as 
the interfragmentary strain (IFS) (Perren 1979), to be under 2%, and the gap between the 
fracture ends also needs to be very small. Direct fracture healing is classified as either 
‘contact’ or ‘gap healing’. Where the fracture ends are in contact (gap <0.01mm) and the 
interfragmentary strain (IFS) is <2%, ‘contact healing’ occurs (Shapiro 1988), whereby 
cutting cones form at the osteons closest to the fracture and cross the fracture site at 50-
100um/day, being trailed by osteoblasts forming osteonal bone directly. However, in any 
visibly compressed fracture, there will be regions where there is no microscopic bone 
contact; ‘gap healing’ will occur if there is a gap <800um-1mm, in which there is 
intramembranous bone formation and formation of lamellar bone, deposited perpendicular to 
the axis of the bone. This is subsequently remodelled to axial osteonal bone, restoring 
integrity (Marsell & Einhorn 2011). Direct fracture healing is a slow process and takes 
months to develop full mechanical competency (McKibbin 1978).  
Comment: Most fracture healing will take place as indirect healing and hence I will identify 
a model system that reflects indirect bone healing. As the recruitment and differentiation of 
stem and progenitor cells are essential for this process, I believe they could be a potential 
point of manipulation to improve fracture healing.  
1.3.4 Role of the mechanical environment in fracture healing 
Although the overall shape of a bone is genetically programmed, bone is constantly 
subjected to direct and indirect loads. Wolff in 1892, observed that trabeculae in the 
proximal femur are aligned along the direction of stresses, leading to “Wolff’s Law of Bone 
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Remodelling”, stating the form and structure of bone is reflected by the loads it is subjected 
to (Wolff, 1892). Wolff’s law is clearly in action when considering the reduction of bone 
mass associated with bed rest (Krølner & Toft 1983), spaceflight (Stupakov et al. 1984), and 
implant stress protection (Lanyon et al. 1981; Baggott et al. 1981), or in contrast, the 
increase in bone mass seen in tennis player’s dominant racket arm (Jones et al. 1977) or 
when bone is subject to increasing strain  and  loading frequency (Lanyon 1984). Fracture 
healing is not exempt, and the influence of mechanical stability on fracture healing has been 
extensively investigated (Betts & Müller 2014). The role of the mechanical environment is 
notably evident when looking at callus formation, particularly using an external fixator 
system to alter the supporting mechanical environment (rigidity of fixation) to influence 
interfragmentary motion (Goodship & Kenwright 1985; Claes et al. 1997; Klein et al. 2003; 
Schell et al. 2005). However, as healing progresses, the tissues developing within the gap 
may influence the interfragmentary motion and strain, making studies difficult to compare 
and variable in outcome. It was Pauwels in the 1960s that first linked the mechanical 
environment to the development of fracture healing tissues, suggesting hydrostatic pressures 
drive stem cells down chondroblastic lines, and shear strains result in osteo and fibroblastic 
lineages (Betts & Müller 2014).  
Interfragmentary strain & other theories 
Consideration of interfragmentary motion and its relationship to the gap size has been 
extensively described by Stefan Perren, and is postulated to dictate whether bone heals by 
direct or indirect means, and the course of that healing. Perren’s interfragmentary strain 
(IFS) theory is based upon the supposition that if tissues were strained beyond their ultimate 
strain tolerance, they could not form within the gap (Perren 1979). Perren went on to 
describe the strain range in context of healing fracture; an IFS greater than 10% would lead 
to non-union, as it would only permit fibrous tissue, whereas between 2-10% cartilage could 
form and endochondral ossification would follow. When strains were under 2%, bone can be 
laid down immediately, and with a suitably small gap, direct bone formation would occur. It 
was also suggested that over time, as tissues develop within and around the fracture gap, 
they would modulate and reduce the IFS, permitting sequentially more vulnerable tissues to 
be deposited until bone formation occurred. Perren’s theory mathematically predicts that a 
bigger fracture gap would have lower IFS and hence improved healing, however the opposite 
is seen in experimental studies, with smaller gaps healing better than larger ones (Claes et al. 
1997; Harrison et al. 2003).  
Carter et al. proposed that the course of healing was not only related to the magnitude of IFS, 
but the differing roles of hydrostatic pressure and octahedral shear stress, and that good 
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vascularisation was critical to outcome (Carter et al. 1988). Their finite element model also 
accounted for eccentric callus formation with asymmetric cartilage deposition associated 
with the tension and compression surfaces of a stabilised fracture. They suggested that the 
fracture drives an osteogenic stimulus and when there is low cyclic stress with good 
vascularisation, bone forms directly. High hydrostatic compressive stress drives 
fibrocartilage and high tensile or shear stress drive fibrous tissue formation. When 
fibrocartilage does form, shear stresses then result in bone formation (Carter et al. 1998). 
They agree with Perren, in as much as too much mechanical stimulation will prevent healing, 
and very low levels will permit direct bone formation. Neither have however, accurately 
depicted what happens between the extremes and current experimental and finite models do 
not fully explain clinical and experimental findings. Inherently, the nature of the fracture and 
the method of stabilisation (rigidity of fixation), will influence the mechanical environment 
experienced at the fracture site, and in turn dictate the balance and course of healing.  
Comment: The effects of the biological environment such as the supply of stem cells to the 
fracture will affect healing, however, the combined effects of biology together with the 
mechanical environment is not that well understood. In order to establish the effects of a 
biological intervention on fracture healing in a model system, I need to take account of the 
mechanical environment. I will seek a highly standardised mechanical environment in order 
to evaluate my hypotheses.  
1.4 Problems with fracture healing: delayed & non-unions 
Bone healing is a protracted process, but a fracture can be considered ‘healed’ when there is 
sufficient mechanical union to restore function. Clinically, this union is usually monitored 
through sequential radiography, looking to see mineralised callus uniting the fracture ends. 
‘Non-unions’ are a failure of the fracture ends to unite and ‘delayed-unions’ are those that do 
not progress as expected. Fixed time lines are not useful due to the diversity of individuals, 
anatomic locations and fracture configuration. However, non-unions have been variably 
defined as; fractures over nine months in duration without any signs of progression for three 
months; a failure to unite within 6-8 months; or when fracture union has not developed after 
twice the typically expected time for union (Harwood et al. 2010). Experimental studies have 
looked towards a consensus definition and based on the somewhat arbitrary ratio of eight 
weeks for human long bone fractures to heal, and a non-union definition of six months, a 
three-fold time span was suggested. A rat non-union is hence defined as incomplete healing 
by 15 weeks, assuming five weeks for normal healing duration, and the same ratio gives a 
non-union definition of 12 weeks in mice (Garcia et al. 2013). Delayed-union is more 
	 49	
straightforward, being defined as “a fracture in which healing has not occurred in the 
expected time and the outcome remains uncertain” (Harwood et al. 2010).  
Non-unions are reported in up to 10% of human clinical fractures, with a treatment cost 
reaching £79,000. However, this does not account for the associated morbidity and 
productivity impact (Mills & Simpson 2013). Upper limb fractures are 60% more likely to 
result in non-union, with the highest level of non-unions found in young men suffering high-
energy fractures and elderly women suffering osteoporotic ‘fragility’ fractures.  
1.4.1 Types & causes of impaired fracture healing 
Weber and Cech (1976) radiographically classified non-unions into hypertrophic and 
atrophic forms. The hypertrophic or ‘hypervascular’ forms are thought to have suitable 
vascularisation and hence biology, but unsuitable mechanics, leading to prolific non-unifying 
callus formation. These have been subcategorised by the relative size of callus and are often 
described as an ‘elephant’s foot’, ‘horses hoof’, or as oligotrophic. The avascular types have 
been thought to lack suitable vascularisation and are biologically as well as mechanically 
compromised. Recent evidence suggests however, that the vascularity of atrophic non-unions 
is not relatively reduced (Reed et al. 2002).  
Atrophic non-union has characteristically sparse callus formation, closure or capping of the 
medullary canal by sclerotic bone and fibrous tissue in the intervening gap between fracture 
ends. If sufficient motion remains at the site of atrophic non-union formation, a 
pseudoarthrosis may form with cartilage deposition and a fluid interface lined with a 
synovial type membrane reminiscent of an articular joint (Heppenstall et al. 1987; Loboa et 
al. 2001). Due to the lack of clarity in defining the pseudoarthrosis, Mills et al. suggested 
defining the pseudoarthrosis as a ‘mobile’ atrophic non-union, in contrast to the more 
common ‘stiff’ atrophic non-union (Mills & Simpson 2012).  
Alluded from the description of fracture healing, different factors influence its progression. 
Giannoudis et al. coined the ‘diamond concept’ of fracture healing, which has four corners 
including: osteogenic cells, osteconductive scaffolds, growth factors and the mechanical 
environment (Giannoudis et al. 2007). It is proposed that failure in any single factor will 
compromise fracture healing. To that end, a lack of adequate vascularisation will prevent the 
recruitment of stem and progenitor cells necessary for de novo tissue formation and growth 
factor production. Open fractures and high energy fractures have increased risk of non-union 
development, likely in part due to their compromised extraosseus and intraosseus blood 
supplies, typified by tibial fractures increased non-union rates appropriated to their 
inherently vulnerable vascular supply (Rhinelander 1974). Surgical or traumatic removal of 
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the blood clot will also deprive the fracture of the initial growth factor rich haematoma 
(Harwood et al. 2010). As discussed above, the mechanical environment will also directly 
affect the progression of fracture healing, with either excessive motion from inadequate 
fixation or insufficient loading both compromising healing. Excessively stiff fixation with 
large gaps will also be unable to heal. Where there is a large gap as a result of comminution, 
poor surgical reduction, or surgical/traumatic removal of bone, there will be loss of the 
osteoconductive scaffold (Nilsson et al. 1993; Harwood et al. 2010).  
The reported risk factors for non-unions will have influence on differing aspects of the 
diamond concept. Gender itself is not a risk factor, although young men and older women 
are over-represented due the types of fractures they sustain; men with high energy traumatic 
fractures, older women with osteoporotic associated fractures (Mills & Simpson 2013). The 
young, as growing individuals, have their bone forming machinery already in play and see an 
accelerated pattern of healing attributed to a thicker periosteum and larger subperiosteal 
haematomas (Lindaman 2001). Increasing age however, does suppress the speed and ability 
of bone to heal itself. Clinical and experimental studies suggest that mesenchymal stem cells 
and endothelial progenitors are reduced in number and the responsiveness of fracture healing 
reduces with increasing age; typified by delayed periosteal reaction, reduced tissue formation 
and slowed endochondral ossification (Gruber et al. 2006). Other comorbidities such as 
diabetes mellitus, thyroid disorders, and malnutrition can also impair healing. 
Experimentally, diabetes mellitus reduces growth factor production (IGF1, VEGF, TGFβ), 
cellular proliferation, collagen synthesis and osteoblast activity. Prescribed medications 
including NSAIDs and steroids, in addition to smoking and alcoholism can all impair the 
biological aspects of fracture healing (Gaston & Simpson 2007).   
1.4.2 Model systems of impaired fracture healing 
Experimentally, non-union can be created through several techniques including mechanical 
instability, damaging the vascular supply with periosteal stripping/removal local soft-tissues, 
reaming the intramedullary cavity, applying distraction and introducing material to prevent 
bridging (Mills & Simpson 2012). The most common method is to establish a critical sized 
defect, which is defined as the “minimum amount of bone loss that will not heal by bone 
formation in an animals lifetime” (Schmitz & Hollinger 1986). ‘Key’s hypothesis’ proposes 
that a gap in the bone of 1.5x the diaphyseal diameter would lead to non-union (Key 1934). 
The actual size varies in terms of the phylogenetic scale of the animal, the position of the 
defect within the bone and how the periosteum and soft-tissues are managed. Typically, a 
critical size defect ranges from 1.5x to 3x the diameter of the bone (Garcia et al. 2013). 
These models are the mainstay of investigation into non-union, however, they are usually 
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created with a background of ‘effective biology’ whereas many non-unions develop in 
subcritical sized defects, with some other aspect, often biological, being compromised. 
Despite these drawbacks, critical sized defects can be standardised and are relatively simple 
to achieve, providing a consistent test scenario for experimentation. Many of these models 
will provide mechanical stability by plate and screws or more commonly an external fixator 
frame or an intramedullary pin. 
When choosing the test species, it is important to consider the feasibility of the procedure, 
husbandry, costs, and similarity to human bone structure and physiology. Historically, large 
animal models have been popular, typically sheep and goats. As noted, their bone formation 
differs with a predominant primary bone structure (plexiform), however their weight and 
size permits direct use of human implants and tools. Pigs are a closer match to human in 
terms of bone structure and healing, however they are more problematic to handle and their 
hind limb long bones are relatively short (Newman et al. 1995). The use of rodent models 
has significantly increased to nearly 50% of all fracture studies over the last two decades, 
associated with availability of rodent molecular tools, their low cost and easy husbandry. 
Rats have primary lamellar bone, with cancellous remodeling, although their cortical 
remodeling is less than in humans (Garcia et al. 2013). Currently, the rat is used for around 
one third of all in vivo fracture studies (Mills & Simpson 2012). The size of a critical sized 
defect in rats varies between studies and reflects in part the differing mechanics of their 
chosen stabilisation, or lack of, and whether periosteal stripping is performed. Typically, 
researchers have used very large defects of around 3-8mm or moderate defects <3mm. It is 
currently recommended to induce an atrophic non-union through either a critical sized defect 
or by periosteal stripping/endosteal damage of a non-critical gap, due to their differing 
aetiopathogeneses (Garcia et al. 2013). Previous work using a relatively rigid rodent external 
fixator developed at the Institute of Orthopaedics, UCL, showed consistent union with a 
0.5mm gap and non-union with a 3mm gap by five weeks (Harrison et al. 2003). Arguably, 
the aforementioned study and many others studies do not give sufficient time to determine 
the development of a non-union as analogous to the human clinical scenario, and hence these 
models may be considered delayed-union models. That said, when a characteristic atrophic 
non-union is visible at five weeks, this end stage remodeled fracture is unlikely develop a 
union, even with more time.  
Comment: Based on the considerations above, I will use a rodent model with a standardised 
critical sized defect, stabilised with an external fixator as the test model system.  
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1.5 Treatments to improve fracture healing 
1.5.1 Biophysical modulation 
Electromagnetic fields and electrical currents have been used in fracture healing modulation, 
in particular for non-union treatment since the 1800s (Brighton et al. 1981; Mollon et al. 
2008). Experimental studies have shown electromagnetic stimulation affects growth factor 
production, collagen turnover and cytokine synthesis (Mollon et al. 2008). The electrical 
potential from current application affects oxygen concentrations, enhancing osteoblast 
activity; induces pH changes affecting the activity balance between osteoblasts and 
osteoclasts; and increases hydrogen peroxide concentrations, which drives release of VEGF 
from macrophages. Indirect application using pulsed electromagnetic fields, appears to 
mediate its effect on cellular activity by increasing cytosolic calcium concentrations and 
subsequent signalling pathways mediated through calmodulin (Schemitsch & Kuzyk 2009). 
A meta-analysis on clinical efficacy however, was unable to show conclusive evidence of a 
positive effect on delayed or non-unions, however the studies were highly variable in design 
and execution (Mollon et al. 2008).  
Low-intensity pulsed ultrasound has been used in a range of clinical scenarios to boost 
fracture healing. Ultrasonic sound waves create pressure effects on tissues, transmitted by 
molecular vibrations and collisions. They are thought to mediate their effects through 
subsequent thermal changes and non-thermal micro-mechanical strains, mediated through 
piezoelectric effects and changes in calcium ion concentrations (Martinez de Albornoz et al. 
2011). Downstream osteoinductive effects include increased gene expression (VEGF, 
osteocalcin, alkaline phosphatase, COL I, fibronectin), blood flow and improved healing, 
however a clinical meta-analysis was unable to identify significant impact conclusively 
(Busse et al. 2009), although NICE guidelines support its use (Nandra et al. 2015).  
1.5.2 Bone graft 
Bone autograft, and in particular cancellous bone grafts (CBG), have been the ‘go to’ 
stimulant for fracture healing for many years and generally considered the ‘gold standard’ 
graft material.  CBG remains the only graft material with osteogenic (provision of donor site 
stem cells or stimulation of resident cells to form bone), osteoinductive (provision of growth 
factors to stimulate recipient site stem cell differentiation) and osteoconductive (provision of 
a framework for tissue deposition and cellular migration) properties. In fulfilling the above 
categories, it has a proven track record in stimulating and aiding fracture healing with non-
union healing rates of up to 87-100%. The most common source of CBG in humans is the 
iliac crest, and in dogs the proximal humerus. The issues are that it is limited in volume and 
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requires a separate harvesting procedure with associated morbidity (Sen & Miclau 2007). 
Cortical bone can also be of benefit, but is less cellular than CBG and its replacement with 
new bone through creeping substitution is significantly slower. However, it does provide 
good mechanical support.  
1.5.3 Demineralised bone matrix (DBM) 
Allograft bone, with its mineral content removed through acid extraction, leaves only the 
osteoinductive proteins of bone including collagen, non-collagenous proteins and growth 
factors that drive endochondral ossification (Khan et al. 2005). First described by Urist, his 
landmark studies demonstrated that bone demineralised with HCL, can form cartilage and 
bone when implanted in extra-skeletal tissues (Urist 1965). Subsequently, it became clear 
that Bone Morphogenic Proteins (BMPs) were underlying this effect (Innes & Myint 2010). 
DBM is now produced by different companies and is generally widely available. The donor 
and the production methodology influence its performance, with some products performing 
better than others. It may be less effective than a CBG (Sen & Miclau 2007), but does avoid 
donor morbidity and is available in large volumes ‘off the shelf’. 
1.5.4 Growth factors, cytokines & signalling peptides 
Of the growth factors or soluble factors used to augment bone healing, Bone Morphogenic 
Proteins (BMPs) are the best known. They are members of the TGFβ superfamily, of which 
BMP2 and BMP7 are most used. Two randomised controlled trials using rhBMP7 in tibial 
non-unions have shown a benefit. The first compared rhBMP7 with autograft and had 
comparable results by two years; the second compared surgical management alone or with 
rhBMP7 and showed significant benefit of rhBMP7 (Simpson et al. 2006).  
FGF2 (Fibroblast Growth Factor 2) and PDGF (Platelet Derived Growth Factor) have also 
been evaluated in randomised controlled trials of fracture healing and arthrodesis 
respectfully. FGF2 increased radiographic union, and PDGF combined with b-tricalcium 
phosphate had equivalent outcomes to autograft (Einhorn & Gerstenfeld 2014).  
Parathyroid hormone (PTH) modulates calcium homeostasis, typically increasing blood 
calcium ion levels by osteoclast mediated bone resorption. PTH can variably have a 
catabolic or anabolic influence on bone depending on its dose, frequency and duration. In a 
femoral rat fracture model, daily pulsed PTH during healing enhanced the stiffness and 
bone/cartilage volume in the callus, although there were no changes in osteoclast density.  
Similar outcomes were seen in treated post-menopausal women with radial fractures and 
pelvic fractures (Einhorn & Gerstenfeld 2014). Teriparatide, a man made recombinant 
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analogue of PTH is currently used clinically in osteoporosis as an anabolic treatment (Saag 
et al. 2007).  
The Wnt signalling pathway has roles in bone formation and fracture healing, by signalling 
osteoblasts to form bone. Sclerostin, which was identified from studies on sclerosing bone 
dysplasias, and the subsequent anti-sclerostin antibody therapy (romosozumab) which blocks 
the inhibitor of Wnt, have shown increased metaphyseal bone formation and tibial defect 
healing in rats (Einhorn & Gerstenfeld 2014).  
1.5.5 Platelet rich plasma (PRP) 
The fracture haematoma has an important role in stemming blood loss, but also provides a 
growth factor rich environment aiding and abetting early cell migration and differentiation. 
Platelets and fibrin make up the haematoma and activated platelets degranulate their alpha 
granules releasing growth factors such as TGFβ, PDGF, VEGF and IGF (Dimitriou et al. 
2005; Alsousou et al. 2009). PRP is an autologous product isolated from plasma where the 
platelets have been concentrated to about five times the normal level; 1,407,640 platelets per 
mL is considered a working definition. Three different production techniques are available 
including cell separators, selective filtration (plateletpheresis) and gravitation sequestration 
(centrifugation protocols) (Alsousou et al. 2009). Currently, the evidence for their efficacy is 
limited and the NIH and a Cochrane review failed to find sufficient evidence to support their 
usage (Nandra et al. 2015). Animal studies whereby PRP has been combined with PDGF, or 
polycaprolactone-tricalcium phosphate scaffolds have shown improved mechanical strength, 
vascular invasion and bone union in bone defects (Nandra et al. 2015).  
1.5.6 Gene therapy 
Gene therapy is most commonly associated with restoring the function of a defective gene, 
however, it is also a means to augment key signals during fracture healing. Critical to this 
type of therapy is the delivery of the desired genetic signal. Typically, this is achieved 
through viral vectors in vivo, either directly to the site of interest or by making use of viral 
tropisms. Alternatively, cells such as stem cells are extracted and transfected with a viral 
vector to enhance certain characteristics, such as homing or retention and deliver them back 
to the fracture site to enhance healing (Ho et al. 2014). BMP2 has been most extensively 
researched for gene therapy to enhance fracture healing experimentally using recombinant 
adenovirus, retro or lentiviruses in segmental defects and spinal fusions (Evans 2012). 
Concerns over the risks associated with viral vectors and the difficulties of in vitro cell 
transfection are hampering translation. 
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1.5.7 Scaffolds/tissue engineering 
Osteoconductive scaffolds, either inert, biologically osteoinductive, or cell-seeded, are under 
investigation for treatment of non-union and bone defects. Critically, when implanting 
foreign materials, they need to be biocompatible and have the correct porosity, appropriate 
mechanical performance, ideally be osteoinductive and biodegradable to allow replacement 
with regenerated bone. 
Scaffolds consisting of natural biological materials such as collagen, fibrin, hyaluronan and 
chondroitin sulphate, mimic bone ECM, and hence provide excellent cellular support, 
however they are usually mechanically limited and complex to manufacture. Collagen type I 
is a key component of all musculoskeletal tissues and beneficially has osteoinductive 
properties. It has been manufactured into membranes, sponges and gels, and enhances 
chondrogenic differentiation of MSCs (Nöth et al. 2010). Structured tissues are also of 
interest, such as demineralised cortical bone (Guo et al. 1991) and de-cellularised cartilage, 
which has shown promise as a means to bypass earlier indirect bone healing steps and start 
with endochondral ossification immediately (Vas et al. 2018) . 
The ideal scaffold pore size should approximate trabecular bone morphology, with the 
average pores size in humans being 223um. Most scaffolds fall into the range of 200-400um, 
with a high level of interconnected porosity, ideally around 90%, to allow cell adhesion and 
bone ingrowth, with exchange of nutrients and waste products throughout the scaffold 
structure (Wu et al. 2017). Natural inorganic materials are usually coral based, mainly 
comprised of calcium carbonate or phosphate, with high porosity and osteoconductivity, but 
poor mechanical strength and osteoinductivity. Treating the coral structure with a 
hydrothermal process leads to transformation of the calcium carbonate into hydroxyapatite. 
Microwave treated squid bone has improved characteristics over coral and has some 
promotive properties for osteogenic differentiation (Wu et al. 2017). A series of studies has 
shown that calcium phosphate derived scaffolds can be osteoinductive (Amini et al. 2012). 
Synthetic scaffolds are usually based on metal or inorganic materials such as glass, calcium 
based structures, or ceramics. Metals used for scaffolds include stainless steel, cobalt chrome 
and most commonly titanium. They are straightforward to manufacture and have superior 
mechanical strength, yet their modulus is significantly stiffer than bone, potentially leading 
to stress shielding. They may also release metal ions under certain circumstances and have 
no biologically inductive properties (Wu et al. 2018).  
Non-metal biological scaffold materials such as hydroxyapatite and tri-calcium phosphate, 
are treated to high temperatures and termed bioceramics. These have been extensively 
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researched and can osseointegrate with osteoinductive and osteoconductive properties. 
However, they are brittle and their biodegradation unpredictable (Wu et al. 2017). Synthetic 
poly(α-hydroxy esters) scaffolds are bio-absorbable and include polyglycolic acid (PGA), 
polylactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA), and poly-ε-caprolactone (PCL). 
They are broken down by hydrolysis, and through chemical modification can have their rate 
of degradation altered. Although easy to manufacture, they carry no significant mechanical 
support, have no osteoinductive properties, and rapid breakdown release of their monomers 
can induce macrophage driven inflammation (Nöth et al. 2010).    
Current limitations of scaffolds may be overcome by combining differing scaffold types to 
provide synergy with the organic and inorganic scaffold properties. A further evolution is the 
development of ‘intelligent scaffolds’ that have signalling molecules/growth factors 
intentionally attached, or indeed be used to seed stem cells prior to application (Shrivats et al. 
2014).  
1.5.8 Stem & progenitor cell therapy 
In the late 1800s, there was an awareness of a need for a source of cells ‘stem cells’ to allow 
certain tissues, such as blood, skin, bone, to renew continuously over a lifetime. Stem cells 
are undifferentiated cells that can self-renew by cellular division, and depending on from 
where and when they are isolated, are variably able to differentiate terminally down a variety 
of cell lineages. Totipotent stem cells can form an entire organism from a single cell and this 
ability is restricted to the stem cells of the embryo ‘embryonic stem cells’, prior to the eight 
cell morula stage (Wobus & Boheler 2005). Pluripotent stem cells can form all the 
embryonic germ layers tissues (endo-, meso-, ectoderm) and finally multipotent stem cells 
are further lineage restricted. Stem cells are considered as either embryonic or adult, with 
adult being defined as those found in the postnatal animal. Finally, there is a category of 
artificial adult stem cell, created in the laboratory from an adult terminally differentiated 
cells; the induced pluripotent stem cell (Fortier 2005).   
Embryonic stem cells 
Embryonic stem cells were first isolated over 30 years ago and are closely associated with 
the in vitro fertilisation revolution. The excitement associated with stem cell therapy is 
directly attributed to these cells, due to their self-renewal, pluripotency and prolonged 
culture sustainability (up to two years) (Fortier 2005), making them a universal tissue 
healing donor (Amini et al. 2012). Adult stem cells generally have a more limited lifespan, 
associated with their shorter telomere length and reduced telomerase activity (Rubin 2002).  
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Osteogenic differentiation of embryonic stem cells has been successfully performed and 
single cell suspensions supplemented with b-glycerolphosphate, ascorbate and 
dexamethasone to induce differentiation, is effective and simple. Combining them with 3D 
scaffolds appears to potentiate their osteogenic differentiation, with increased expression of 
ALP and osteocalcin when compared with 2D culture (Tian et al. 2009). BMP 3D scaffolds 
of PLGA and hydroxyapatite have regenerated bone in vivo, and embryonic stem cell 
derived osteoblasts will form bone when implanted in the soft-tissues of donor mice (Kim et 
al. 2008). They have also been differentiated down a chondrogenic pathway prior to 
transplantation, mimicking endochondral ossification and used to treat critical sized defects 
in rats (Jukes et al. 2008). Embryonic stem cells remain a source of ethical debate in human 
research as they are derived from fertilised embryos, specifically the inner cell mass of the 
blastocyst, and autogenous therapy in adults is not possible by their nature.  
Perinatal derived stem cells 
These stem cells are sourced from the tissues associated with the neonate, including the 
umbilicus, placenta and Wharton’s jelly. They are considered an intermediate between 
embryonic and adult stem cells. Beneficially, they can be isolated from tissues usually 
discarded after birth. Amniotic fluid derived stem cells, amniotic membrane isolated and 
chorion derived stem cells have all been described (Si 2015). Ectopic bone formation has 
been demonstrated with chorionic derived stem cells combined with hydroxyapatite/tri-
calcium phosphate implanted into SCID mice (Kusuma et al. 2015).  
Due to their ease of isolation, umbilical cord blood and the connective tissue between the 
umbilical arteries and vein, known as Wharton’s jelly, are also of interest. The blood in the 
umbilicus is unusually rich in pluripotent stem cells and have healed critical sized defects 
when combined with a collagen/TCP scaffold in nude rats (Jäger et al. 2007). 
Adult stem cells 
In the tissues of the post-natal animal, there are adult stem cells, also known as somatic stem 
cells, which are responsible for the maintenance, repair and replacement of body tissues; 
from the rapid turnover of blood cells and intestinal linings, to the slow turnover of brain 
tissue. Bone marrow is a relatively straightforward tissue to isolate cells from and hence 
adult stem cell research began there in the 1950s. Adult stem cells are generally considered 
lineage restricted relating to their source tissue, typically being multipotent. The best 
characterised adult stem cell is the haematopoietic stem cell, from the seminal work of Till 
and McCulloch (Till & McCulloch 1961; Becker et al. 1963). 
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1.5.8.1.1 Haematopoietic stem cells 
The ‘atomic era’ drove significant research into the irradiation of tissues and several 
important observations were noted. Firstly, mice could be spared the effects of lethal 
irradiation by protecting either their femur or spleen with lead shielding, and later, Lorenz et 
al. demonstrated that intravenous infusion of bone marrow after irradiation would also spare 
them (Little & Storb 2002). Eventually, it became clear that haematopoietic stem cells 
residing within the bone marrow were able to reconstitute lifelong multilineage 
haematopoiesis in transplanted hosts (in vivo). Bone marrow transplantation remains a key 
feature in the treatment of haematological malignancies to this day (Little & Storb 2002).  
1.5.8.1.2 Bone marrow derived mesenchymal stem cells 
At the same time as bone marrow was being researched for its potential to recapitulate the 
blood system, researchers were becoming aware if its osteogenic potential (Tavassoli & 
Crosby 1968). However, it was the Russian Alexander Friedenstein, who identified the 
responsible osteogenic sub population of bone marrow stromal cells (Friedenstein et al. 
1968). In further work, Friedenstein identified them as fibroblastic-like cells, isolated by 
their adherence to tissue culture plastic and ability to form colonies (CFU-F). These bone 
marrow stromal cells, or skeletal stem cells, or mesenchymal stem cells (MSCs), a term 
coined by Caplan in the 1990s (Caplan 1991), have unique properties that are used to 
describe MSCs, namely, tissue culture plastic adherence, self-renewal, and tri-lineage 
differentiation (bone, cartilage and fat). Notably, when bone marrow stromal cells are 
transplanted in vivo, they can develop into a fully fledged ‘bone organ’ without the need for 
exogenous growth factors to cue bone formation (Owen & Friedenstein 1988; Bianco et al. 
2013). Within the bone marrow, they are a rare population equating for approximately 1 in 
every 10,000 nucleated bone marrow cells (Friedenstein et al. 1970; Owen & Friedenstein 
1988; Pittenger et al. 1999). 
Bone marrow MSCs are found on the surface of sinusoidal blood vessels within the bone 
marrow, below the endothelium, where they form on the perivascular stromal strata of bone 
marrow. It is here that osteogenic committed cells are found and invade the bone during 
development. In postnatal bone marrow, MSCs have a supportive role for haematopoietic 
stem cells. They also provide a source of osteoblasts and adipocytes during growth and 
remodeling, and chondrocytes during fracture healing. The transcriptome of these cells 
includes osteogenic genes such as Runx2 (Bianco et al. 2013). 
Bone marrow aspirates have clearly demonstrated a beneficial effect on fracture healing in 
numerous animal studies (Hadjiargyrou et al. 2014). Clinically, Hernigou used concentrated 
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bone marrow aspirates to treat tibial non-unions and was able to correlate efficacy to a 
critical number of colony forming units, i.e. the number of MSCs (Hernigou et al. 2005). 
This has been developed experimentally with improved healing of critical sized defects using 
culture expanded bone marrow MSCs (Kadiyala et al. 1997; Bruder et al. 1998). Despite 
numerous pre-clinical studies, clinical evidence in humans is not currently available, 
although they have been used in veterinary clinical patients (Smith et al. 2014; Kriston-Pál et 
al. 2017). What remains clear from in vivo transplantation assays, is that bone marrow MSC 
are a bona fide skeletal stem cell capable of regenerating an entire bone organ (Bianco et al. 
2013). 
1.5.8.1.3 Other tissue derived mesenchymal stem cells  
Bone marrow MSCs have been the most extensively researched, however, the same in vitro 
criteria of plastic adherence, tri-lineage differentiation and self-renewal has been shown by 
cells isolated from a range of adult connective tissues (da Silva Meirelles et al. 2006). 
Despite this, identification of an in vivo MSC niche has been problematic, although evidence 
emerged that pericytes, which are mural branched cells on the abluminal side of small blood 
vessels, share some markers with MSCs including CD44, CD73, CD90, CD105 and CD146 
(Shi & Gronothos 2003). These cells could demonstrate in vitro characteristics of MSCs 
(Augello 2010), however, whether or not they represent a true niche remains unclear. 
Criteria for identification of MSCs has varied between studies due to a lack of consensus and 
the variability of MSCs relating to their method of isolation, species of isolation, passage 
number and culture conditions. In 2006, a position statement was made for the minimal 
criteria for defining multipotent human mesenchymal stromal cells. The International 
Society for Cellular Therapy position statement identified the following criteria: 1) tissue-
culture plastic adherence, 2) expression of CD105, CD73, CD90 and lack of CD45, CD34, 
CD14 or CD11b, CD79a or CD19, HLA-DR and 3) capacity to differentiate down 
osteoblastic, adipogenic and chondrocytic lineages under in vitro differentiating conditions 
(Dominici et al. 2006). This in vitro criteria does not require in vivo transplantation evidence 
as demonstrated by haematopoietic stem cells or bone marrow derived mesenchymal stem 
cells.  
1.5.8.1.3.1 Adipose mesenchymal stem cells 
First discovered by Zuk et al. from processed lipoaspirate (Zuk et al. 2001), there is interest 
in adipose derived stem cells due to their ease of availability and the relatively greater yield 
of stem cells compared with an equal volume of bone marrow aspirate (Knight & Hankenson 
2013). Although they can be in vitro tri-differentiated, rat adipose MSCs have reduced 
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osteogenic capacity compared with bone marrow MSCs, as demonstrated by lower ALP and 
osteocalcin expression, and negligible in vivo bone formation (Hayashi et al. 2008). Their 
apparent efficacy in some rodent and canine studies on fracture healing (Barba et al. 2013) 
may be indirect by recruitment of ‘tissue resident’ stem cells through paracrine signalling, 
and the possible benefit of their immunomodulatory effects (Knight & Hankenson 2013). It 
remains unclear and of debate as to whether administered stem cells contribute directly to 
repair tissues, or whether they have a role in orchestration through trophic and/or 
immunomodulatory effects, probably through recruitment and signalling to tissue resident 
and host migrating stem cells (Fortier 2005). 
1.5.8.1.3.2 Periosteal progenitor cells/mesenchymal stem cells 
As discussed in the fracture healing section, the periosteum is a source of progenitors for 
fracture healing (Colnot 2009; Hadjiargyrou et al. 2014) and damage to their niche leads to 
non-union (Nicholls et al. 2013). Tracking studies have identified that these cells develop 
into cartilage and bone producing cells in the callus (Colnot 2009) and have shown in vitro 
tri-lineage differentiation (Wang et al. 2010). When transplanted in a carrier scaffold, these 
cells were tracked forming new bone. Although seemingly important in fracture healing, 
they are not a viable source for therapy because they are difficult to obtain. Clinically, it is 
rare to see non-union in the skeletally immature individuals, possibly attributed to their thick 
periosteum and likely increased niche of periosteal stem cells.  
1.5.8.1.4 Induced pluripotent stem cells 
These cells have been artificially manipulated through altered gene expression to have 
pluripotency. They were first developed in 2006 by retroviral delivery of four transcription 
factors into fibroblasts; Oct4, Sox2, Klf4 and myc (Takahashi & Yamanaka 2006), and since 
then, human terminally differentiated cells have also been de-differentiated back to 
pluripotency (Takahashi et al. 2007). Although these cells appear to have in vitro 
equivalence to embryonic stem cells, the epigenetic imprint of the native transformed cell 
may remain and influence their in vivo function. They also raise a therapeutic concern due to 
the presence of oncogenes to drive their ‘stemness’, with reports of teratoma formation 
(Takahashi et al. 2007). Induced pluripotent stem cells have been differentiated down an 
osteoblastic lineage and have successfully formed new bone when implanted in SCID mice, 
however to avoid teratoma formation, irradiation of the cells was required prior to 
transplantation (Hayashi et al. 2012). The potential risk of oncogenesis and concerns over 
viral transfection are currently limiting their application.  
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Endothelial progenitor cells & CD34+ cells 
Endothelial progenitor cells (EPCs) were first described by Asahara et al. in 1997. They 
were isolated from peripheral blood mononuclear cells selected for CD34 expression and 
then grown on fibronectin in the presence of certain growth factors. They expressed 
endothelial cell markers VEGFR2 and CD31, and could form microvascular tube-like 
networks (Asahara et al. 1997). EPCs isolated from the blood have been shown to form 
chimeric vessels in the host when injected into ischaemic models, suggesting a key role in 
neovasculogenesis through differentiating into mature endothelial cells (Patel et al. 2016). 
They have been the focus of intense research in cardiovascular disease, as a potential therapy 
for myocardial infarcts and peripheral vascular disorders (Chong et al. 2016; Ward et al. 
2007). There is a proposed influence on fracture healing as vascularisation is essential for 
bone formation (Keramaris et al. 2008; Hankenson et al 2011; Rhinelander 1968). In 
experimental models, cultured transplanted EPCs have improved healing possibly through 
promoting neovascularization (Li et al. 2011). However since Asahara et al., various 
isolation techniques and definitions of EPCs have been described leading to some confusion 
in the field. 
CD34+ expressing cells include EPCs and haematopoietic stem cells, and have been isolated 
from the peripheral blood and bone marrow of humans. In a series of rodent studies, human 
CD34+ cells have been transplanted into immunocompromised rats and shown improved 
fracture healing. It is thought that these cells improve fracture healing through both 
differentiation into osteoblasts (Chen et al. 1997) and endothelial cells and by releasing 
VEGF (Kuroda et al. 2014). The composition of CD34+ cell populations is mixed and hence 
the proportion and cell type from that population that actually contributes remains unclear.  
Circulating skeletal stem cells 
Although only recently an area of focus (Kuznetsov et al. 2001; Zvaifler et al. 2000), there 
has been an awareness of peripheral blood circulating skeletal progenitors since the 
nineteenth century, when they were first described by Paget (Chesney & Bucala 1997). 
Zvaifler et al. were the first to isolate MSCs from blood conclusively, by expanding them on 
glass in DMEM + 20% FCS, and could induce osteogenic differentiation (Zvaifler et al. 
2000). Others have found isolating these cells controversial and difficult, with positive and 
negative results in the literature (Kassis et al. 2006; Kamal et al. 2014). Clinical evidence 
from fracture patients supports a role of circulating skeletal/mesenchymal stem cells (Alm et 
al. 2010) and EPCs (Ma et al. 2012) in fracture healing. Experimental parabiotic mouse 
studies also support the mobilisation of progenitors to fracture sites (Kumagai et al. 2008). 
Currently these cells are thought to circulate in small numbers of around 1 per 106-8 blood 
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mononuclear cells in mice, rabbits, guinea pigs and humans (Khosla & Eghbali-Fatourechi 
2006). 
1.6 Migration & homing of stem cells: SDF1-CXCR4 axis  
1.6.1 SDF1-CXCR4 structure & expression 
In development, homeostasis and inflammation, cells need to navigate successfully through 
the body to complete their tasks. Chemokines are small, mostly secreted proteins of 8–14 
kDa, and function to recruit and activate cells. Based upon the position of two cysteine 
residues, they are categorised into four groups: CXC, CC, C, and CX3C. Cells have G-
protein-coupled seven-transmembrane receptors, which bind their respective chemokine, 
driving cell migration or chemotaxis, usually along a concentration gradient of the 
chemokine. Their main functions are in immune cell activation and recruitment, however, a 
key function in stem cell migration and homing has been identified, not to mention their role 
in pathologies such as autoimmunity, inflammatory disease, HIV and cancer (Lewellis & 
Knaut 2012). The chemokine stromal cell derived factor 1 (SDF1), also known as CXCL12, 
binding to its classical receptor CXCR4 and alternative receptor CXCR7, has numerous roles 
in guiding cells in development and adulthood. The CXCR4 receptor is thought to have 
primary responsibility for migration whereas CXCR7 plays a role in cell adhesion (Puchert 
& Engele 2014; Chen et al. 2015). Activation of the receptors initiates several signalling 
cascades including MAPK, phospholipase C and PI3kinase pathways, to drive cellular 
migration and adhesion molecule expression (Janssens et al. 2017). 
1.6.2 SDF1-CXCR4 physiology 
SDF1 was initially identified as a soluble agent that activated B-lymphocytes, and its 
importance in primordial germ cell migration was demonstrated with SDF1 or CXCR4 
knockouts being lethal. SDF1 also has a role in cortical brain development, with the 
expression of CXCR4 on Cajal-Retzius and GABAergic interneurons being essential for 
correct spatial arrangements (Lewellis & Knaut 2012). SDF1 has two splice variants; α and β, 
with α being the ubiquitous form. SDF1 is rapidly cleared from the circulation due to the 
active form being unstable and through its binding to charged GAGs on endothelial cells, 
which shield the active form from proteolytic cleavage. This binding facilitates haptotactic 
gradients in diapedesis, facilitating cell migration into tissues (Netelenbos et al. 2003; 
Teixidó et al. 2018).  
In addition to migration, this chemokine-receptor pair is essential for temporospatial 
maintenance of cells in locations within the body. Extensive work on haematopoietic stem 
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cells identified the endosteal surface of bone as their homing site (Wilson & Trumpp 2006). 
More precisely, haematopoietic stem cells are found within perivascular regions, in 
association with reticular cells that express SDF1 (Sugiyama et al. 2006). SDF1 is therefore 
essential for maintaining haematopoietic stem cells in their ‘niche’ as notation for a “defined 
spatial structure in which stem cells are housed and maintained by self-renewal in the 
absence of differentiation” (Wilson & Trumpp 2006) (Figure 1.5a). 
Beyond maintaining the bone marrow stem cell niche, SDF1-CXCR4 functions in the 
migration and homing of stem cells from the circulation to the bone marrow (Peled 1999). 
Under resting physiological conditions, stem cells will migrate from one location and home 
to another within the body. This phenomenon is best researched in haematopoietic stem cells, 
which have been shown to leave the bone marrow niche, enter the circulation, extravasate 
into different tissues and then return to the bone marrow, with circadian rhythms influencing 
this process (Wright et al. 2001; de Lucas et al. 2017). Bone marrow engraftment of human 
haematopoietic stem cells transplanted into SCID mice demonstrated the importance of 
SDF1-CXCR4 to this process, with monoclonal CXCR4 blocking antibodies preventing 
migration and engraftment (Peled 1999). An underlying driver of SDF1 expression pattern in 
the bone marrow is thought to be the reduced oxygen tension at endosteal surfaces (Eliasson 
& Jönsson 2010). Similar migratory patterns have also been identified after intravenous 
transplantation of MSCs; initially they locate to the lungs and liver, possibly due to 
microvascular entrapment, however by three days in the presence of a fracture, they 
subsequently home to the fracture (Granero-Moltó et al. 2017). Again only MSCs expressing 
CXCR4 were capable of this migration, with CXCR4 null cells remaining in the lungs.  
1.6.3 SDF1-CXCR4 in repair & fracture healing 
SDF1 is constitutively expressed in a range of adult tissues including brain, spleen, stomach, 
intestines, thymus and lymphatics (Nagasawa et al. 1994). After damage, SDF1 expression is 
increased in the heart (Askari et al. 2003), kidney (Tögel et al. 2005), skin (Toksoy et al. 
2007), and brain (Imitola et al. 2004), with an associated migration of CXCR4 expressing 
cells, including stem cells to the damaged regions. This is also true of fracture healing, which 
needs to recruit a range of cells including inflammatory cells, endothelial cells and stem cells 
in order to heal without a scar (Marsell & Einhorn 2011; Einhorn & Gerstenfeld 2014; 
Tawonsawatruk et al. 2012). Experimentally, distraction osteogenesis, stress fractures and 
segmental defects have all demonstrated local increases in SDF1 (Lee et al. 2010; Kidd et al. 
2010; Toupadakis et al. 2012). SDF1 is increased in hypertrophic and immature cartilage 
near cortical bone in fractures, and the co-localisation of hydroxyprobe (identifies hypoxic 
cells) (Toupadakis et al. 2012) suggests a mechanism mediated by vascular damage leading 
to hypoxia, which in turn increases SDF1 expression via HIF1α (Hirota & Semenza 2006; 
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Ceradini et al. 2004). When a fracture occurs therefore, it is postulated that a chemotactic 
gradient develops, with high levels of SDF1 at the fracture site, and subsequently increased 
levels in the blood steam, facilitating stem cell migration (Yellowley 2013) (Figure 1.5b). 
Corroborating this theory, the vast majority of cells in the fracture including chondrocytes, 
osteoblasts, osteoclasts and MSCs, express CXCR4 (Toupadakis et al. 2012). 
 
Figure 1.5: a) Diagram showing stem cells bound by their CXCR4 receptors to the bone marrow niche 
which expresses SDF1. b) Diagram illustrating stem cells migrating along an SDF1 concentration 
gradient, from the bone marrow niche into the peripheral circulating and then homing to a fracture 
expressing high levels of SDF1.  
 
Otsuru et al. demonstrated the essential role of CXCR4 for systemically delivered GFP 
labelled osteoblast progenitors to migrate to the sites of fracture (Otsuru et al. 2008). Other 
elegant parabiotic GFP studies have shown stem cells from the labelled donor will travel via 
the circulation and home to a fracture site of the conjoined partner, and these cells expressed 
ALP at similar levels to other cells in the fracture callus (Kumagai et al. 2008). Notably, 
there is a low level of donor cells relocating to the uninjured bone marrow after four to seven 
weeks, however when a fracture is introduced, there is significantly higher homing within 
two weeks, but this homing is more evident between 7-14 days than 0-7 days. A role for 
SDF1 and CXCR4 with EPC migration in fracture healing is also supported from 
experimental studies, where CXCR4 conditional knock-out sourced EPCs had reduced 
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migration and colony forming ability in vitro, and reduced fracture healing in vivo 
(Kawakami et al. 2015).  
For migration and subsequent homing to occur, stem cells need to be able to undergo 
diapedesis with its associated stages, much like a neutrophil or other white blood cell 
(Nitzsche et al. 2017). MSCs do have some of the same adhesion molecules such as selectins 
and integrins (Sohni & Verfaillie 2013), and MSCs, like haematopoietic stem cells, can bind 
to endothelial cells from the umbilicus with TNFα potentiating this effect (Rüster et al. 2006). 
MSCs therefore, also have the required tools to home and migrate.  
Comment: The published literatures shows the interaction of SDF-1 and CXCR4 is essential 
in stem cell niche maintenance and for migration to a site of injury to facilitate healing. 
Therefore, if I intervene with the SDF1-CXCR4 axis, I may be able to utilise endogenous 
stem cell therapy for fracture healing, potentially through MSC and EPC mobilisation. 
1.7 Stem cell mobilisation 
An intentional forced egress of cells, termed ‘mobilisation’, has been in clinical use for some 
time with haematopoietic stem cells. These cells are mobilised from the bone marrow for 
bone marrow transplantation to treat a range of blood related malignancies (Broxmeyer et al. 
2005; Liles et al. 2003; Martin et al. 2006; Bendall & Bradstock 2014). GCSF was the first 
growth factor used to mobilise haematopoietic stem cells from the bone marrow and into the 
peripheral circulation for stem cell transplantation (Bendall & Bradstock 2014). The 
mechanism of stem cell mobilisation by GCSF involves increased production of CD34+ 
cells within the bone marrow, proteolytic cleavage of VCAM-1 (Lapidot & Petit 2002), and 
SDF1 (Lévesque et al. 2003), such that the adherence of stem cells to their niche is reduced 
allowing their mobilisation into the peripheral circulation.  
1.7.1 AMD3100 in haematopoietic stem cell mobilisation 
AMD3100, (1,1-[1,4-Phenylenebis(methylene)] bis-1,4,8,11-tetraazacyclotetradecane 
octahydrochloride), is a symmetric bicyclam derivative and was initially found as a 
functional contaminant when screening commercially available cyclams for HIV treatment. 
AMD3100 affects the CXCR4 receptor, which was shown to be the route of entry for HIV 
into T cells. AMD3100, as a non-peptide antagonist, is now thought to cause conformational 
constraint upon the CXCR4 receptor (Gerlach et al. 2001), preventing SDF1 binding.  
During phase I clinical trials, it caused further unexpected results with a leukocytosis in 
treated patients. Later work confirmed mobilisation of a population of CD34+ 
haematopoietic stem cells into the peripheral circulation by highly selective, high affinity 
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competitive blockade of the CXCR4 receptor (Rosenkilde et al. 2004; De Clercq 2009), 
displacing them from the bone marrow niche. Currently, it is used as MozibilTM, to mobilise 
rapidly high numbers of haematopoietic stem cells from the bone marrow into the peripheral 
circulation for transplantation in haematological cancers, sometimes in synergistic 
combination with GCSF (Lévesque et al. 2003; Hendrix et al. 2000; Calandra et al. 2008) 
(Figure 1.6a).  
1.7.2 AMD3100 in non-haematopoietic stem cell mobilisation 
Although haematopoietic stem cells have been successfully mobilised, work on MSC and 
other progenitors is limited. These cells do not seem to be as migratory as hematopoietic 
stem cells, potentially due to their larger size and increased niche adherence (Lévesque et al. 
2007). Pitchford’s seminal work on different mobilisation protocols in mice, demonstrated 
that AMD3100 combined with VEGF rather than GCSF, preferentially mobilises a 
population of MSCs and EPCs, rather than haematopoietic stem cells (Pitchford et al. 2009). 
 
Figure 1.6: a) Diagram showing the postulated effect of mobilising MSCs from their niche, by the 
binding of AMD3100 to the CXCR4 receptor leading to displacement into the circulation. b) Diagram 
showing the proposed beneficial mechanism of mobilising MSCs from the niche in the presence of a 
fracture with high expression of SDF1 to increase the numbers of MSCs available to home to the 
fracture.  
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Only a few groups have started to investigate mobilisation of stem cells to augment bone 
healing. If it is possible to increase the pool of circulating stem and progenitors cells by 
using mobilising agents, this could increase the number of cells available to home to the 
fracture site, and potentially enhance healing (Figure 1.6b). To date, critical sized calvarial 
defects have shown enhanced healing with 15 daily injections of AMD3100 in mice (Wang 
et al. 2011), and McNulty showed significant improvement in intramedullary trabecular bone 
re-formation with a single dose of AMD3100 (McNulty et al. 2012). For evaluation in 
diaphyseal long bone fracture healing, there are two publications in mice. Kumar et al. 
mobilised MSCs using IGF1 with AMD3100 in a tibial segmental defect that was externally 
coapted. On DXA scan, they showed a significant increase in bone mineral density and an 
increase in bone mineral content, however their paper did not give detailed assessment of 
fracture healing (Kumar & Ponnazhagan 2012). Yellowley’s group used AMD3100 alone 
once daily for three days after creating an Einhorn style mouse femoral fracture stabilised 
with a single intramedullary pin. They showed a significantly larger fracture callus at 21 
days which became significantly smaller by 84 days, suggesting accelerated remodelling 
(Toupadakis et al. 2013). Kumar’s study did not provide much detail on the fracture healing, 
and both Kumar and Toupadaki’s studies were subject to a highly variable mechanical 
fracture healing environment and used models expected to heal. Notably, it has also been 
shown that prolonged treatment with AMD3100 over the course of fracture healing has an 
inhibitory effect, reducing the mineralised and cartilaginous callus volume, down regulating 
genes associated with endochondral ossification, probably by blocking homing to the 
fracture itself (Toupadakis et al. 2012).   
Comment: There is a role of SDF1 and CXCR4 in fracture healing, and evidence for 
selective stem cell population mobilisation, potentially enhancing fracture healing. I 
intended to evaluate this proposition using a mechanically standardised model, without 
guaranteed healing, to determine whether endogenous stem cell mobilisation, in particular 
MSC mobilisation may improve compromised fracture healing. I shall evaluate AMD3100 
with growth factors that have been used to mobilise stem and progenitor cells for boosting 
fracture healing.  
1.8 Research gap & context of thesis 
It is currently unknown whether the combination of VEGF and AMD3100 will mobilise 
MSCs and EPCs in a rat model. Further, evaluation of endogenous mobilisation has not been 
performed in a mechanically standardised fracture model, which has impaired healing, more 
akin to the translational clinical situation. A direct comparison between differing 
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combinations of growth factors and AMD3100 to boost fracture healing is also not currently 
available.  
The research questions were: 
1. Is it possible to mobilise MSCs and EPCs in rats by administering AMD3100 
combined with VEGF? 
2. What is the ideal critical sized defect, stabilised with a micro external fixator, to 
evaluate endogenous mobilisation? 
3. What is the most effective combination of growth factor with AMD3100 to improve 
fracture healing? 
1.9 Thesis aims & hypothesis 
The aims were:  
1. To establish whether it is possible to increase the circulating numbers of MSCs and 
EPCs, as measured by CFU count, through mobilisation in a rat model, and to 
compare them to bone marrow stromal cells and adult endothelial cells.  
2. To improve the ease and consistency of application, and to reduce complications 
such as pin tract loosening, with the micro femoral fixator system used at IOMS. 
3. Using the updated rat femoral fixator system, to determine the preferred osteotomy 
gap to evaluate endogenous mobilisation to improve fracture healing, in addition to 
establishing the effect on interfragmentary strain and construct stiffness.  
4. Using the improved fixator and the preferred mechanical environment, to evaluate 
different mobilisation strategies on impaired fracture healing in vivo.  
The main hypothesis of my thesis was: Antagonism of the CXCR4-SDF1 axis can 
mobilise stem and progenitor cells into the circulation of rats and by increasing the 
available pool of cells early in fracture healing, improve fracture healing.  
1.10 Potential benefits 
Should this methodology of endogenous mobilisation show potential, this may be an 
appropriate prophylactic adjunct to give to ‘at risk’ fractures, such as fragility fractures, 
tibial fractures, open high energy comminuted fractures, or those with comorbidities for 
impaired healing. Endogenous mobilisation may provide an additional biological stimulus 
when operatively treating established non-unions. 
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CHAPTER 2: Isolation & Characterisation of Mesenchymal 
Stem Cells & Endothelial Cells 
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2.1 INTRODUCTION 
The potential of bone marrow to generate a bone ossicle dates back to classical 
transplantation experiments of Goujon in the nineteenth century, where bone marrow from 
rabbits and chickens formed ectopic bone with marrow, in muscle recipient beds (Bianco et 
al. 2008). Alexander Friedenstein went on to identify a fibroblastic type cell with plastic 
adherence, within bone marrow stromal cells (Friedenstein et al. 1968). Following 
Friedenstein’s seminal work, different methods have been used to isolate MSCs from bone 
marrow, including isolation by plastic adherence (Friedenstein et al. 1970), gradient density 
separation (Pittenger et al. 1999) and sorting combined with selection through cell surface 
markers (Gothard et al. 2014). Due to the ease of obtaining cells, and the small volumes of 
tissue available in rodent models, direct plating of bone marrow for plastic adherence is 
commonly used, however, this technique results in a population of cells that are not a pure 
stromal culture, although this may actually be beneficial with improved growth of CFU-Fs 
(Mareschi et al. 2012). 
2.1.1 Characterising mesenchymal stem cells 
Once a culture is obtained, it is necessary to confirm ‘stemness’ or multipotency by 
differentiation down at least two lineages in vitro (Pittenger et al. 1999). In vitro 
differentiation of MSCs by incubation with insulin, 1-methyl-3-isobutylxanthine, 
indomethacin and dexamethasone will drive adipogenic differentiation and lipid vacuole 
development (Pittenger et al. 1999; Augello et al. 2010). Alternatively, when supplemented 
with dexamethasone, ascorbate and β-glycerolphosphate, MSCs become cuboidal and 
produce calcium deposits as osteoblasts (Friedman et al. 2006). Finally, if centrifuged to 
create a pelleted micromass and cultured without serum but with TGFβ supplementation, the 
cells form a proteoglycan rich matrix, consistent with cartilage production (Pittenger et al. 
1999; Augello et al. 2010). Their in vitro ability to differentiate is classically used in 
conjunction with their CFU-F forming self-renewal as confirmation of cell type. Importantly, 
in the contradictory and complex field of mesenchymal stem cell biology, when bone 
marrow stromal cells are transplanted in vivo they can develop into a fully fledged ‘bone 
organ’, without the need for exogenous growth factors to cue bone formation (Owen & 
Friedenstein 1988; Bianco et al. 2013). Although there is evidence that MSCs can be sourced 
from a range of adult tissues based upon in vitro criteria (da Silva Meirelles et al. 2006), the 
in vivo evidence is lacking. There is a consideration that bone marrow MSCs are currently 
the most appropriate target for managing bone tissue related healing (Bianco et al. 2013) and 
hence is the stem cell source of choice to improve fracture healing. 
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Cell surface markers are a further method to characterise cells. Again, this is complex as 
there is no defining unitary cell surface marker for MSCs, and many of the markers used to 
identify MSCs are expressed on a range of other cells types. Ultimately, a panel of absent 
and present markers are employed, however, species antibody cross-reactivity, variable 
expression levels and lack of cell type-specific expression creates difficulties (Boxall et al. 
2012). Although there is an international consensus statement for a set of markers which 
should or should not be expressed on human MSCs (Dominici et al. 2006), many research 
publications have used different markers, or differing combinations. This is further 
complicated by the effect of in vitro culture on marker expression and inherent species 
differences (Boxall & Jones 2012; Spencer et al. 2011). Although there are numerous 
monoclonal antibodies available for the human and mouse, there are significantly fewer for 
the rat, however the rat is a better model for bone research due to its increased size over the 
mouse. Based on previous work in the rat, the working definition of MSCs used in this thesis 
included low expression of both CD45 (leukocyte marker) and CD34 (haematopoietic stem 
cell marker) and high expression of CD29 and CD90 (Boxall et al. 2012; Davies et al. 2015; 
Spencer et al. 2011; FafianLabora 2015).  
CD34 was first identified on haematopoietic stem cells and is used for cell isolation and 
enrichment in bone marrow transplantation. CD34 is a transmembrane phosphoglycoprotein, 
however its function has not been fully elucidated, although a role in cell adhesion, 
differentiation and proliferation is suggested (Lin et al 2013). Usually considered a marker of 
haematopoietic stem cells, it is also seen in some endothelial progenitors, embryonic 
fibroblasts, potentially some isolates of MSCs, dendritic cells and epithelial progenitors 
(Sidney et al. 2014; Lin et al. 2012). Notably, it is positively expressed in adipose derived 
MSCs, although in vitro culture does reduce this (Lin et al 2013).  
CD45, a receptor-like protein tyrosine phosphatase cell surface marker, is expressed on all 
haematopoietic cells (other than red blood cells), platelets and plasma cells, and hence 
considered a pan-leukocyte marker, with a role in signal transduction. Nearly all literature 
sites absence of CD45 as a criterion for MSC identification and there is only one report of 
CD45 expression on MSCs (Yeh et al. 2006). Currently, the prevailing literature identifies 
the co-absence of CD34 and CD45 as characteristics of MSCs in culture (Boxall et al. 2012; 
Dominici et al. 2006). 
CD90 (Thy-1), originally discovered as a thymocyte antigen, is a glycophosphatidylinositol 
(GPI) coupled receptor, thought to mediate cell to cell interactions (Lin et al 2013). It may 
have a role in MSC differentiation (Moraes et al. 2016), and molecular targeting to reduce 
expression of CD90 in MSCs resulted in increased adipogenic and osteogenic differentiation. 
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CD90 is universally expressed on MSCs isolated from any source, however it is not 
exclusive to MSCs (Boxall et al. 2012).  
CD29, also known as integrin beta-1, is a transmembrane protein with a role in cell to extra-
cellular matrix adhesion. Again, it is expressed on a range of cells types including MSCs in a 
range of species (Boxall et al. 2012) and is frequently used in combination with CD90 in 
panels to identify MSCs (Boxall et al. 2012; Davies et al. 2015). 
Currently, the international Society for Cellular Therapy have established three criteria for 
identification of human MSCs: 1) tissue-culture plastic adherence, 2) expression of CD105, 
CD73, CD90 and lack of CD45, CD34, CD14 or CD11b, CD79a or CD19, HLA-DR, and 3) 
capacity to differentiate down osteoblastic, adipogenic and chondrocytic lineages under in 
vitro differentiating conditions (Dominici et al. 2006). The cells in this chapter were 
evaluated for plastic adherence, in vitro tri-differentiation and cell surface marker expression. 
Of the four CD markers in my panel, CD90 (Thy-1), CD45 and CD34 are all cited as key 
markers in the position statement.  
2.1.2 Characterising endothelial progenitor cells  
Endothelial progenitor cells (EPCs) were also of interest as the mobilisation strategies used 
in chapters 3 and 6 mobilise EPCs as well as MSCs into the peripheral circulation (Pitchford 
et al. 2009). Further, there is also a role for vascularisation during bone formation and 
fracture healing	 (Keramaris et al. 2008; Hankenson et al 2011; Rhinelander 1968) and 
blocking angiogenesis has been shown to drive atrophic non-union development 
experimentally (Hausman et al. 2001). Clinical data also supports their role in fracture 
healing, with EPCs being significantly increased in the peripheral blood after fracture (Ma et 
al. 2012). Additionally, models of distraction osteogenesis and fracture healing have shown 
increases in circulating EPCs, peaking at day three, but remaining high throughout healing 
(Lee et al. 2010). Culture expanded and locally transplanted EPCs have also increased bone 
healing and avoided non-union development in a rat femoral defect model. The subsequent 
microCT analysis showed a significant increase in bone volume, trabecular number, 
trabecular thickness and spacing (Li et al. 2011). However, it is unclear how EPCs improve 
fracture healing (Atesok et al. 2010). The previous paradigm of blood vessel formation was 
that new blood vessels form from proliferation and migration of the local undamaged 
endothelium, known as ‘sprouting’. However, in the 1960s, it was noted that Dacron patches 
would become covered in endothelium (Stump et al. 1963) and the source was circulating 
CD34+ bone marrow cells (Shi et al. 1998), now referred to as EPCs. More recent studies 
have shown that EPCs can differentiate into endothelial cells and contribute to 
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neovascularisation (Ward et al. 2007). 
Peripherally circulating bone marrow derived EPCs were first described by Asahara et al., 
after culturing CD34+ cells on fibronectin in the presence of certain growth factors. After 
seven days in culture they showed endothelial characteristics, including amongst others, 
expression of endothelial markers VEGFR2 and CD31, and the ability to form tube-like 
structures (Asahara et al. 1997). CD31 is also known as platelet endothelial cell adhesion 
molecule (PECAM-1) and is expressed on several cell types but reliably seen on endothelial 
cells (DeLisser et al. 1994). VEGFR2 is a receptor tyrosine kinase, (also known as KDR 
(kinase domain region) and Flk-1), that has a key role in proliferation, migration and survival 
of endothelial cells (Ferrara et al. 2003). 
Since Asahara et al., some groups have corroborated and others have shown different marker 
expression and described different types of EPCs, leading to confusion in this field (Mund & 
Case 2011; Patel et al. 2016; Minami et al. 2015). The confusion is further confounded by 
the presence of two distinct cell morphologies seen in culture. The “early-outgrowth EPCs” 
with a spindle shaped morphology (Hur et al. 2004), have been most extensively studied and 
are from monocytic lineages, poorly proliferate and often die during prolonged culture 
(Ward et al. 2007). The “late-outgrowth EPCs” are usually seen after two weeks of culture 
and colonies of cells typically show a cobblestone morphology (Hur et al. 2004), resembling 
differentiated endothelial cells. Current thinking is that the two EPCs types may have 
complimentary roles, with early EPCs expressing inflammatory cytokines and paracrine 
angiogenic factors, whereas late EPCs express proliferation and angiogenesis genes driving 
tubulogenesis (Cheng et al. 2013). This difference may also influence their effect on fracture 
healing, as when transplanted, early-outgrowth EPCs improved segmental fracture healing 
more than late EPCs. The early-outgrowth EPCs appear to have trophic effects with higher 
VEGF expression (Giles et al. 2017); perhaps having similarity to the functional paracrine 
properties of MSCs. In a similar vein, in vitro plasticity of human MSCs towards an 
endothelial gene expression profile and morphology, has been shown experimentally 
(Janeczek Portalska et al. 2012). 
2.2 Plan for chapter 2 
In this chapter I planned to isolate and evaluate rat bone marrow MSCs, to form a baseline 
comparison for assessment of endogenously mobilised blood MSCs in chapter 3. In order to 
develop the methodology and assess the EPCs isolated in chapter 3, I chose to work with 
human umbilical vein endothelial cells (HUVECs) as a gold standard for endothelial cells. 
Owing to the confusion in definitions for EPCs, and the possible isolation of late or early-
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outgrowth cell populations, I sought a clearly defined population with known characteristics 
including VEGFR2 and CD31 expression, microvascular network formation and a clear 
monolayer polygonal cell morphology, “cobblestones”, distinct from fibroblasts (Jaffe et al. 
1973). Additionally, HUVECs are readily available at relatively low cost and are frequently 
the cell of choice to compare endothelial progenitors against (Bou Khzam et al 2015; 
Asahara et al. 1997; Shi et al. 1998; Bompais et al. 2004). I therefore planned to evaluate the 
expression of my monoclonal antibodies for CD31 and VEGR2, and also functionally test in 
vitro tube formation using extracellular matrix synthesised by Engelbreth-Holm-Swarm 
tumour cells, often referred to as Matrigel or Geltrex on HUVECs (ThermoFisher, UK) 
(Faulkner et al. 2014; DeCicco-Skinner et al. 2014).  
Hypotheses: 
• Bone marrow derived MSCs isolated by tissue culture plastic adherence from 
rat femoral bone marrow form CFU-Fs, and can be expanded and 
differentiated into osteoblasts, adipocytes and chondrocytes in vitro, and have 
high expression of CD90 & CD29, and low expression of CD45 & CD34. 
• Adult endothelial cells (HUVECs) have a cobblestone cell morphology, are able 
to form tubule-like arrangements in vitro when plated on Geltrex 
(ThermoFisher, UK), and would positively express endothelial cell markers 
CD31 & VEGFR2.  
 
The aims and objectives of this chapter were: 
1. To isolate bone marrow MSCs and expand in 2-dimensional cell culture. 
2. To identify bone marrow MSCs by their cell surface marker expression and cell 
culture characteristics. 
3. To differentiate bone marrow MSCs into osteoblasts, adipocytes and chondrocytes. 
4. To expand Human Umbilical Vein Endothelial Cells (HUVEC) in 2-dimensional 
cell culture. 
5. To confirm Endothelial cell identity by their cell surface marker expression, cell 
culture characteristics and in vitro tube formation assay. 
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2.3 MATERIALS & METHODS 
2.3.1 Bone marrow MSC isolation & characterisation 
Healthy, ex-breeder female wistar rats were the donors (n=3). All procedures were carried 
out according to the Home Office Animals Scientific Procedures Act of 1986. The rats were 
euthanised via cervical dislocation. The skin over the femur was clipped and aseptically 
prepped with 4% chlorhexidine solution (Hibiscrub, UK). The limb was draped with a sterile 
fenestrated drape and under aseptic conditions, a lateral skin incision from dorsal to the 
greater trochanter to the proximal tibia was made to expose the musculature of the femur, 
and the femur was dissected out. Femora were placed in a sterile universal container with 
Dulbecco’s Modified Eagle Medium low Glucose (DMEM) (Sigma-Aldrich UK) with 1% 
Pen-strep (Invitrogen, UK) for transport. Under a tissue culture hood, the femora were 
washed in 70% isopropyl alcohol and then sterile PBS. All soft tissues were removed and 
both ends of the bone were resected using a no.10 scalpel blade to expose the medullary 
canal. The medullary canal was flushed with 5mls of stem cell culture media (DMEM 4500 
mg/L glucose, Sigma-Aldrich, UK) with 20% fetal calf serum (FCS) and 1% 
penicillin/streptomycin) using a 21g needle and syringe, into a 25cm2 polystyrene cell 
culture flask (Corning, USA). The cells were cultured in a humidified incubator at 37°C, 
95% air and 5% CO2. The media was changed after 5-7 days to remove non-adherent cells 
and every 3-4 days thereafter. Within 7-10 days, colonies became apparent. Once they had 
reached 70-80% confluence, they were “passaged” or expanded, typically around 10-14 days 
post seeding using 1% Trypsin-EDTA (Sigma-Aldrich, UK), applied to cover the surface of 
the flask. The flask was incubated at 37°C for five minutes, during which time the cells lost 
their adhesion to the cell surface, rounded and lifted off. The trypsin was neutralised by the 
addition of at least the same volume of media. Passage 3 (P3) cells were used in subsequent 
studies. The cell suspension was pelleted by centrifugation at 2000rpm for five minutes. The 
supernatant was discarded and the cells were re-suspended in media and plated in 75cm2 cell 
culture flasks (Corning, USA).  
A cell viability count was performed using a 0.4% Trypan Blue solution (Sigma-Aldrich, 
UK); a small quantity of the cell suspension was removed and then added in a 1:1 ratio with 
Trypan Blue. A haemocytometer was used to count the number of viable cells. Trypan Blue 
has a negatively charged azo chromophore which binds to damaged cell membranes only. 
Therefore, unstained bright cells are live, and dark blue stained cells are considered dead. 
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Cell surface marker analysis of rat bone marrow MSCs 
After trypsinisation and washing in PBS, P3 cells were suspended in 200ul 4% formalin for 
15minutes at room temperature. Cells were then centrifuged at 2000rpm for five minutes to 
pellet the cells and remove the formalin. They were then washed twice with flow cytometry 
buffer (PBS + 0.5% Bovine serum antigen (BSA) (Sigma-Aldrich, UK)). The cells were then 
aliquoted into micro-Eppendorf tubes for staining (30,000 per group) with the appropriate 
antibodies at the recommended concentration for one hour, in the absence of light, at room 
temperature. After one hour, the cells were pelleted and then washed twice in blocking 
buffer (PBS+0.5% BSA) and kept at around 40C by placing on wet-ice. Analysis was 
performed using a flow cytometer (Cytoflex, Beckman Coulter, UK) with Cytexpert 
(Beckman Coulter, UK) software. Debris was removed from analysis via gating on a forward 
- side scatter plot. Doublets were subsequently gated out and colour compensation was 
applied.  
Two negative markers for MSCs were used based on published literature for rat MSCs: 
• CD34 (Anti-CD34 antibody [ICO-115] Phycoerythrin, IgG1 K, abcam ab187284) 
• CD45 (Anti-Rat CD45 APC, IgG1 K, eBioscience 17-0461)  
Two positive markers for MSCs were used based on published literature for rat MSCs: 
• CD90 (Anti-Mouse/Rat CD90.1 (Thy-1.1) APC, Mouse IgG2a K, eBioscience, 17-
0900) 
• CD29 (Anti-Mouse/Rat CD29 (Integrin beta 1) FITC, Armenian Hamster IgG, 
eBioscience, 11-0291) 
Isotype controls for each CD marker as follows: 
• For CD34: Mouse IgG1 K Isotype Control PE (eBioscience 12-4714) 
• For CD45: Mouse IgG1 K Isotype Control APC (eBioscience 17-4714) 
• For CD90: Mouse IgG2a K Isotype Control APC (eBioscience 17-4724) 
• For CD29: Armenian Hamster IgG Isotype Control FITC (eBioscience 11-4888) 
MSC tri-differentiation 
Plastic adherent cells with fibroblastic morphology were isolated and expanded by serial 
passage. Tri-differentiation capacity (osteogenic, adipogenic and chondrogenic potential) 
was determined from P3 cells (n=3). Cells were freed using trypsin-EDTA (Sigma-Aldrich, 
UK) and then counted by Trypan blue staining (Sigma-Aldrich, UK) and then subdivided to 
achieve appropriate cell suspension densities for subsequent experiments.  
	 77	
2.3.1.1.1 Osteogenic differentiation 
Osteogenic media consisted of standard media with 100nM dexamethasone (Sigma-Aldrich, 
UK), 50µg/ml L-ascorbic acid 2-phosphate (Sigma-Aldrich, UK) and 10mM Glycerol-2-
phosphate disodium salt hydrate, (Sigma-Aldrich, UK). For osteogenic differentiation, 
30,000 P3 cells (n=3) were seeded into a sterile 48 well plate in triplicate and initially 
cultured in standard media for 48 hours, which allowed the cells to adhere and form a 
confluent monolayer. After this period, the media was changed for osteogenic media and 
subsequently changed every 3-4 days for 21 days. For controls, 30,000 P3 cells were seeded 
into a sterile 48 well plate, in triplicate, with standard media throughout. Cells were grown at 
37°C, 95% air and 5% CO2. 
To identify calcium phosphate deposits positively from differentiated osteoblasts, Alizarin 
red stain was applied. The stain is an anthraquinone derivate and binds positively charged 
ions such as magnesium, strontium and calcium, staining them red. The osteogenic media 
was carefully aspirated to avoid disturbing calcium phosphate deposits and the wells were 
washed in 150µl of PBS. 150µl of 10% formalin was added to each well and then left at 
room temperature for 30 minutes. The formalin was then carefully aspirated and the wells 
washed again in 150µl of PBS. Prepared Alizarin red stain (0.2 Molar, pH 4.32, Sigma-
Aldrich, UK) was added to each well to cover the surface of the base of the well and then left 
at room temperature for 30 minutes, in the dark. The stain was then carefully removed and 
the wells were washed three times in PBS until the solution became clear. A small amount of 
PBS was added to cover the base of the well prior to visualisation using light microscopy.  
2.3.1.1.2 Adipogenic differentiation 
Adipogenic media consisted of standard media with 0.1mM dexamethasone (Sigma-Aldrich, 
UK), 0.45 mM 3-Isobutyl-1-methylxanthine (Sigma-Aldrich, UK), 10mg/ml Insulin 
(1.7mmol/L) (Sigma-Aldrich, UK), and 50mM Indomethacin (Sigma-Aldrich, UK). For 
adipogenic differentiation, 30,000 P3 cells were seeded into a sterile 48 well plate in 
triplicate. After 48hours of culturing in standard media, the cells were confirmed to have 
adhered and the media was changed for adipogenic media and subsequently changed every 
3-4 days for 21 days. For negative controls, 30,000 P3 cells in triplicate were fed with 
standard media throughout. Cells were grown at 37°C, 95% air and 5% CO2. The Oil red O 
stain was used to confirm adipogenic differentiation by staining intracellular lipid droplets. 
Oil red O is a lysochrome diazo dye that binds to neutral triglycerides and lipids, staining 
them red. A 0.5% (w/v) Oil Red O stock solution was prepared in isopropyl alcohol and 
incubated at room temperature for one hour and then filtered through a 0.22µm filter to 
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remove precipitates. After 21 days of culture, cells were washed with PBS and fixed in 4% 
formalin for five minutes, then washed with PBS. Adipogenic media was aspirated and the 
wells were carefully washed in PBS. Wells were then fixed using 4% paraformaldehyde for 
three minutes at room temperature, which was then carefully removed and washed with PBS. 
A 60% isopropanol solution was then added to cover the bottom of the wells and incubated 
for 15 minutes, and then aspirated. Working Oil Red O solution was added to ensure the base 
of each well was covered, and then left for 15 minutes at room temperature. After removal, 
the wells were washed twice with PBS and then covered in a small volume of PBS to 
identify staining at x40 using a light microscope.  
2.3.1.1.3 Chondrogenic differentiation 
Chondrogenic media consisted of 100ml StemPro® Osteocyte/Chondrocyte Differentiation 
Basal Medium StemPro® (Gibco, UK), + 10ml serum free, transforming growth factor-β3 
supplemented (StemPro® Chondrogenesis Differentiation Kit, Gibco, UK), Chondrogenesis 
Supplement. For chondrogenic differentiation, 1,000,000 P3 cells were suspended in a sterile 
universal container, in triplicate. The cells were pelleted by centrifugation at 2000rpm for 
five minutes. After 48 hours of culture in standard media, the media was changed for 
chondrogenic media: serum free, supplemented with transforming growth factor-β3, and 
subsequently changed every 3-4 days for 21 days. For negative controls, 1,000,000 P3 cells 
were pelleted as described and fed with standard media, in triplicate, and changed every 3-4 
days. Cells were grown at 37°C, 95% air and 5% CO2. After 21 days, cells were stained with 
Alcian Blue, a polyvalent basic dye that binds to acidic polysaccharides such as 
glycosaminoglycans in cartilage, staining them blue. Cell spheroids were washed in PBS and 
fixed with 10% formalin for 60 minutes at room temperature, before being washed with 
distilled water. Alcian blue solution (Sigma-Aldrich, UK) was added and then the spheroids 
were incubated for 24 hours at room temperature. The stain was removed and then a de-
staining solution (30mls Ethanol (pure: 98-100%), + 20mls Acetic Acid) was added and 
removed twice. Spheroids were then viewed for blue staining indicating cartilage matrix 
deposition. 
2.3.2 Endothelial cell characterisation 
HUVECs from a single donor (500,000 cryopreserved Promocell C-12200, Promocell, UK) 
passage 5, cell line 1915, were evaluated. Cells were grown in a 75cm2 polystyrene cell 
culture flask and cultured in a humidified incubator at 37°C, 95% air and 5% CO2. 
Endothelial growth media was made from EBM-2 Basal Medium 500 ml (Lonza, UK) 
combined with EGM-2 MV BulletKit  (CC-3202, Lonza, UK), containing 5% fetal bovine 
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serum, human VEGF-1, human fibroblast growth factor-2, human epidermal growth factor, 
insulin-like growth factor-1, ascorbic acid, amphotericin and gentamycin. The media was 
changed after one day and then every 3-4 days. Once they had reached 70-80% confluence, 
they were subject to tubule assays and flow cytometric analysis. 
Cell surface marker analysis of HUVECs.  
P5 cells were passaged using Trypsin-EDTA as previously described. For each analysis 
100,000 P5 cells were suspended in 100µl 4% formalin for 15 minutes at room temperature. 
Cells were then centrifuged at 2000 rpm for five minutes to remove the formalin. They were 
then washed twice with flow cytometry buffer (PBS + 0.5% BSA). The cells were aliquoted 
into micro-Eppendorf tubes for staining with the appropriate antibodies for one hour, in the 
absence of light at room temperature. After one hour, the cells were pelleted and then 
washed twice in blocking buffer (PBS + 0.5% BSA). All work was carried out on ice. Flow 
cytometry analysis was performed as described for the MSCs. Cells were evaluated for EPC 
markers: 
• Anti-VEGFR-2 (KDR/EIC) (Fitc) (abcam ab184903) 
• CD31 (TLD-3A12) (Fitc) (abcam ab33858) 
Cells were also evaluated for lack of CD34 expression indicative of haematopoietic 
progenitors, and CD90 indicative of mesenchymal stem cells: 
• CD34 (Anti-CD34 antibody [ICO-115] Phycoerythrin, IgG1 K, abcam ab187284) 
• CD90 (Anti-Mouse/Rat CD90.1 APC, Mouse IgG2a K, eBioscience, 17-0900) 
Controls included unstained cells, and isotype controls for each CD marker as follows: 
• For CD34: Mouse IgG1 K Isotype Control PE (eBioscience 17-4714) 
• For CD90: Mouse IgG2a K Isotype Control APC (eBioscience 17-4724) 
• For VEGFR2: Mouse IgG1 (ICIG1) (Fitc) (abcam ab91356) 
• For CD31: Mouse IgG1 (ICIG1) (Fitc) (abcam ab91356)	
Functional 3D tube forming assay  
When the HUVECs were confluent, the media was removed and cells were serum deprived 
by replacing with low serum media: EBM-2 Basal Medium 500 ml (Lonza, UK) + 1% FCS 
and incubated in a humidified incubator at 37°C, 95% air and 5% CO2 for two hours. A 96 
well plate was pre-cooled to 5°C and then all work was performed on ice. Per well, 2µl of 
5°C Geltrex™ ‘LDEV-Free Reduced Growth Factor Basement Membrane Matrix’ 
(ThermoFisher Scientific, UK) was placed in the centre of each well and then carefully 
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spread across the entire base of each well using a sterile applicator (Faulkner et al. 2014). 
Control and inducted wells were performed in triplicate. The plate was then incubated at 
37°C for 45 minutes to polymerise the Geltex. After two hours of serum deprivation, cells 
were trypsinised as previously described and then re-suspended in serum-deprived media 
and counted. Cells were re-suspended to achieve 5,000 cells per well, in 100µl of either full 
media (containing associated growth factors) or low serum media. Phase-contrast images 
were acquired using a Leica DMIRB (Leica, Germany) inverted microscope (×10 
magnification).  
2.4 RESULTS  
2.4.1 Isolation & culture of rat bone marrow MSCs 
By seven days of primary culture, fibroblastic-spindle shaped cells were adherent to the 
surface of the plastic culture flask and fibroblastic colony-forming units (CFU-F) were seen 
(Figure 2.1a). Each colony had originated from a single precursor mesenchymal stem cell. 
The cells had a clear flat fibroblastic morphology at later passages (Figure 2.1b and c). 
 
Figure 2.1: Light microscopy images of bone marrow MSCs at various stages. a) Passage 0 MSCs 
colony (day 10, x4 magnification). b) Passage 3 MSC (day 10, x5 magnification). c) Passage 3 MSCs 
(day 10, x10 magnification). Cells were flat and spindle shaped, characteristic of a CFU-F. 
 
200μm%
a b#
c#
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Cell surface marker analysis of rat bone marrow MSCs 
A scatter plot of forward scatter versus side scatter showed a distribution of similar sized 
cells indicative of a cultured mono-population with a region of dead cells and debris relating 
to the processes involved in preparation for flow cytometry (Figure 2.2a). A dot plot of 
forward scatter area versus forward scatter height showed minimal variation indicative of a 
largely single cell pollution, however, it was gated to eliminate any possible doublets (Figure 
2.2b). This cell population showed a lack of positive shift of increased fluorescence when 
compared with isotype fluorochrome control background levels, indicative of low/negative 
expression of known negative MSC markers CD34 and CD45 (Figure 2.3). Concomitantly, 
these cells showed a right shift indicating increased fluorochrome intensity compared with 
the isotype control level for mesenchymal stem cell markers CD90 and CD29 (Figure 2.4). 
Cells isolated from all three rat donors showed similar cell surface expression patterns, being 
predominantly CD34 negative (99.8%), CD45 negative (94.3%), CD29 positive (98.4%), 
and CD90 positive (98.9%). (Table 2.1).  
a  b  
Figure 2.2: a) Flow cytometry dot plot for bone marrow MSCs, showing forward scatter vs side 
scatter for all events read. The gated region excluded dead cells and debris in the lower left corner. b) 
The gated region of live cells from the previous plot was assessed for clumping of cells. A close 
population was selected for all further analyses. (SSC-A = side scatter area, FSC-A = forward scatter 
area, FSC-H = forward scatter height.) 
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a b  
Figure 2.3: Flow cytometry histogram fluorescence counts for bone marrow MSCs. a) The red plot 
shows cells stained with PE conjugated isotype control and the green plot shows cells stained with PE 
conjugated CD34 antibody. b) The red plot shows cells stained with APC isotype control and the 
green plot shows cells stained with APC conjugated CD45 antibody. (PE-A = Phycoerythrin, APC-A 
= Allophycocyanin). In both plots, there is no right shift in fluorescence, indicating no staining above 
background, and therefore no expression of CD34 or CD45 markers on the MSCs.  
 
a  b  
Figure 2.4: Flow cytometry histogram fluorescence counts for bone marrow MSCs. Figure a) The red 
plot shows cells stained with FITC conjugated isotype control and the green plot shows cells stained 
with FITC conjugated CD29 antibody. b) The red plot shows cells stained with APC conjugated 
isotype control and the green plot shows cells stained with APC conjugated CD90 antibody. (FITC-A 
= Fluorescein isothiocyanate, APC-A = Allophycocyanin). In both plots, the right shift in fluorescence 
indicates positive expression of CD29 and CD90 markers on the MSCs. 
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Table 2.1: Individual and mean±SD flow cytometry expression levels (%) of the markers evaluated 
for bone marrow MSCs. 
 
Osteogenic differentiation of rat bone marrow MSCs 
Cells formed a monolayer on the base of the well within three days. The cell morphology 
became less spindaloid and more cuboidal and multiple small granules became apparent. 
Staining for Alizarin red after 21 days clearly demonstrated red granules indicative of 
calcium deposits, consistent with osteoblast differentiation and activity (Figure 2.5). 
a  b  
Figure 2.5: Light microscopy images of osteogenic differentiation at x4 magnification after 21 days 
culture. a) Control sample post Alizarin red staining where confluent MSCs have been treated with 
standard media. b) Positive Alizarin red staining of calcium deposits indicative of osteogenic 
differentiation.  
 
Adipogenic differentiation of rat bone marrow MSCs 
Cells formed a monolayer on the base of the well within three-five days. After 21 days of 
incubation with adipogenic media, a change in morphology was evident with cells appearing 
less spindle shaped, being shorter with longer extensions. Positive Oil Red O staining was 
evident by red dots indicating the presence of lipid and therefore adipogenesis (Figure 2.6).  
Rat % CD45+ % CD34+ % CD29+ % CD90+ 
1 0.30 0.11 99.74 99.50 
2 6.42 0.24 96.86 97.74 
3 10.29 0.22 98.54 99.59 
Mean±SD 5.7±5.0 0.2±0.1 98.4±1.4 98.9±1.0 
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a  b  
Figure 2.6: Light microscopy images of adipogenic differentiation, at x40 magnification after 21 days 
culture. a) Control sample post Oil Red O staining where confluent MSCs have been treated with 
standard media. b) Test samples with accumulations of red staining lipid droplets indicative of 
adipogenic differentiation.   
 
Chondrogenic differentiation of rat bone marrow MSCs 
Under gross observation, the chondrogenic supplemented pellets appeared to increase in size 
marginally when compared to the control samples. Staining with Alcian Blue at 21 days 
showed blue staining indicative of glycosaminoglycan synthesis, consistent with 
chondrogenic differentiation (Figure 2.7).  
 
Figure 2.7. Photographs of the pelleted MSCs after 21 days culture. a) Control media pellet without 
any blue staining. b) Pellet cultured in chondrogenic media, with positive Alcian Blue staining 
indicating chondrocyte differentiation. c) Shows the two pellets at increased zoom (control sample on 
the left, test sample on the right).  
  
a" b"
c"
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2.4.2 HUVEC cell culture 
HUVECs were grown to confluence and exhibited cobblestone morphology, distinct from 
that of the MSCs (Figures 2.8 & 2.9). 
a  b  
Figure 2.8: Light microscopy images of HUVECs in culture x4 magnification. a) At two days. b) Full 
confluence by seven days. 
 
a  b  
Figure 2.9: Light microscopy images of confluent HUVECs in culture. a) At three days. b) After 
seven days at x10 magnification. Clear cobblestone morphology quite distinct from the planar 
elongated MSCs was seen. 
 
HUVEC cell surface marker analysis 
A scatter plot of forward scatter versus side scatter showed a distribution of similar sized 
cells indicative of a cultured mono-population with a region of dead cells and debris relating 
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to the processes involved in preparation for flow cytometry. HUVECs showed positive 
expression of endothelial markers CD31 and VEGFR2 (Figure 2.10) and lacked expression 
of stem/progenitor markers CD90 and CD34 (Figure 2.11).  
a  b  
Figure 2.10: Flow cytometry histogram fluorescence counts for HUVECs. a) The red plot shows cells 
stained with FITC conjugated isotype control and the green plot shows cells stained with FITC 
conjugated VEGFR2 antibody. b) The red plot shows cells stained with FITC conjugated isotype 
control and the green plot shows cells stained with FITC conjugated CD31 antibody. In both plots, the 
right shift in fluorescence of the test population from the control indicates positive expression of 
VEGFR2 and CD31 on the HUVECs. 
 
a  b  
Figure 2.11: Flow cytometry histogram fluorescence counts for HUVECs. a) The red plot shows cells 
stained with APC conjugated isotype control. The green plot shows cells stained with APC conjugated 
CD90 antibody. b) The red plot shows cells stained with PE conjugated isotype control. The green 
plot shows cells stained with PE conjugated CD34 antibody. In both plots there is no right shift in 
expression for the test group indicating no staining above background and therefore no expression of 
CD90 or CD34 markers on the HUVECs.  
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HUVEC in vitro tube formation assay 
HUVECs plated on a Geltrex matrix and treated with full growth medium were able to form 
a clear ‘vascular’ network by 16 hours (Figure 2.12).  
a  b  
Figure 2.12: Light microscopy images at x10 magnification of HUVECs plated on Geltrex matrix. a) 
The arrangement and morphology of cells at 0 hours. b) 16 hours post plating, cells had elongated, 
aligned and formed a network.  
 
2.5 DISCUSSION 
The aim of this chapter was to characterise rat bone marrow MSCs and HUVECs as a 
benchmark for assessment of the cells I would mobilise in chapter 3. Bone marrow MSCs 
were chosen as the circulating pool of stem cells that I am interested in mobilising and are 
thought to be mainly from the bone marrow (Pitchford et al. 2009; Otsuru et al. 2008). Direct 
plating of rat bone marrow successfully resulted in the formation of CFU-Fs, with a clearly 
fibroblastic spindaloid morphology visible by five days, consistent with the work by 
Friedenstein et al. (1970). These cells were successfully passaged to P3 for all subsequent 
experiments, with an unchanged morphology indicative of replication as undifferentiated 
cells (Pittenger et al. 1999). It is acknowledged that selection by plastic adherence, although 
common, does make it impossible to obtain a pure stromal culture, however, it may be the 
best way to maximise initial yields of CFUs (Mareschi et al. 2012). 
In vitro tri-differentiation, an agreed characteristic of MSCs (Dominici et al. 2006; Pittenger 
et al. 1999) was demonstrated with the rat bone marrow MSCs I isolated. The methods I 
used to confirm stem potency were functional in vitro assays. These tests assess for the 
production of matrix, presumed to be from lineage differentiated osteoblasts and 
chondrocytes and for the production of intracellular lipid droplets, a characteristic of 
adipocytes (Pittenger et al. 1999). When subjected to osteogenic or adipogenic stimulation in 
vitro for 21 days, all samples isolated by plastic adherence formed a calcium based matrix, 
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confirmed by Alizarin Red staining, and produced lipid droplets characterised by Oil Red O 
staining respectively. Chondrocytic differentiation was also shown with pellet culture by 
staining with Alcian Blue. Chondrocyte pellet culture required a very large number of cells, 
at 1x10^6 per pellet, and when controls and replicates are used this test requires 6x10^6 cells 
per individual evaluated. It is likely therefore, that if insufficient mobilised cells are cultured 
in Chapter 3, only bi-differentiation down the osteoblastic and adipogenic pathways will be 
evaluated. Although not performed here, a further functional assay of osteoblastic 
differentiation would be to measure alkaline phosphatase production (Oreffo et al. 1998). 
In addition to classical functional assays to identify MSCs, I evaluated cell surface markers, 
as outlined in the International Society for Cellular Therapy position statement (Dominici et 
al. 2006). CD29 and CD90, although not exclusively expressed on MSCs, are considered 
mesenchymal stem cell markers, and these two markers are expressed across species and are 
widely used (Davies et al. 2015). The selection of four cell surface markers, notably the 
presence of CD29 and CD90, and absence of haematopoietic CD34 and leukocytic CD45, 
has been used for identification of rat MSCs in other studies (Fafián-Labora et al. 2015; Fu 
et al. 2012; Dezawa et al. 2004). In the absence of a single unifying stem cell marker, 
increasing the numbers of markers used increases the certainty of identity. There are several 
drawbacks however. One is the increased cost and the other is the ability to combine markers 
for simultaneous measures per cell, which is limited by the mechanics of the flow cytometry; 
the number of lasers and filters, and the available antibody fluorochromes. Often therefore, 
more cells are required for a larger panel of markers, and different combinations will have to 
be run on different batches of cells. This means there may be no definitive confirmation that 
the markers assessed between samples from the same population are truly co-expressed. 
Finally, the availability of rat cross-reactive marker antibodies is more limited than for 
human and mouse.  
The aforementioned functional assays and cell surface marker analyses are well established, 
if not without some controversy, and form the mainstay of any mesenchymal stem cell 
research. Over recent years however, some have investigated molecular assessments such as 
characteristic transcription factors to identify and understand the different aspects of MSCs 
and their differentiation. An alternative assessment of MSCs for their ‘stemness’ would be to 
look for markers of pluripotency in mRNA transcripts including Rex1, Oct4, Sox2 and 
Nanog (Fafián-Labora et al. 2015). Post in vitro differentiation, transcriptomic analysis is 
also possible for identification of lineages and associated hierarchies (Kubo et al. 2009). For 
osteoblast differentiation, runt-related transcriptome factor 2 (Runx2), also known as Cbfa1, 
is a key transcription factor of osteoblast differentiation of MSCs (Ducy et al. 1997; Frith & 
Genever 2008). Runx2 knock-out mice have a purely cartilaginous skeleton and lack 
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osteoblasts. A similar cartilaginous skeleton has been seen with another key regulator knock-
out, osterix (Giuliani et al. 2013). Current thinking is that Runx2 drives MSCs down an 
osteochondral lineage, and downstream, osterix directs to osteoblastic exclusivity (Frith & 
Genever 2008). For chondrogenic differentiation, SOX9, and its down stream pair of 
transcription factors SOX5 and 6, promote early differentiation of chondroblasts into 
chondrocytes (Ikeda et al. 2004), with knock-out studies leading to chondrodysplasias 
(Akiyama et al. 2002). For adipogenesis, peroxisome proliferator activated receptor (PPAR), 
which is a nuclear hormone receptor, is thought to play a critical role in adipogenesis (Frith 
& Genever 2008), with the absence of PPAR preventing adipogenic differentiation (Rosen et 
al. 2002). A further ‘level’ of analysis would be to look at epigenetic modulation 
(Eslaminejad et al 2013; Im & Shin 2015). These molecular means were not additionally 
pursued here due to associated costs and time limitations, and their limited benefit when 
considering the objective of this thesis. 
An important consideration of all the assays described, other than perhaps a transcriptomic 
analysis, is that it is not possible to know whether individual cells from one ‘population’ are 
truly MSCs in terms of tri-, bi- or uni-differentiation potential. Even Pittenger’s seminal 
MSC paper noted that all isolated cells could form bone, however, not all could tri- or bi-
differentiate, and the heterogeneity of cultured MSCs is now well established (Augello et al 
2010). Invariably, only a serial dilution approach or colony picking could allow evaluation 
of clonal populations. Although this is an interesting area of stem cell biology, it is not 
directly relevant to the research question addressed by this thesis, as inevitably an 
endogenously mobilised population will be heterogeneous. Perhaps a clonal population 
might be undesirable? It has been shown that homogeneity by selection for CD29 and CD90 
expression can lead to reduced ability for osteogenic and adipogenic differentiation 
compared with the unsorted mixture (Davies et al. 2015). In this situation, there may have 
been inadvertent selection of a population that suppresses or has reduced bone-forming 
ability. Heterogeneity, which is my expectation from the endogenous mobilisation, may 
provide the necessary variety and diversity of cells, including those that promote bone tissue 
formation. It is possible that the inter-relationship and paracrine signalling between a 
heterogenous group may be more important than having a mono-population of stem cells for 
bone healing and hence heterogeneity should not be viewed as necessarily bad.  
As a baseline for characterisation of EPCs, I chose HUVECs, which are well characterised 
and straightforward to obtain (Jaffe et al. 1973). The vast majority of in vitro angiogenesis 
assays have used HUVECs (Staton et al. 2009) however, it is known that there is 
heterogeneity in endothelial cells, affected by their location and hence associated organ 
function, as well as the vessel size and whether from an artery or vein (Staton et al. 2009). 
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Despite this, the optimum choice for a comparison to an EPC is unknown and hence 
HUVECs are a suitable starting point, not to mention the numerous studies evaluating EPCs 
against HUVECs (Bou Khzam et al 2015; Asahara et al. 1997; Shi et al. 1998; Bompais et al. 
2004). As expected, the HUVECs I cultured formed a monolayer of large polygonal 
cobblestones (Jaffe et al. 1973). These cells had clear expression of endothelial and EPC 
markers CD31 (Asahara et al. 1997) and VEGFR2 (Peichev et al. 2000). CD31, also known 
as platelet endothelial cell adhesion molecule (PECAM-1) is expressed on several cell types 
but reliably seen on endothelial cells (DeLisser et al. 1994), and VEGFR2 has a key role on 
proliferation, migration and survival of endothelial cells (Ferrara et al. 2003). Asahara’s 
landmark paper identified EPCs from blood within a haematopoietic CD34+ population with 
expression of VEGR2 (Asahara et al. 1997). CD133 (another haematopoietic stem marker) 
has also been used to isolate EPC cells and hence many studies relied on co-expression 
(Bongiovanni et al. 2014). These markers are thought to be associated with juvenile EPCs, 
within the bone marrow, and as they move into the peripheral circulation, CD133 and CD34 
decrease and CD31, VE-Cadherin and Von Willebrand factor are expressed (Hristov et al. 
2003). Rather than choosing early stem markers which will include precursors of lineage 
determined EPCs, I looked at later markers seen in both differentiated endothelial cells and 
EPCs. From in vitro cell culture, the early outgrowth spindaloid EPC has been shown to 
express only low levels of CD34 and CD133, moderate CD31, and high CD45. The late 
outgrowth cobblestone EPC however, have low CD45, moderate CD34 and high CD31 and 
VEGFR2 (Cheng et al. 2013). In that particular study they compared the EPCs to HUVECs 
that had high CD31 and VEGR2, and low CD133, CD34 and CD45 expression. By including 
markers that are differentially seen with bone marrow EPCs compared to circulating, and 
early-outgrowth culture compared with late-outgrowth cultured EPCs, I hope to be able to 
identify these cells in chapter 3. Alternative or additional cell surface marker analysis could 
have been performed with Von Willebrand or VE-Cadherin (Hristov et al. 2003), but again, 
there are cost considerations and more importantly there could be an issue of having 
insufficient cells for multiple analyses.  
The functional assay performed for the EPCs was in vitro 2D microvascular tubulogenesis, 
where cells are encouraged to form capillary-like tubes. 3D tube formation is possible, but is 
complex and time consuming and hence most groups only use 2D assays (Staton et al. 2009). 
Often known as a Matrigel or Geltrex assay, it involves plating the cells on a growth factor 
enriched extracellular matrix synthesised by Engelbreth-Holm-Swarm tumour cells and is 
the classical functional in vitro assay of endothelial cells and their progenitors (Faulkner et al. 
2014; DeCicco-Skinner et al. 2014). The assay involved plating endothelial cells on the top 
surface of a gel matrix, and in my study, I used the modified thin layer angiogenesis assay 
which is more sparing on the Geltrex volumes required (Faulkner et al. 2014). The 
components of the matrix signal the endothelial cells to elongate and form links leading to 
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structures akin to blood vessels and is considered to recapitulate the differentiation stage of 
angiogenesis (Staton et al. 2009). Although this is the benchmark test of function, there is 
debate, as some have shown true lumen formation others have not (Connolly et al. 2002; 
Bikfalvi et al. 1991). It is also the case that other cell types have been able to form similar 
networks, including glioblastoma cells, prostate carcinoma and primary human fibroblasts 
(Donovan et al. 2001). The test can be interpreted in a binary manner for simple 
characterisation, however it is possible to determine specific characteristics such as tube 
length, number, area and branch points for studies investigating cell function or 
pharmacological agents (Staton et al. 2009). In my study, HUVECs were able to form 
microvascular networks by 16 hours post plating and this provided a good benchmark for 
Chapter 3. A further potential functional assay is uptake of low-density lipoprotein through 
scavenger pathways (Voyta et al. 1984). Asahara initially showed the cells they isolated as 
EPCs would uptake DiI-labeled acetylated LDL (Asahara et al. 1997), and this has been 
shown elsewhere, however other cell types including macrophages and pericytes are also 
capable of LDL uptake (Whitman et al. 2000; Voyta et al. 1984). Due to the lack of 
specificity and the potential for myeloid cell contamination in populations isolated from 
peripheral blood (Chong et al. 2016), I chose not to use this test for evaluating EPCs.  
In conclusion, I have established baseline characteristics and shown efficacy of methodology 
in chapter 2 for characterisation of endogenously mobilised stem and progenitor cells in 
chapter 3. 
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CHAPTER 3: Endogenous Mobilisation of Peripheral Blood 
Mesenchymal Stem Cells & Endothelial 
Progenitor Cells 
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3.1 INTRODUCTION 
In order for bone to heal successfully, there is a need to recruit a range of cells including 
inflammatory cells, endothelial cells and stem cells, from different tissue sources including 
muscle, bone marrow, adipose tissue or periosteum (Marsell & Einhorn 2011; Einhorn & 
Gerstenfeld 2014; Tawonsawatruk et al. 2012). At rest, there are low basal levels of 
peripherally circulating skeletal progenitors, approximately 1 per 106-8 blood mononuclear 
cells (Kuznetsov et al. 2001; Zvaifler et al. 2000; He et al. 2006), and the levels of MSCs, 
(Alm et al. 2010) and EPCs (Ma et al. 2012) increase post bone fracture, with progenitor 
cells migrating from the bone marrow to a fracture site (Kumagai et al. 2008). Bone marrow 
is a well described niche for a range of stem and progenitor cells, including haematopoietic 
stem cells, EPCs and MSCs (Wilson & Trumpp 2006), and the chemokine axis of SDF1-
CXCR4 has a major role in the retention of haematopoietic stem cells within the bone 
marrow (Lévesque et al. 2003). Beyond niche maintenance, SDF1-CXCR4 has a global role 
in migration of stem cells from the circulation to the bone marrow (Peled 1999) as shown by 
CXCR4 blocking antibodies preventing bone marrow engraftment of human haematopoietic 
stem cells transplanted into SCID mice. The SDF1-CXCR4 axis also plays a role in fracture 
healing where local increases in SDF1 expression have been measured in distraction 
osteogenesis, stress fractures and segmental defects (Lee et al. 2010; Kidd et al. 2010; 
Toupadakis et al. 2012). Vascular damage causes hypoxia and increases SDF1 expression 
via HIF1α (Hirota & Semenza 2006; Ceradini et al. 2004) creating a chemotactic gradient, 
with high levels of SDF1 at the fracture site and subsequently increased levels in the blood 
facilitating stem cell migration (Yellowley 2013).  
Mobilisation of haematopoietic stem cells is a mainstay of clinical bone marrow 
transplantation to treat a range of blood related malignancies (Broxmeyer et al. 2005; Liles et 
al. 2003; Martin et al. 2006; Bendall & Bradstock 2014). GCSF was the first growth factor 
used to mobilise haematopoietic stem cells from the bone marrow into the peripheral 
circulation for transplantation (Bendall & Bradstock 2014). AMD3100, a highly selective, 
high affinity competitive antagonist of the CXCR4 receptor (Rosenkilde et al. 2004; DeClerq 
2006) commercially known as MozibilTM, rapidly mobilises high numbers of haematopoietic 
stem cells by blocking their interaction with SDF1 in the marrow niche, and is used for 
transplantation in haematological cancers (Wan 2013; Lévesque et al. 2003; Hendrix et al. 
2000; Calandra et al. 2008). In experimental rodent models, AMD3100 has been shown to 
have a ‘bell-shaped’ type dose response, with peak dosage effects of 5mg/kg and peak 
elution at one hour post administration (Broxmeyer et al. 2005).  
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Although haematopoietic stem cells have been successfully mobilised, work on MSCs and 
other progenitors is limited and these cells do not seem to be as migratory as hematopoietic 
stem cells, potentially due to their larger size and increased niche adherence (Lévesque et al. 
2007). However, MSCs share some of the adhesion molecules such as selectins and integrins 
(Sohni & Verfaillie 2013) required to undergo diapedesis, and can bind endothelial cells 
(Rüster et al. 2006). Pitchford’s seminal work on different mobilisation protocols in mice, 
demonstrated that AMD3100 combined with VEGF rather than GCSF, preferentially 
mobilises a population of MSCs and EPCs (Pitchford et al. 2009), rather than haematopoietic 
stem cells. Using this protocol and based on the number of CFUs enumerated, they were able 
to increase blood-circulating MSCs from one MSC/ml in non-mobilised controls to 15 
MSCs/ml. Likewise, EPCs increased from six to 230 CFUs/ml. They also showed that 
although AMD3100 alone increased MSCs and EPCs above resting levels (3 MSCs/ml and 
40 EPCs/ml), the combination of VEGF with AMD3100 was synergistic. This mobilising 
protocol is of interest as MSCs (Mansilla et al. 2006; Y. Wang et al. 2006; Kumagai et al. 
2008; Alm et al. 2010; Khosla & Eghbali-Fatourechi 2006; McNulty et al. 2012; Wang et al. 
2011) and EPCs (Kawakami et al. 2015; Lee et al. 2010) have both been shown to influence 
fracture healing.  
In chapter 6 I planned to evaluate the effect of endogenous stem cell mobilisation on fracture 
healing, using a mechanically controlled rat fracture model. To date, no studies have shown 
this in rats. I therefore needed to demonstrate proof of concept that VEGF and AMD3100 
could mobilise MSCs and EPCs in rats, by comparing the peripheral blood mobilised cells 
with the bone marrow isolated MSCs and HUVECs as characterised in chapter 2. 
3.1.1 Question & plan for chapter 3 
Question: Could the number of MSCs and EPCs be increased within the peripheral 
circulation by the administration of VEGF and AMD3100 in a rat model? 
Hypothesis: 
• The number of MSC CFU-Fs and EPC CFUs isolated from peripheral blood 
would be significantly higher after mobilisation using AMD3100 and VEGF 
(VEGF-AMD). 
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The aims and objectives of this chapter were: 
1. To select a methodology to prepare peripheral blood optimally for cell culture. 
• To compare red blood cell lysis and density gradient separation techniques for 
the numbers of mononuclear cells and CFUs isolated.   
2. To isolate MSCs and EPCs from rat peripheral blood with and without mobilisation 
using VEGF with AMD3100. 
3. To expand peripheral blood MSCs (PBMSC)s and peripheral blood EPCs (PBEPC)s 
in 2-dimensional cell culture and characterise them by cell morphology, surface 
marker expression and cell culture characteristics:  
• MSCs were characterised by their adherence to tissue culture plastic, formation 
of CFU-Fs, differentiation into osteoblasts and adipocytes in vitro and their high 
expression of CD90 and CD29, and low expression of CD45 and CD34.  
• EPCs were characterised by their ability to form early (spindaloid) and/or late 
CFUs (cobblestone), their expression of CD31 and/or VEGFR2, with a low 
expression of CD90 and CD45. Their ability to form microvascular type 
networks on basement membrane extract (Geltrex) was also assessed. 
3.2 MATERIALS & METHODS 
3.2.1 Assessment of techniques for isolation of mononuclear cells & CFUs 
Female Wistar rats, 12-14 weeks old (n=3) had their blood collected by terminal cardiac 
sample, without any administration of mobilising protocols. Rats were anaesthetised using 
isoflurane and placed in dorsal recumbency. The ventral midline was shaved from mid 
abdomen to mid-sternum. The skin was prepped with 4% chlorhexidine solution (Hibiscrub) 
and 70% isopropyl-alcohol. Wearing sterile gloves, the xiphoid process was palpated at the 
caudal sternum. A 1 inch 21 gauge needle attached to a 10 mL syringe and pre-primed with 
sterile heparin sodium 1,000 I.U./ml (Wockhardt, UK), was inserted midline, dorsal to the 
xiphoid and directed toward the heart. Once through the skin, gentle negative pressure was 
applied. After removing the blood, pentobarbitone was injected intra-cardiac followed by 
cervical dislocation for euthanasia. The blood was transferred to a sterile heparinised 
container (BD Vaccutainer 9 ml Lithium – Heparin, BD, UK) for transport. All procedures 
were performed at the Royal Veterinary College, under project and personal licenses 
approved by the Home Office. 
For each rat, the blood was thoroughly mixed and then divided equally between a red blood 
cell lysis procedure and a density separation protocol to isolate MNCs. Previous pilot work 
had shown that culturing unprocessed whole blood did not produce viable cultures. I also 
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determined that endothelial progenitor cells could be grown from non-mobilised peripheral 
blood, whereas MSCs could not. For that reason, the assessment of isolation efficacy was 
performed by mononuclear cell counts (MNC) and PBEPC CFU counts.  
Density gradient separation method 
For density gradient separation, whole blood was diluted 1:1 with PBS and carefully layered 
upon ficoll (Ficoll-PaqueTM PLUS, GE Healthcare life sciences, UK), and centrifuged at 
400g (RCF) for 30-40 minutes, without brake. The buffy layer was identified and carefully 
aspirated and washed with 6mls of PBS, and then centrifuged at 60-100g for 10 minutes. The 
supernatant was removed and the cell pellet was re-suspended in EPC culture media (as 
described in chapter 2 (2.3.2) for HUVEC culture. A cell viability count was performed 
using a 0.4% Trypan Blue solution (Sigma-Aldrich, UK), using a haemocytometer under a 
phase-contrast microscope.  
Red blood cell lysis method 
For Red blood cell (RBC) lysis, 10mls of lysis solution (Red Blood Cell lysing Buffer Hybri-
Max solution Sigma-Aldrich, UK), at room temperature, was added per 1ml of blood and 
mixed in a 50ml Falcon tube (Corning, USA). After five minutes, 35mls of PBS was added 
to neutralise the lysis solution and then centrifuged at 400g for five minutes. The supernatant 
was aspirated and the cells were re-suspended in EPC culture media. A cell viability count 
was performed using a 0.4% Trypan Blue solution (Sigma-Aldrich, UK), using a 
haemocytometer under a phase-contrast microscope.  
Fibronectin flask preparation & cell culture 
To determine the number of PBEPC CFUs, fibronectin coated flasks were prepared. Bovine 
fibronectin (F1141 Sigma-Aldrich, UK) was dissolved in sterile PBS to achieve a 10ug/ml 
solution. Each 25cm2 polystyrene cell culture flask (Corning, USA) was then coated with 
3mls of working fibronectin solution and each 75cm2 flask was coated with 10mls of 
fibronectin working solution to achieve 1.25ug/cm2, and then incubated at 37°C overnight. 
After incubation, excess fibronectin was aspirated and the flask washed once with PBS, prior 
to storage at 4°C in a sealed sterile container for up to four weeks.  
After the MNC count, cell suspensions were plated onto the fibronectin coated T25 flasks. 
The culture media used for EPC isolation and expansion was the EGM-2 MV (Lonza CC-
3202) media, as described in chapter 2 (2.3.2). The cells were cultured in a humidified 
incubator at 37°C, 95% air and 5% CO2. The media was changed after 5-7 days to remove 
non-adherent cells and then every 3-4 days thereafter. Colonies were counted at x4 
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magnification under a phase-contrast light microscope, using a custom-made acetate grid 
placed below the flask (Figure 3.1). Final CFU count was performed at 20±2 days. 
3.2.2 Endogenous mobilisation with VEGF and AMD3100 
Growth factor & pharmaceutical preparation 
Rat Vascular Endothelial Growth Factor 165 (VEGF) (PeproTech, USA, 400-31) was 
prepared by dissolving the lyophilized product in sterile water to make a 0.1mg/ml stock 
solution. A working solution was prepared by adding 1ml of stock solution to 4mls of sterile 
PBS + 0.1% BSA (Sigma-Aldrich, UK) to achieve a 100ug/ml injection solution which was 
then aliquoted and stored at -20°C until needed. AMD3100 (octahydrochloride hydrate, 
Sigma-Aldrich, UK A5602) stock solution was prepared by dissolving 5mg lyophilized 
product in 0.5mls sterile water, and then added to 4.5mls PBS to produce a 1mg/ml injection 
solution, which was then aliquoted and stored at -20°C until needed. 
Experimental protocol  
For the mobilisation study, the VEGF-AMD group (n=8) and PBS treated controls (n=6) 
were healthy, ex-breeder female Wistar rats (380-600g). Rats were pre-treated with VEGF 
(Peprotech, USA), at 100ug/kg, once daily i.p. for four days, at a volume of 0.5mls/100g. On 
day 5, rats received a single 5mg/kg dose of a CXCR4 receptor antagonist (AMD3100 
Sigma A5602) at a volume of 0.5mls/100g. One hour post administration, rats were 
anaesthetised for terminal cardiac venipuncture as previously described.  Figure 3.2 outlines 
the timing of the mobilisation protocol. Controls were treated with PBS i.p. at the same 
volume dose and time intervals. 
 
Figure 3.1: Photograph showing a T25 cell culture flask with the acetate grid in position to facilitate 
colony counting. 
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Figure 3.2: Diagram depicting the temporal sequence of events for endogenous mobilisation of stem 
cells into the peripheral circulation. 
 
Preparation of blood for assessment of VEGF AMD3100 mobilisation  
The blood was fully mixed and then split between EPC culture and MSC culture. All blood 
was processed with the RBC lysis protocol, as described above (3.2.1.2). The MNCs were 
re-suspended in MSC media (DMEM, 20% fetal calf serum, 1% Penicillin Streptomycin), or 
EPC media (EGM2 MV) and carefully plated into 25cm2 polystyrene cell culture flasks for 
MSC culture, or fibronectin coated T25 flasks for EPC culture, and then cultured as 
described in chapter 2. 
The media was changed after five to seven days to remove non-adherent cells and thereafter 
every 3-4 days. Colonies were counted at x4 magnification placed under a phase-contrast 
light microscope using a custom-made acetate grid overlay (Figure 3.2). Final CFU count 
was performed at 20±2 days. After P0 CFUs were counted, cells were passaged when they 
were 70-80% confluent. 
Cell surface marker analysis of cultured PBMSCs & PBEPCs 
P3 cells were prepared in the same manner as described in chapter 2 (2.3.1.1 & 2.3.2.1). In 
this instance, the same set of surface markers were evaluated for PBMSCs and PBEPCS, 
with 30,000 cells per group: 
• CD34 (Anti-CD34 antibody [ICO-115] Phycoerythrin, IgG1 K, abcam ab187284) 
• CD45 (Anti-Rat CD45 APC, IgG1 K, eBioscience 17-0461)  
• CD90 (Anti-Mouse/Rat CD90.1 (Thy-1.1) APC, Mouse IgG2a K, eBioscience, 17-
0900) 
• CD29 (Anti-Mouse/Rat CD29 (Integrin beta 1) FITC, Armenian Hamster IgG, 
eBioscience, 11-0291) 
• Anti-VEGFR-2 (KDR/EIC) (Fitc) (abcam ab184903) 
• CD31 (TLD-3A12) (Fitc) (abcam ab33858) 
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Isotype controls for each CD marker as follows: 
• For CD34: Mouse IgG1 K Isotype Control PE (eBioscience 12-4714) 
• For CD45: Mouse IgG1 K Isotype Control APC (eBioscience 17-4714) 
• For CD90: Mouse IgG2a K Isotype Control APC (eBioscience 17-4724) 
• For CD29: Armenian Hamster IgG Isotype Control FITC (eBioscience 11-4888) 
• For VEGFR2: Mouse IgG1 (ICIG1) (Fitc) (abcam ab91356) 
• For CD31: Mouse IgG1 (ICIG1) (Fitc) (abcam ab91356) 
Differentiation potential of PBMSCs & PBEPCs 
As previously described in chapter 2 for bone marrow MSCs, plastic adherent fibroblastic 
morphology cells were isolated by serial passage. Due to the lower yield and slower growth 
seen with the peripheral blood mobilised cells, only osteogenic and adipogenic 
differentiation was assessed. 
3.2.2.1.1 Osteogenic differentiation & Alizarin Red staining 
Osteogenic differentiation of 30,000 P3 cells per well (48 well plate), in triplicate, was 
performed and then stained for calcium deposits exactly as described in chapter 2 (2.3.1.2). 
3.2.2.1.2 Adipogenic differentiation & Oil Red O staining 
Adipogenic differentiation of 30,000 P3 cells per well (48 well plate), in triplicate, was 
performed and then stained for lipid exactly as described in chapter 2 (2.3.2.2). 
Functional 3D tube forming assay of PBEPCs 
P3 PBEPCs cells were subjected to in vitro tube forming assay as described for HUVECs in 
chapter 2 (2.4.2.2).  
3.2.3 Statistical analysis 
Due to the relatively small group sizes (n<9), a non-parametric Mann-Whitney U (MWU) 
test was used. Significance was set a p<0.05 and tests were analysed with SPSS version 24 
(IBM, Chicago, USA). 
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3.3 RESULTS 
3.3.1 Assessment of cell isolation techniques 
The mean±SD number of mononuclear cells isolated after RBC lysis was 2.0±0.8x10^6 
cells/ml (n=3) and Ficoll was 0.6±0.4x10^6 cell/ml (n=3), (Figure 3.3a). Analysis using the 
Mann Whitney-U test showed no significant difference in the number of MNCs/ml isolated 
by each technique. In terms of CFUs formed, RBC lysis yielded 2.8±3.4 CFU/ml blood, 
whereas the Ficoll did not produce any CFUs after 20±2 days culture (Figure 3.3b). The 
PBEPC CFUs that did form were comprised of cobblestone cells; some forming 
circumscribed luminal type configurations (Figure 3.4). Again there was no significant 
difference between the numbers of CFUs/ml isolated between these techniques, however a 
type II error owing to the small sample size should be considered. On balance, the RBC lysis 
technique was used despite the increased yields not being statistically significant, as it was 
also quicker and simpler to perform and in line with Pitchford’s protocol (Pitchford et al. 
2009). The full results are outlined in table 3.1 
.
	 101	
a   
b  
Figure 3.3: a) Boxplot comparing the number of mononuclear cells (MNCs) per ml blood after 
isolation using a RBC lysis protocol or a ficoll protocol. b) Boxplot comparing the number of EPC 
colonies per ml blood after a RBC lysis protocol or a ficoll protocol. The cells were isolated from the 
peripheral blood without any prior mobilisation. 
 
 
Table 3.1: The effect of isolation technique for isolating mononuclear cells (MNCs) per ml blood 
isolated and the number EPC colonies per ml blood, in non-mobilised rats. Results are mean±SD. 
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a 		b  
Figure 3.4: Light microscope images of adherent PBEPCs at x4 magnification. a) Early EPC colony 
forming at day 9. b) Large confluent colony also at day 12.  
 
3.3.2 Endogenous mobilisation of PBMSCs.  
There were no adverse reactions seen in the PBS treated control group (n=6) or the VEGF-
AMD group (n=8). The mean±SD MNC count for controls (n=5) was 2.0±0.7x10^6 cells/ml 
and mobilised (n=6) was 2.8±1.3x10^g cells/ml (Figure 3.5a) There was no significant 
difference between groups. Due to some remaining red blood cell contamination after the 
RBC lysis protocol, it was not possible to identify any adhesion of cells to the surface of the 
tissue culture plastic until after the first media change at five to seven days. The control 
blood culture showed adherence of a round MNC-type cell by day seven. There were a few 
elongated cells but the typical MSC type morphology was absent in 5/6 of the controls. 
Initially attached cells continued to detach over the culture period of 20±2 days. Cells 
isolated from one rat did produce a single CFU-F, however, these cells proliferated poorly up 
to day 14 and subsequently began to detach.  
The VEGF-AMD group formed CFU-Fs in 6/8 individual cultures. Initially, round 
mononuclear cells were present with some immature elongating cells (Figure 3.6a). Over 
time, the cells began to take on a similar morphology to those obtained by bone marrow 
isolation; spindle or fibroblastic-shaped cells, with a centrifugal arrangement of cells to form 
a colony (Figure 3.6b, 3.7a, 3.7b). Notably however, they took longer to form clear CFUs, 
typically around 14-18 days, when compared with bone marrow isolated cells. The mean 
CFU-F/ml for controls was zero, and for VEGF-AMD was significantly higher at 2.9±1.8 
CFU-F/ml (p=0.029) (Figure 3.5b). 
Present in all cultures, but to varying extents, were small round adherent mononuclear cells 
that did not form CFUs or demonstrate cell division (Figure 3.6a). Over time, in the control 
cultures, large multi-nucleate cells were seen and again no clear cell division was observed 
(Figure 3.8). Cultures from the VEGF-AMD group were passaged to P3 for further analysis.
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a   
b  
Figure 3.5: a) Boxplot showing the number of MNC x10^6 per ml of blood taken after RBC lysis 
protocol prior to plating. b) Boxplot showing a significant (* p=0.029) increase in CFU-Fs per ml of 
blood in the VEGF-AMD group. 
 
a  b  
Figure 3.6: Light microscope images of P0 PBMSCs from the VEGF-AMD group, at x4 
magnification. a) Adhered round mononuclear cells (black arrow) and early elongating cells, 
presumed MSCs (white arrow) at seven days. b) Early CFU-F forming at 14 days.  
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a  b  
Figure 3.7: Light microscope images of P3 PBMSCs at 12 days from the VEGF-AMD group. a) 
Spindaloid fibroblastic cells, at x4 magnification. b) At x10 magnification, cells had a flat, spindle 
shaped morphology, similar to the bone marrow MSCs. 
 
 
Figure 3.8: Light microscope images of P0 PBMSC culture from the control group (x4 magnification, 
21 days). The cells had detached and there was no evidence of CFU-Fs or any other cell population. 
Some cellular debris remained. 
 
Cell surface marker analysis of cultured PBMSCs 
Flow cytometry analysis was performed on P3 cells (n=3). In common with the bone marrow 
MSCs in chapter 2, the plastic adherent CFU-F cells were CD34 negative, however CD45 
which is typically negative in MSCs, was positive on some cells with both CD45+ and 
CD45- cells present (Figures 3.9 and 3.10), varying from 9 to 60% positive within any 
population. MSC markers CD90 and CD29 were highly expressed at 78% and 64% 
respectively (Figure 3.11). There were negligible to minimal expression of endothelial 
markers CD31 and VEGFR2 (Figure 3.12). See table 3.2 for full results.  
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a  b  
Figure 3.9: Flow cytometry histogram fluorescence counts for VEGF-AMD PBMSC CD34 and CD45 
expression. a) Red plot shows cells stained with PE conjugated isotype control. Green plot shows cells 
stained with PE conjugated CD34 antibody. b) Red plot shows cells stained with APC isotype control. 
Green plot shows cells stained with APC conjugated CD45 antibody. In plot a, there is no right shift 
in expression, indicating no staining above background and therefore no expression of CD34 in 
PBMSCs. In plot b however, there is a clear right shift in fluorescence indicating CD45 expression in 
PBMSCs. Additionally, a small peak in the same region as the red control histogram was seen 
indicating a smaller second CD45- population. 
 
 
Figure 3.10: Flow cytometry scatterplot for VEGF-AMD PBMSCs showing CD34 PE and CD45 APC 
expression, with two dominating populations: the largest is a CD45+CD34- population, in addition to 
a significant CD34-CD45- population, and a scattering of CD45-CD34+ cells and CD45+CD34+ 
cells. 
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a   b  
Figure 3.11: Flow cytometry histogram fluorescence counts for VEGF-AMD PBMSC CD29 and 
CD90 expression. a) Red plot shows cells stained with FITC conjugated isotype control. Green plot 
shows cells stained with FITC conjugated CD29 antibody. b) Red plot shows cells stained with APC 
conjugated isotype control. Green plot shows cells stained with APC conjugated CD90 antibody. In 
both plots, the right shift in fluorescence indicates positive expression of CD29 and CD90 markers on 
the PBMSCs. 
 
a b  
Figure 3.12: Flow cytometry histogram fluorescence counts for VEGF-AMD PBMSC VEGFR2 and 
CD31 expression. a) Red plot shows cells stained with FITC conjugated isotype control. Green plot 
shows cells stained with FITC conjugated VEGFR2 antibody. b) Red plot shows cells stained with 
FITC conjugated isotype control. Green plot shows cells stained with FITC conjugated CD31 
antibody. In both plots there is no right shift in fluorescence, indicating no expression of VEGFR2 or 
CD31 in PBMSCs. 
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Table 3.2: Individual and mean±SD flow cytometry percentage expression levels (%) of the markers 
evaluated for PBMSCs from VEGF-AMD treated group. 
 
Osteogenic differentiation of PBMSCs 
VEGF-AMD mobilised PBMSCs formed a monolayer along the base of the well within 
seven days. During supplementation with osteogenic media the cell morphology became less 
spindaloid and more cuboidal and multiple small granules became apparent. Staining for 
Alizarin red after 21 days demonstrated red stained calcium deposits in all samples, 
consistent with osteoblast activity (n=5). (Figure 3.13a). 
a   b  
Figure 3.13: a) Light microscopy images of osteogenic differentiation (x10 magnification), after 21 days of 
osteogenic supplementation of VEGF-AMD PBMSCs (n=5). Wells were stained with Alizarin red and 
there were no stained mineral deposits in the control wells and significant staining in the supplemented 
group. b) Light microscopy images of adipogenic differentiation (x40 magnification above the horizontal 
dividing line, x10 below), post staining with Oil Red O of VEGF-AMD PBMSCs (n=5). There were no 
visible stained lipid droplets in the control group, and only 1/5 showed any signs of adipogenesis, which 
was less evident than seen with the bone marrow MSCs from chapter 2. The panels from top to bottom 
represent cultures from different individual rats. 
Osteogenic*Control* Osteogenic*
Adipogenic*Control* Adipogenic*
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Adipogenic differentiation of PBMSCs 
VEGF-AMD PBMSCs formed a monolayer along the base of the well within seven days. 
After 21 days of incubation with adipogenic media a change in morphology was evident, 
with cells appearing less spindle shaped, being shorter with longer extensions. Positive Oil 
Red O staining was not seen in 4/5 samples and therefore these cells did not appear to have 
adipogenic lineage potential (n=5) (Figure 3.13b). 
3.3.3 Endogenous mobilisation of PBEPCs.  
The mean±SD mononuclear cell count post RBC lysis was significantly higher for VEGF-
AMD with 2.9±0.9x10^6 cells/ml compared to controls with 1.8±0.5x10^6 cells/ml 
(p=0.035) (Figure 3.14a).  
a   
b  
Figure 3.14: a) Boxplot showing the number of MNC x10^6 per ml of blood taken after red blood cell 
lysis protocol (* p=0.035). b) Boxplot showing a significant (** p=0.036) increase in EPC CFUs per 
ml of blood in the VEGF-AMD group. 
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At 20±2 days, the EPC CFU count for the VEGF-AMD group was significantly increased at 
2.9±3.3 CFUs/ml compared with 0.3±0.6 CFUs/ml blood for controls (p=0.036) (Figure 
3.14b). 
Two distinct EPC cell morphologies were seen. An ‘early-outgrowth’ spindle type 
morphology (Figure 3.15a) was seen within the first 10 days. Latterly, I saw more classical 
‘late-outgrowth’ type morphology, characterised by a cobblestone appearance, not visible 
until at least 10 days, and most notably after 14 days of culture (Figure 3.15b). The cells 
grew slowly, sometimes taking up to 30 days to achieve confluence and their morphology 
was more varied than seen in the PBMSC cultures (Figures 3.16, 3.17, 3.18). In a few 
samples there were occasional islands of rare colonies that were tightly packed and 
circumscribed with elongated ovoid cells. These cells were distinct from the spindaloid cells, 
and were not seen in all cultures and did not proliferate significantly (Figure 3.19). 
a 	b 	 
Figure 3.15: Light microscopy images showing P0 VEGF-AMD PBEPC CFUs on fibronectin coated 
flasks in the presence of endothelial media, at x4 magnification. a) An early outgrowth style colony 
showing mostly spindle shaped cells at day 7. b) Late outgrowth style colony showing cobblestone 
shaped cells at day 15. 
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a 	b 	 
Figure 3.16: Light microscopy images showing P0 VEGF-AMD PBEPC CFUs at day 18, with 
classical cobblestone cells and some elongated cobblestone cells. a) At x4 magnification. b) At x10 
magnification.  
 
a 	b  
Figure 3.17: Light microscopy images taken at x10 magnification. a) P3 VEGF-AMD PBEPCs at day 
30. b) HUVECs P5 at day 7. These two cultures had a similar cell morphology and were unlike the 
fibroblastic MSCs.  
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a 	b  
Figure 3.18: Light microscopy images of VEGF-AMD PBEPCs in culture. a) Dense P3 PBEPC 
colonies with cobblestone appearance, with some elongated EPCs between, shown at x4 
magnification. b) P2 cells at day 19, at x10 magnification, displaying a swirling pattern. These cells 
were more elongated than other seen. 
 
a  b  
Figure 3.19: Light microscopy images of P0 VEGF-AMD PBEPC culture showing an isolated, 
circumscribed, rare colony morphology, seen in some cultures with a morphology distinct from the 
typical early- or late-outgrowth cells, day 10. a) At x4 magnification. b) At x10 magnification. 
 
Cell surface marker analysis of cultured PBEPCs 
P3 VEGF-AMD PBEPCs cells showed a monopopulation in terms of size and complexity. 
All analysed populations (n=4) were uniformly CD34- CD45- (Figure 3.20a-c). All 
expressed CD29 to varying levels (Figure 3.20d). One population had no EPC markers and 
very high CD29 and CD90 expression, rather like an MSC expression profile (Figure 3.21). 
Two populations had CD31 expression, one relatively low with high CD29 and low CD90 
expression, the other had very high CD31 and CD29, and low CD90 (Figure 3.22). Only one 
population had some VEGFR2 expression with low CD29, CD90, and CD31. Based on the 
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morphology and cell surface marker analysis, these cells were quite different to the PBMSCs, 
however they didn’t uniformly express classical EPC markers. See table 3.3 for all marker 
expression profiles. 
a  b  
c  d  
Figure 3.20: Flow cytometry fluorescence histograms and scatterplots for VEGF-AMD PBEPCs. a) 
Red plot shows cells stained with PE conjugated isotype control. Green plot shows cells stained with 
PE conjugated CD34 antibody. b) Red plot shows cells stained with APC conjugated isotype control. 
Green plot shows cells stained with APC conjugated CD45 antibody. c) Fluorescence scatterplot of 
CD34 PE vs CD45 APC fluorescence for PBEPCs. d) Red plot shows cells stained with FITC 
conjugated isotype control. Green plot shows cells stained with FITC conjugated CD29 antibody. In 
plots a and b, there is no right shift in fluorescence, indicating no expression of CD34 and CD45 in 
PBEPCs. In plot c, the vast majority of cells represent a CD34-CD45- population, with a scattering of 
CD34+CD45- cells. In plot d there is a clear right shift in fluorescence indicating high expression of 
CD29.  
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a  b	 		
c	  
Figure 3.21: Flow cytometry fluorescence histograms for VEGF-AMD PBEPCs. a) Red plot shows 
cells stained with APC conjugated isotype control. Green plot shows cells stained with APC 
conjugated CD90 antibody.  b) Red plot shows cells stained with FITC conjugated isotype control. 
Green plot shows cells stained with FITC conjugated CD31 antibody. c) Red plot shows cells stained 
with FITC conjugated isotype control. Green plot shows cells stained with FITC conjugated VEGF2 
antibody. In plot a, there is a right shift in fluorescence, indicating expression of CD90. In plots b and 
c, there is no right shift in fluorescence, indicating no expression of endoethelial markers CD31 and 
VEGFR2 (n=2). 
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a b	 	
c	  
Figure 3.22: Flow cytometry fluorescence histograms for VEGF-AMD PBEPCs. a) Red plot shows 
cells stained with APC conjugated isotype control. Green plot shows cells stained with APC 
conjugated CD90 antibody. b) Red plot shows cells stained with FITC conjugated isotype control. 
Green plot shows cells stained with FITC conjugated CD31 antibody. c) Red plot shows cells stained 
with FITC conjugated isotype control. Green plot shows cells stained with FITC conjugated VEGF2 
antibody. In plots a and c there is a no right shift in fluorescence, indicating no expression of CD90 or 
endothelial marker VEGR2. In plot b there is a right shift in fluorescence, indicating expression of 
endoethelial marker CD31 (n=2). 
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Table 3.3: Individual and mean±SD flow cytometry percentage expression levels (%) of the markers 
evaluated for VEGF-AMD PBEPCs. For assessment of in vitro microtubule formation, ++ is 
equivalent to HUVECs, + indicates at least two luminal structures, ± indicates some cellular 
connections and – indicates no evidence of change above control.  
 
Osteogenic differentiation of PBEPCs 
P3 PBEPCs formed a monolayer along the base of the well within seven days. Staining for 
Alizarin Red after 21 days of osteogenic supplementation did not demonstrate red granules 
indicative of calcium deposits and therefore the PBEPCs do not appear to have formed 
osteoblasts at the time point investigated (Figure 3.23a). 
 Adipogenic differentiation of PBEPCs 
P3 PBEPCs formed a monolayer along the base of the well within seven days. After 21 days 
of incubation with adipogenic media a change in morphology was evident, with cells 
appearing less spindle shaped, being shorter with longer extensions. Positive Oil Red O 
staining was evident by red dots indicating the presence of lipid (Figure 3.23b) and therefore 
adipogenesis in all samples tested (n=3). One sample formed lipid granules in the control 
media. 
Rat CD45+ CD34+ CD29+ CD90+ VEGFR2+ CD31+ 
CD34- CD34+ CD45+ CD45+ Tube 
formation CD45- CD45- CD34- CD34+ 
R3A 0.4 1.7 85.9 95.0 0.8 1.4 95.9 3.1 0.8 0.2 + 
R1B 9.4 6.8 4.3 7.3 8.5 2.5 82.2 7.2 8.9 1.7 ± 
R2B 0.6 0.7 64.8 0.8 1.1 90.3 97.8 0.8 1.3 0.7 - 
R3B 1.3 2.1 77.6 1.0 0.6 7.7 90.9 3.9 4.0 1.1 + 
Mean±SD 2.9±4.3 2.8±2.7  58.2±36.9  26.0±46.1 2.8±3.8 25.5±43.3 91.7±7.0 3.8±2.6 3.8±3.7 0.9±0.6 
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a   b  
Figure 3.23: a) Light microscopy images showing the results of osteogenic media supplementation 
(x10 magnification), on VEGF-AMD PBEPCs after 21 days of supplementation. There was no visible 
red staining post Alizarin Red, indicating no calcium deposition and therefore no osteoblastic 
differentiation. b) Light microscopy images showing the results of adipogenic media supplementation 
on VEGF-AMD PBEPCs (x40 magnification above the horizontal dividing line, x10 below). Post 
being fixed and stained with Oil Red O, multiple red lipid droplets were evident in the supplemented 
media compared with the standard media. In the middle panel, the control group also shows some 
positive staining indicative of lipid deposition without adipogenic stimulation. The panels from top to 
bottom represent cultures from different individual rats. 
Osteogenic*Control* Osteogenic* Adipogenic*Control* Adipogenic*
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Functional 3D tube forming assay  
VEGF-AMD PBEPCs plated on Geltrex and treated with full growth medium (n=4) formed 
fewer connections and appeared less organised than seen with HUVECs. Two samples partly 
formed capillary-like structures, however, the remainder did not look especially different 
from the control group (Figure 3.24 and table 3.3). 
 
Figure 3.24: PBEPCs plated on Geltrex, treated with growth factor depleted media (low serum) or full 
growth factor enriched media, at 18±2 hours post plating (x40 magnification). In the top and bottom 
panels, there is evidence of a capillary like network forming, with cellular connections and luminal 
type spaces emerging. However, the middle two panels do not show such advanced structural 
arrangements. Results are summarised in table 3.3. The panels from top to bottom represent cultures 
from different individual rats.   
 
Low$serum$control$ Full$growth$factor$$
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3.3.4 Qualitative observations: PBEPC-like cells in a PBMSC culture system 
A P0 PBMSC VEGF-AMD mobilised culture was passaged when confluent after colony 
counting. The P1 PBMSC culture however, did not thrive and only a few CFU-F colonies 
formed and subsequently detached, and those cells that remained appeared senescent (Figure 
3.25a). In spite of this, the culture was continued and after 16 days, several small ‘late-
outgrowth’ style EPC-like CFUs began to form (Figure 3.25b-d). By day 21 multiple CFUs 
were present and several very large and tight colonies developed by day 30 culture (Figure 
3.25e & f). 
a  b   
c  d   
e  f  
Figure 3.25: Light microscopy images of P1 VEGF-AMD PBMSC culture that failed to establish after 
passage, and multiple ‘late-outgrowth’ style PBEPC CFUs developed after 16 days. a) Senescent cells 
at day 16 after passage. b) Late outgrowth style PBEPC colony that appeared, shown at x4 
magnification. c) Further late outgrowth PBEPC colonies developed over the following five days, (at 
x10 magnification) and figures d) and e) at x4 magnification. f) By day 30, several very large, dense, 
tightly packed colonies were present (x4 magnification). 
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These cells were passaged to P2 and subsequently tested for bi-differentiation, tube 
formation (in triplicate) and cell surface marker characteristics. Despite their EPC style 
morphology, these cells were more like the PBMSCs, having CD29 expression with a mixed 
CD45 expression without CD34 (Figure 3.26a & b), however they had low CD90 (Figure 
3.26c), no CD31 and some expression of VEGFR2 (Figures 3.26d &e), more similar to 
PBEPCs. In terms of bi-differentiation they mirrored the PBMSCs being able to only 
differentiate down an osteoblastic lineage (Figure 3.27 a & b). Interestingly, they could form 
microvascular networks when plated in Geltrex (Figure 3.27 c). 
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a b  
c d  
e  
Figure 3.26: Flow cytometry fluorescence histograms and scatterplots for P2 PBMSC late outgrowth 
EPC like cells. a) Red plot shows cells stained with FITC conjugated isotype control. Green plot 
shows cells stained with FITC conjugated CD29 antibody. b) Fluorescent scatterplot showing PE 
conjugated CD34 against APC conjugated CD45 showing a predominantly CD34- CD45- negative 
population with a smaller secondary population of CD34- CD45+ cells. c) Red plot shows cells 
stained with APC conjugated isotype control. Green plot shows cells stained with APC conjugated 
CD90 antibody. d) Red plot shows cells stained with FITC conjugated isotype control. Green plot 
shows cells stained with FITC conjugated CD31 antibody. e) Red plot shows cells stained with FITC 
conjugated isotype control. Green plot shows cells stained with FITC conjugated VEGFR2 antibody.  
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a      
b  
c  
Figure 3.27: Light microscopy images post differentiation and plating on Geltrex of P2 VEGF-AMD 
PBEPC-like cells, that developed in a PBMSC failed culture. a) The results of osteogenic media 
supplementation (x4 magnification), after 21 days of supplementation. There was significant staining 
in the supplemented culture indicative of calcium deposition from osteoblast differentiation. b) The 
results of adipogenic media supplementation (x40 magnification). Post being fixed and stained with 
Oil Red O, no red droplets indicative of lipid deposition was seen, indicating no adipogenic lineage 
differentiation. c) Microvascular type network formation at 20 hours after plating on Geltrex when 
supplemented with full growth factor EPC media (x40 magnification). 
 
Osteogenic*Control* Osteogenic*
Adipogenic*Control* Adipogenic*
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3.4 DISCUSSION 
3.4.1 Mobilisation 
In this chapter I was able to support my hypothesis and showed a significant increase in 
peripheral blood circulating PBMSCs and PBEPCs post VEGF with AMD3100 
administration. However, the actual yields were surprising low. Conceptually, a single CFU 
is produced from a single stem/progenitor	(Friedenstein et al. 1974; Bianco et al. 2013) and 
in my model system this equated to an average yield of three stem/progenitor cells per ml of 
blood. When considering the total volumes available were around 6-8mls, cell evaluation 
became more challenging than predicted. To that end, in vitro identification with expansion 
was necessary and allowed a wider platform of evaluation, although cell expansion was also 
slow. In terms of methodology, my work was comparable to Pitchford’s work in mice 
(Pitchford et al. 2009). The cells isolated in this chapter were evaluated functionally and on 
surface marker expression from third passage samples. A human or large animal study would 
have allowed significantly greater blood volumes and potentially serial sampling, facilitating 
a longitudinal view of mobilisation, potentially on non-cultured cells. These studies however, 
are significantly more costly, particularly in terms of the amount of growth factors required. 
One further issue with primary cytometric analysis would be the large number of leukocytes 
mobilised making stem progenitor cell identification difficult (Pitchford et al. 2010), and 
there are significantly fewer monoclonal antibodies available for species such as sheep.  
Pitchford’s work in mice showed greater MSC mobilisation of 15 MSCs/ml blood. Likewise, 
EPCs increased from six EPCs/ml to 230 CFUs/ml, whereas I only achieved around 
3cells/ml for PBMSCs and PBEPCs. They also showed that although AMD3100 alone 
increased MSCs and EPCs above resting levels (3 MSCs/ml and 40 EPCs/ml), the 
combination of VEGF with AMD3100 was the most effective (Pitchford et al. 2009). The 
relatively poor results in my study could be an artefact of in vitro culture and the processing 
performed to remove red blood cells prior to culture, or related to species or age differences 
in the donors. A further theory is the known requirement for bone marrow CFU-Fs to have at 
least four growth factors present for sufficient growth and perhaps there was insufficient 
paracrine stimulation with my PBMSCs due to the low initial seeding density (He et al. 
2006) The problems of isolating stem cells from the peripheral circulation is not new 
however. Other groups had to modify their techniques, such as using fibrin microbeads that 
bind matrix-dependent cells to concentrate the proportion of MSCs within MNCs to improve 
subsequent plating density and yields (Kassis et al. 2006). 
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A further issue is the single time point of sampling, which essentially provides only a ‘snap-
shot’ of the circulating pool of cells at the predicted peak elution time of one hour post 
administration of AMD3100 (Broxmeyer et al. 2005). When evaluating the potential of 
endogenous mobilisation for fracture healing in vivo, it must be considered that the single 
time point measurement may be misleading. The duration and character of the profile of cell 
elution into the circulatory system is probably more important and so the true kinetics of the 
mobilisation I induced is unknown. It is also clear that mobilised cells home back to the bone 
marrow, or indeed other tissues such as liver, spleen, or lungs and therefore mobilisation has 
to be considered as a highly dynamic and complicated process, which begets the 
inadequacies of a single ‘snap-shot’ evaluation (Pitchford et al. 2010; Wilson & Trumpp 
2006). 
It is assumed that the mobilised cells are of bone marrow origin, however with systemic 
administration of the mobilising agents, they may also be from other niches, particularly 
when considering the conservation of SDF1-CXCR4 axis beyond the bone marrow niche 
(Lee et al. 2010; Kidd et al. 2010; Toupadakis et al. 2012). To confirm a bone marrow based 
source of the mobilised cells, the options would be to either perform bone marrow ablation 
with recapitulation using labelled cells, or to isolate a vascular compartmental, such as 
Pitchford performed in later studies, with isolation of the femoral artery and vein (Pitchford 
et al. 2009). The bone marrow recapitulation is complicated and high risk, and the isolated 
femoral component actually only informs of all possible niches within the hind limb, and not 
exclusively the bone marrow compartment. As the exact location of the mobilised cells was 
not my primary focus, this was not pursued further.  
3.4.2 PBMSCs 
For my control samples, I could not isolate any PBMSCs. Others have had more success 
using young animals however (Kamal et al. 2014). The influence of age on the function of 
donor MSCs has been looked at with neonatal (0 days), infant (seven days), young (14 days), 
pre-pubertal (35-38 days), pubertal (45 days) and adult (two months) rats (Fafián-Labora et 
al. 2015). In contrast, my study used ex-breeders that are at least adult through to geriatric; 
with increasing age, there was no change in surface marker expression, (CD34, CD45 
negative, and 75% CD90 and 30% CD29 positive). However, there were age related changes 
in differentiation, proliferation and cell metabolism (Fafián-Labora et al. 2015). Although 
there are contradictions in the literature, likely relating to issues of species, gender, and 
consideration of what constitutes ‘old’, the consensus is that older rats have fewer CFUs, 
fewer MSCs in the bone marrow (Sethe et al. 2006), and indeed humans also show reduced 
CFUs with ageing (Kuznetsov et al. 2001). This could create an issue with endogenous 
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mobilisation strategies, as those individuals with compromised healing may simply have a 
smaller reservoir to mobilise. A recent study also showed an age relationship with CXCR4 
dependent migration (Sanghani-Kerai et al. 2017) and hence the effect of antagonism of the 
CXCR4-SDF1 axis may also reduce with age. Should my mobilised cells have grown more 
reliably, the growth kinetics could have been evaluated with population doubling assays 
(Tawonsawatruk et al. 2012) and compared with bone marrow cells to determine if the 
differences were due to age, the individual, an inherent difference between PBMSCs and 
bone marrow MSCs, or the low seeding density. 
As noted, the VEGF-AMD mobilised PBMSCs proved more difficult to culture than the 
bone marrow MSCs. They established colonies later and grew more slowly, resulting in 
prolonged periods of culture of up to 30 days per passage.  Although passage is frequently 
talked about in terms of cell function, the passage number is a derivative of doublings or the 
number of times the cell has replicated itself. Studies looking at PBMSCs have shown the 
cells become flatter and bigger, and growth stops with increased numbers of apoptotic cells 
as passage increases (Fu et al. 2015). Therefore, if the seeding density is low, as was the case 
in my study, the number of replications required to get to the point of passage will be greater, 
and hence cells will be ‘replicatively older’ than their passage number may imply. Obtaining 
P3 cultures in my study was challenging whereas Fu et al. managed to achieve up to 25 
passages (Fu et al. 2015), however they used rabbits, which would provide a significantly 
bigger volume of blood and hence higher numbers of seeding stem cells. A recurring theme 
in the literature is the relative difficulty in expanding peripheral blood cells as effectively as 
bone marrow derived cells (Kamal et al. 2014). Most studies looking at peripheral blood 
circulating stem cells and mobilisation in animal models have used immature animals (Fu et 
al. 2015; Pitchford et al. 2010; Toupadakis et al. 2013; Kamal et al. 2014), and therefore 
there may be merit in evaluating the role of age in mobilisation potential. In terms of clinical 
translation however, it is likely to be an older population that is more at risk of non-union, 
perhaps in part for this reason of impaired and reduced numbers of stem cells. 
The traditional view is that a single MSC would be able to produce cells that were capable of 
differentiation into osteoblasts, chondrocytes and adipocytes. The PBMSCs mobilised and 
cultured were unable to undergo adipogenic differentiation, but were effective at osteoblastic 
differentiation with effusive calcium precipitates. Even classical bone marrow stem cell 
work has shown different clonal populations frequently do not have full tri-differentiation, 
whilst interestingly the osteogenic lineage is always present (Pittenger et al. 1999). Other 
studies have suggested a hierarchy of sequential lineage loss with the potential for 
osteogenic differentiation remaining (Muraglia et al. 2000). They showed that only 1/3 of 
clones were capable of tri-differentiation and the majority were osteo or chondro orientated. 
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In my study, due to the paucity of cells and the long duration of culture required, there were 
insufficient cells for pellet culture and chondrogenic differentiation, and therefore it remains 
unclear if the PBMSCs were osteo-chondro bi-potent or osteo uni-potent. Liu et al. (2018), 
used Cobalt Chloride with AMD3100 to mobilise MSCs and their cells also had osteo and 
chondro potential and reduced adipogenic potential. In any case, it is not unreasonable to 
suggest that the PBMSCs with osteogenic potential that I mobilised could contribute to 
fracture healing in a positive manner. It is also conceivable that mobilised cells may also 
provide trophic/paracrine support to tissue resident cells after homing, which may stimulate 
fracture healing. 
In terms of cell surface marker expression, the PBMSCs were the same as the bone marrow 
MSCs expect for the presence of two CD45 populations; CD45- and CD45+ groups. CD45 is 
a key leukocyte marker and MSCs are universally considered to be CD45- (Boxall et al. 
2012; Dominici et al. 2006). However, in patients with haematological malignancies, CD45+ 
MSCs have been cultured, and hence under certain circumstances the CD45 rule may be 
broken (Yeh et al. 2006). For my study, it was impossible to tell if these cells were simply 
contaminants or represented a true CD45+ MSC population. Studies in rabbits (Fu et al. 
2014) and a comprehensive comparison of rat bone marrow to blood MSCs showed no 
difference in CD marker expression, morphology or tri-lineage potential, although growth 
and differentiation potential are reduced in peripheral blood isolated MSCs (Fu et al. 2012). 
Their study used GCSF with AMD3100 and Ficoll isolation, and perhaps the use of a 
different growth factor affected the cell types identified. Interestingly, they had no CD45 
expression in their cells and they noted a slower growth rate than bone marrow derived 
MSCs. A human study that compared bone marrow MSCs to circulating MSCs after burn 
injuries also showed that circulating cells were identical to bone marrow MSCS in terms of 
surface markers (Mansilla et al. 2006). 
In summary, an MSC like cell was mobilised following VEGF-AMD administration with 
strong osteogenic potential and hence I hypothesise that these circulating cells could have a 
positive influence on fracture healing. 
3.4.3 PBEPCs 
Broadly speaking, I saw two morphologically distinct cells types in the EPC culture system. 
The initial fibroblastic style population was overtaken by a cobblestone style of cell, 
although there were several iterations of this squarer cell type. The first description of EPCs 
by Asahara et al. identified a spindle shaped cell grown on fibronectin in enhanced media 
from CD34+ MNCs. These cells expressed VEGFR2, formed microvascular networks, and 
took up acLDL, and appeared to support collateral blood vessel formation in an ischaemia 
	 126	
model (Asahara et al. 1997). CD34 is a haematopoietic stem cell marker and hence EPCs 
were thought to share a common lineage. Subsequently, early outgrowth phenotype cells 
were frequently isolated by sorting for haematopoietic markers CD34 or CD133 with 
expression of endothelial VEGFR2 (Bongiovanni et al. 2014). Later studies showed these 
cells could only differentiate down haematopoietic lineages and did not produce endothelial 
cells. These cells were hence not considered to be the true endothelial progenitor, but a 
trophoblastic or supportive cell in vasculogenesis (Case et al. 2007). Other researchers also 
identified spindle shaped cells that developed early in culture with similar features to above, 
and called them ‘early-outgrowth’ EPCs. These have been suggested to be from a CD34 
fraction and potentially have a monocytic origin due to CD14 expression (Medina et al. 
2010), although that may be from contamination or a result of culture conditions (Chong et 
al. 2016). It has now been widely reported that these cells are trophic and not direct 
contributors to blood vessel formation (Cheng et al. 2013; Minami et al. 2015; Rehman et al. 
2003).  In my study, after prolonged culture and passage, there were few if any of these cells 
present based on cell morphology. The current nomenclature for these cells includes early 
outgrowth cells (EOCs) (Minami et al. 2015), circulating angiogenic cells (CACs), or early 
EPCs (eEPCs) (Chong et al. 2016).  
The population I have evaluated here were the ‘late-outgrowth’ EPCs, also known as non-
haematopoietic EPCs or endothelial colony forming cells (ECFCs) (Chong et al. 2016). 
These are more frequently grown on a collagen substrate in endothelial enriched media 
(Ormiston et al. 2015), but have also been grown on other substrates such as fibronectin 
(Pitchford et al. 2009). These cells have the characteristic cobblestone morphology, emerge 
later in culture and are not thought to have a haematopoietic origin or lineage (Chong et al. 
2016). Late-outgrowth cells express lower VEGFR2 than early outgrowth cells, high CD31 
and form microvascular tubular structures and proliferate well (Bou Khzam et al 2015). They 
have also been shown to have endothelial ultrastructures on electron microscopy imaging, 
such as adheren junctions, and a gene expression more similar to dermal microvascular 
endothelium than monocytes (Medina et al. 2010). The chronology of the emergence of 
these cells also appears to affect their ability to drive neovascularisation with the latest ones 
providing the best re-vascularisation in ischaemic models (Minami et al. 2015). Interestingly, 
in some studies late EPCs show higher CD31 and VEGFR2 expression than early (Cheng et 
al. 2013). 
The cell surface marker expression of my ‘late outgrowth’ EPCs was negative for CD34 
which is characteristic of  “an early out growth EPC” and fits with cultures being ostensibly 
cobblestone. There was no CD45 expression as expected. One culture had low expression of 
VEGFR2, and cells from two cultures were positive for CD31, which is a late-outgrowth 
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EPC marker. These CD31+ cells did not co-express VEGFR2. Surprisingly, one culture 
fitted my criteria for MSCs. A clear relationship between the microvascular network 
formation and CD marker expression was not evident, with networks forming on Geltrex 
clearly in two, and moderately in one out of four cultures tested. This may indicate a 
fundamental inability of these cells to perform this activity and fits with the marker 
expression not being as convincing as some studies, or potentially indicates the need for 
further optimisation of this in vitro test for blood mobilised cells.  
EPCs are not expected to have any differentiation potential. Unusually and unrelated to CD 
marker expression or tube formation potential, all cultures were able to move down an 
adipogenic lineage. This begs the question of whether the PBEPCs were actually MSCs with 
the ‘adipogenic switch’ turned on, favouring adipogenesis only (Moerman et al. 2004).  
3.4.4 Relationship between PBEPCs & PBMSCs? 
The PBMSC culture that failed to establish but subsequently developed cobblestone cells in 
prolonged culture is particularly interesting. These cells were morphologically identical to 
the ‘late-outgrowth’ cobblestone PBEPCs that I grew, and could form a clear microvascular 
network and had some VEGFR2 expression. Despite this, they had the PBMSC osteogenic 
lineage exclusivity rather than the PBEPC adipogenic exclusivity. This prompts two 
thoughts. Firstly, are EPCs routinely present in MSC cultures, but are simply outcompeted 
by the rapid growth of MSCs. Clearly the cobblestone morphology is not dependent upon 
fibronectin coating or an endothelial enriched growth media and hence their morphology is 
not dictated by those factors. Secondly, are the PBEPCs I mobilised truly EPCs or MSCs, or 
a precursor to both? As a precursor is expected to be less lineage limited, the results seen 
may be due to the different culture conditions influencing lineage exclusivity. Certainly, one 
isolate of PBEPCs was CD34- CD45- CD90+ CD29+, fulfilling my criteria for MSCs in 
chapter 2 and yet the cell morphology was completely different to the fibroblastic MSC.  
The relationship between MSCs and EPCs is not well understood, however, human bone 
marrow MSCs have been differentiated to ‘endothelial like’ cells by adding VEGF to the 
media which induced VEGFR2 and Von Willebrand expression, although no CD31. These 
cells could form microvascular networks, although cell morphology remained typically 
fibroblastic, unlike my PBEPCs. They also showed that standard bone marrow MSCs in the 
presence of VEGF were also able to form microvascular networks, albeit less well than the 
growth factor conditioned MSCs (Oswald et al. 2004). In vitro expanded MSCs that have 
been conditioned by culture in EGM-2, which is growth factor enriched media, (similar to 
my EPC media), could form tubes on Matrigel and expressed CD31 and VEGFR2 at higher 
levels than MSCs did, but lower than EPCs. They also showed no difference in CD90 
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expression. However, the transformed MSCs did not look like cobblestones and they also 
demonstrated a relative increase in CD34, which I did not see. Interestingly, they noted 
depressed adipogenic tendencies (Liu et al. 2007), compared with my lineage tendency. 
What this suggests is the plasticity and influence of culture environment on cells needs to be 
considered in these studies. If my PBMSCs and PBEPCs had been more numerous, a cross 
culture study to determine the influence on morphology and function would be a viable next 
step for assessing these two cell populations. However, it would not explain the cobblestone 
morphology cell establishment in the MSC culture system. Substrate differences may have 
also played as a role, as fibronectin has increased the ability of MSCs to form Matrigel 
microvascular networks compared with cells cultured on gelatin (Muscari et al. 2010). In any 
case, if VEGF-AMD mobilises ‘late-outgrowth’ EPCs and MSCs together, this combination 
may well have benefits in fracture healing. 
Could I have mobilised a common precursor? Despite MSCs having been the subject of 
research for over 40 years and EPCs for 20 years, their developmental origins remain unclear. 
MSCs, haematopoietic stem cells and EPCs are derived from the middle of three embryonic 
primary germ layers in the embryo, the mesoderm, with MSCs also having a neural crest 
source in addition to the lateral plate mesoderm (Sheng 2015). Work using embryonic stem 
cells has shown two mesenchyme derived sub lineages; the haemangioblast and a 
mesenchymoangioblast lineage which lead to MSCs and EPCs (Vodyanik et al. 2010; 
Slukvin & Vodyanik 2011). The haemangioblast is thought to be a source of haematopoietic 
stem cells and endothelial precursors and again work on embryonic stem cells supports this 
theory (Huber et al. 2004). Therefore, an inter-related origin of these cells and hence a 
common precursors or possible plasticity between them may be possible. This could 
potentially explain some of the mixed in vitro findings, the relative roles of ‘early- 
outgrowth’ and ‘late-outgrowth’ EPCs (Cheng et al. 2013), a potential role for MSCs alone 
(Kumar et al. 2010) and in combination with EPCs for angiogenesis (Aguirre et al. 2010) 
and perhaps the relationship of MSCs and pericytes (Cano et al. 2017) with their vascular 
intimacy (da Silva Meirelles et al. 2006). 
3.4.5 Conclusion 
The very act of in vitro cell culture changes the cells, including their cell surface 
characteristics (Bara et al. 2014), and although the cells mobilised were not exactly as 
expected, VEGF-AMD treatment clearly increased the available stem/progenitor pool in rats, 
even when using this ‘snap shot’ in vitro assessment. Critically, there was an increase in 
circulating osteoprogenitor cells that may show promise for fracture healing. As atrophic 
non-unions in rats have some residual cells that can differentiate within the non-union and 
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bone marrow has increased MSCs when a non-union fracture develops (Tawonsawatruk et al. 
2014), it seems appropriate to evaluate whether this protocol can boost fracture healing in an 
in vivo rat model of delayed/non-union. Having established proof of concept for mobilisation, 
and due to the difficultly in precisely determining the number and type of cells that are 
mobilised by in vitro investigation, it is entirely appropriate to investigate the potential 
effects of mobilisation in a fracture healing model system. In order to make this as 
informative as possible, this model needs to have consistent biomechanics to ensure any 
outcome differences are likely attributable to the effect of mobilisation. To that end, chapter 
4 and 5 were focused on the development of the fixator model and evaluation of its 
biomechanics. 
Pitchford et al. (2009) indicated that VEGF with AMD3100 was the most potent 
combination for mobilising MSCs and EPCs in a mouse model, however, I acknowledge that 
other growth factors may also have potency for mobilising stem cells. In this chapter, I chose 
to investigate the effect of VEGF with AMD3100 on stem and progenitor mobilisation from 
Wistar female as they are the chosen species and breed for the fracture model, and secondly, 
Pitchford’s work indicated that VEGF with AMD3100 would mobilise MSCs and EPCs, 
both considered important in fracture healing. I could have gone on to investigate the 
mobilisation of MSCs and EPCs using other growth factors such as GCSF or IGF1, in the 
same manner as in this chapter, however as the number of stem cells were relatively low and 
as there was difficulty in characterising these cells, I considered it prudent to proceed to a 
translationally informative in vivo rat fracture model. This remained the only way to evaluate 
the potential for endogenous mobilisation to boost healing accurately, as it allowed for the 
full kinetic profile of mobilisation of unaltered cell combinations that may boost fracture 
healing. 
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CHAPTER 4: Redevelopment of a micro external fixator 
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4.1 INTRODUCTION 
4.1.1 Models of fracture healing 
In order to determine whether endogenous mobilisation could influence fracture healing, a 
standardised, repeatable and reliable fracture model system was required. Ideally, any model 
should mirror the clinical scenario in terms of location, fixation and pathology as closely as 
possible. However, no model can completely reflect a clinical scenario and the ability for the 
model to be highly consistent and reproducible is also critical to discriminate between 
treatments, and may be paramount depending on the questions being asked. Other factors 
also require consideration, such as cost, technical expertise, size and the intended questions 
to be asked. Reflecting these varied needs, there are several options for modelling fracture 
healing. Historically, large animal models were more popular for fracture healing, but the 
use of rodent models has significantly increased to nearly 50% of all fracture studies. This 
increase has in part been associated with the advent of the gene/molecular age and the 
availability of those tools in rodents, particularly the mouse (Garcia et al. 2013). The rat 
however, is a good model as they have straightforward husbandry, are readily available, not 
overly expensive and not so small that they prohibit an accurate, repeatable surgical 
procedure. In terms of bone physiology, rats have lamellar bone with cancellous remodeling, 
although their cortical remodelling is less than in humans. Currently, the rat is used for 
around one third of all in vivo fracture studies (Mills & Simpson 2012).  
To model a fracture, a discontinuity in the bone is needed. This can be induced by 
application of external forces giving a realistic degree of associated soft-tissue trauma, but 
can result in variable fracture patterns, complicating the interpretation of results. 
Alternatively, a reproducible but arguably artificial ‘surgical fracture’ can be created by 
osteotomy or ostectomy. Typically, a method of stabilisation will follow. Stabilisation is 
usually designed with either direct bone union or indirect bone union in mind, as discussed 
in chapter 1. Clinically, indirect bone healing is seen in most fractures, including 
conservatively managed fractures, those stabilised by intramedullary nails or external 
fixators and when internal fixation is applied without compression and accurate reduction 
(Marsell & Einhorn 2011). Hence, indirect bone healing is the main mode of fracture healing 
evaluated in rodent research (Garcia et al. 2013) and several stabilisation options are 
available. A common method referred to as the ‘Einhorn technique’ (Bonnarens & Einhorn 
1984) uses a guillotine weight to fracture the bone and stability is then provided by an 
intramedullary pin. This system is known to give reproducible stiffness, but there is variation 
in interfragmentary and torsional stability inherent to the nature of the stabilising device. 
Fixation with an internal plate and screws is an option, but the close apposition of the plate 
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to the bone creates difficulty with the analysis of the healing zone and the internal implants 
are more difficult to remove. Hence plate and screw studies are far less commonly 
undertaken and direct bone union in rats using close approximation and compression plating 
has only been studied once (Savaridas et al. 2012). Both internal fixation with a plate and 
screws, and intramedullary pins can interfere with fracture healing assessment, and hence the 
external fixator is a popular choice, as the implants are at a distance from the fracture site 
and can be easily removed (Mills & Simpson 2012). Additionally, mechanical modulation of 
the fracture through changes in stiffness of the construct or by the size of the fracture gap 
can be easily accommodated using external fixation (Goodship & Kenwright 1985). The 
main issue with external fixation is the relatively high level of pin tract complications, which 
are universally regarded as common and have been reported in up to 100% of clinical cases 
(Kazmers et al. 2016). A recent Cochrane review however, was unable to identify 
management regimes to reduce this (Lethaby et al. 1996).      
4.1.2 A brief history of external (skeletal) fixation 
External fixators or ‘external skeletal fixators’ as they are referred to in veterinary medicine, 
have a variety of indications including open and closed fracture repair, joint immobilisation 
and angular limb corrections. Principally, an external method to stabilise bone fragments 
dates back to around 400 BC with Hippocrates treating tibial fractures using leather rings 
with cherry wood rods (Hippocrates 1939). French surgeon Malgaigne devised the first true 
external fixator with transcutaneous implants in 1840. Colloquially known as the Malgaigne 
patellar clamp, this device with skin puncturing hooks was used to treat transverse patellar 
fractures by grasping the upper and lower poles of the patella and then compressing them 
together with an external screw mechanism (Malgaigne 1847). However, it was British 
surgeon Mr. Keetley who first described an external fixation device with percutaneous iron 
pins deliberately implanted within the bone. The first readily available external fixator, the 
‘Parkhill clamp’, subsequently appeared in 1897. It was devised by an American surgeon 
and consisted of four screws, with two placed either side of the fracture, interconnected with 
external winged metal plates. Parkhill would apply this with an adjunctive posterior plaster-
of-Paris splint and published a case series of nine individuals with 8/9 going on to bone 
union  (Parkhill 1897). At the time, Belgian surgeon Lambotte had heard of the Parkhill bone 
clamp but could not access a copy of Parkhill’s paper. He went on to develop his own device, 
which was designed to be the sole fixation for the fracture, and had parallel placed pins with 
adjustable clamps (Lambotte 1913). Some years later, Roger Anderson, an American 
military surgeon developed a fixator that consisted of connecting rods and single or double 
clamps, to create a modular system of fixation, known as the Anderson splint.  
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In veterinary medicine, US veterinarian Otto Strader pioneered external skeletal fixators in 
1934. Dr. Strader began to treat long bone fractures in animals, and one of his animal 
patients was seen by surgeons working at the Bellevue Hospital, New York, leading to a 
collaboration and design modifications for humans. In the 1940s, Emerson Ehmer worked 
with the Kirschner company to develop the Kirschner-Ehmer splint, a veterinary 
modification of the Anderson splint for humans in 1947 (Pettit 1992). Versions of this 
system remained in widespread veterinary usage until the late ‘90s when other more 
adaptable and mechanically robust systems were developed.  
In human orthopaedics, the popularity of external fixation declined in the mid 20th Century 
due to poor results caused by errors of application and the rise of the AO principles 
associated with stable internal fixation. However, unbeknown and inaccessible to the West 
during the Cold War, Gavriil Ilizarov from the Soviet Union began to develop a circular 
fixation system, initially from recycled bicycle parts. He went on to pioneer circular frames 
to treat non-union fractures in humans in the 1950s, which used small diameter crossing 
pins/wires that were fixed to external metal rings. After working with this system, it became 
apparent that by applying traction to the frame it was also possible to grow or lengthen bone 
through ‘distraction osteogenesis’ (Ilizarov 1990; Hernigou 2016). These techniques are now 
widely used to correct complex limb deformities, complex fractures, and to regain bone 
length, all over the world, often using extremely sophisticated computer-planning systems.  
4.1.3 Fixator classification 
Fixators are typically classified as linear, circular, hybrid or free form. Linear fixators consist 
of pins, bars (rods) and clamps (Figure 4.1). Different frame configurations can be created, 
which affect the strength/stiffness of the frame:  
• Type Ia = unilateral, uniplanar, half-pins; Type Ib = unilateral, biplanar, half-pins. 
• Type II = bilateral, biplanar, full-pins; Type IIb ‘Modified Type II’ = bilateral, 
biplanar, full and half-pins. 
• Type III = bilateral, biplanar, full and half-pins. 
Circular or ring fixators use supporting rings, connective rods, bolts and tensioned 
transfixation wires. Hybrid fixators are fixators that combine elements of linear and circular, 
and free-form/acrylic/epoxy putty fixators are related to linear fixators, however the bars and 
clamps are replaced by epoxy putty, or by acrylic that is poured into a malleable tubular 
mould. 
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4.1.4 Construction of the modern external fixator 
The modern linear external fixator has three components making up the fixator montage or 
construct (Figure 4.1): 
1. Transcutaneous bone implants – smooth Kirschner wires or threaded pins that pass 
through the skin and fix the bone fragments in place. Pins are termed ‘half-pins’ if 
they penetrate only one skin surface and ‘full-pins’ if they exit the other side. Pins 
are usually placed bi-cortically. 
2. Connecting bars ‘rods’ – are rigid external structures (bars, circles, or set acrylic) 
that connect and immobilised the fixation pins.  
3. Linkage device – a method of linking the pins to the connecting bar (clamps).  
a  b  
Figure 4.1: a) Schematic showing the basic components of a linear type 1a external skeletal fixator 
placed on a stylised canine femur. b) Radiograph showing the revised Stanmore micro-Fixator at day 
0 on a rat femur. 
 
4.2 REDESIGN OF THE STANMORE RODENT MICRO-
FIXATOR SYSTEM 
A miniaturised skeletal fixator from the Institute of Orthopaedics and Musculoskeletal 
science, UCL, Stanmore, has been used in several prior studies (Harrison et al. 2003; Ho et 
al. 2014; Smitham et al. 2014). It is a unilateral uniplanar (Type Ia) external fixator with two 
pins proximal and two pins distal to a surgically created osteotomy. It had a double 
connecting bar with two connecting blocks which can slide axially along the bar, allowing 
alteration of the osteotomy gap size. In early studies, the blocks were made of anodized 
aluminum with stainless steel bars and bar bushings. In later iterations the blocks were 
manufactured from titanium, with titanium bars and eventually carbon fiber bars to improve 
radiographic imaging and to reduce the weight of the fixator (Figure 4.2).  
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Figure 4.2: a) Photograph showing the first generation fixator; aluminum block and stainless steel bars 
b) The evolved version of the original fixator, with square titanium blocks and carbon fiber bars. 
 
Despite its success, several issues were noted with the fixator and delivery system that 
warranted improvement: 
1) Loosening of the pin to bone interface, sometimes within days, sometimes within 
weeks (Figure 4.3).  
2) Fixator block interference with hindlimb soft-tissues. 
3) The jig system was cumbersome and did not provide tactile instrument feedback 
during surgery. Additionally, the apparatus could not be sterilised increasing the risk 
of infection (Figure 4.4). 
a  b  
Figure 4.3: a) Radiograph showing failure of the fixator at three weeks, with complete pin extraction 
from the bone proximally. b) Radiograph at three weeks, showing the bone without the fixator. The 
red arrow shows a large osteolytic hole where the pin tract was. Blue arrow suggests the formation of 
a ring-sequestrum around the other pin tract.   
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4.2.1 New jig system to produce a highly repeatable pin location 
Rather than using the table-top drilling and pin driving apparatus (Figure 4.4), a miniaturised 
guide-block was designed (Figure 4.5) to ensure consistent and standardised pin placement. 
The block had a concavity to allow it to sit on the craniolateral surface of the femur and was 
manufactured from Polyether ether ketone (PEEK) for durability, machinability and heat 
resistance allowing autoclave sterilisation. It also had indentations to facilitate the 
application of a precision micro-ratchet forceps (Kyon, Switzerland) to stabilise the guide on 
the bone. The guide-block could universally accept either a drilling insert-sleeve designed 
specifically for the drill bit size intended, or pin insert-sleeve, again designed to accept the 
fixator pin specifically (see Figure 4.5b). The insert-sleeves were manufactured from 
titanium and heat treated to change their colour, which aided in their identification; the drill 
sleeve was ‘silver’ and had a conical top, whereas the pin sleeve was ‘gold’ and had a flat 
top (Figure 4.5b). 
 
Figure 4.4: Photograph showing the previous drill and pin guide apparatus. This apparatus allowed for 
the table-top to be moved intra-operatively using precision XY axis adjustment dials, allowing the 
hand driven chuck to be positioned correctly.  
 
a  b  
Figure 4.5: a) Photograph showing the revised miniaturised drill and guide-block, which sits directly 
on the craniolateral femoral surface. i) Shows the lateral surface with the concavity on the underside. 
ii) Shows the top surface with recesses to accept insert-sleeves and micro-ratchet recesses. iii) Shows 
medial surface. b) Photograph showing the titanium pin sleeve (i) and the drill sleeve (ii). The guide-
block universally accepts either of the two sleeves (iii). 
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4.2.2 Block redesign 
Titanium remained the preferred material for the blocks due to its reduced X-ray artifact 
generation in 3D imaging, its lightweight nature and wear resistance properties. To make the 
fixators truly modular, the connecting bars in the proximal block were no longer chemically 
bonded in place, but secured with M2 stainless steel grub screws. To reduce skin rubbing, 
the edges of the blocks were chamfered (Figure 4.6a). As before, these fixators are designed 
to allow axial displacement of the fragments such that any desired fracture gap size can be 
created within the range of the bar length (Figure 4.6b). The bars remained as 2mm diameter 
carbon-fiber-epoxy resin matrix (Goodfellow, UK). 
a  b  
Figure 4.6: a) Photograph showing different aspects of the revised fixator. i) Shows the cranial surface 
of the fixator, which reveals the M2 stainless steel grub screws to secure the proximal and distal 
blocks. The distal screws can be loosened to allow sliding and distraction of the osteotomy. ii) Shows 
the lateral surface of the fixator; notably, the pin-holes are eccentric such that the bulk of the block 
can be positioned caudal to the pins, as most of the rubbing occurred on the cranial surface. iii) Shows 
the caudal surface of the fixator, which has the four M2 stainless steel grub screws that secure each 
individual pin. b) Photograph showing the various degrees of axial distraction available.  
 
4.2.3 Pin redesign 
The pin-bone interface is considered the mechanical ‘weak link’ in an external fixation 
construct	 (Lewis et al. 2001; Briggs & Chao 1982) and its stability is influenced by the pin 
design and methodology of its placement. Initially, a 1mm hole was predrilled into the bone 
using a high-speed dental burr (Hand Engine No.5, Royal, UK) to facilitate pin placement. 
Early pin loosening and concerns over initial pin stability during surgery inevitably related to 
the mechanical adequacy of initial pin placement. The original pins were 1.2mm diameter 
stainless steel, end threaded with a domed ‘blunt trochar’ leading edge (Figure 4.7a & c). 
These pins were difficult to place in the bone leading to noticeable hand wobble when driven 
with hand chucks. Hand wobble has been shown to create a conical deformation and hence 
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reduce the ‘goodness’ of fit of the pin in the cis (near) cortex (Bible & Mir 2015). Studies 
looking at screw insertion into pre-drilled holes have shown that a sharp trochar tipped screw 
required similar insertion torque to a pre-tapped hole. The blunt tipped screw was considered 
thread forming and caused more bone damage than the sharp trochar tipped screw, which 
was considered ‘self-tapping’ (Kuhn et al. 1995). Therefore, in order to improve pin 
placement, a self-tapping/cutting ability was sought. New pins were made by end-threading 
trochar tipped 316LVM stainless steel Kirschner wires, of 1.25mm diameter, with a three-
point 450 trochar (Veterinary Instrumentation, UK) (Figure 4.7b & d). Trochar tip pins 
should improve stability, as they have been shown to have a higher initial pull-out resistance 
in canine metatarsals, when inserted at slow speeds, compared with other designs (Namba et 
al. 1987).  
Pins inserted into a hole that is smaller than the pin itself generate a circumferential 
compressive interaction between the pin and bone, which increases pin stability, known as 
‘radial preload’ (Biliouris et al. 1989). Canine experimental studies have shown however, 
that if the hole is excessively reduced, there is an increase in bone micro-fracture. A pilot 
hole that approximates but does not exceed the core diameter of a threaded pin is thought to 
provide the best compromise between increase initial pin stability and microstructural 
damage that may subsequently lead to necrosis and loosening (Clary & Roe 1996). Similar 
microstructural damage has also been shown in human samples with misfits greater than 
0.4mm (Biliouris et al. 1989). A 1.2mm die produced a core diameter of 0.955mm, and 
therefore the pre-drill was reduced from 1.0mm to 0.9mm for the 1.25mm trochar tipped 
pins, with the aim of creating a tighter fit and increased radial pre-load, without undue 
microstructural damage. No early pin loosening was seen after these changes were 
implemented and immediate surgical pin stability in cadavers and in vivo was excellent 
(n=8). However, late pin loosening from around three weeks was still seen in 50% of 
individuals.   
 
Figure 4.7: Photographs showing the original blunt trochar tipped pins (a, and c), and the revised 
sharp cutting trochar tipped pins (b and c). 
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4.2.4 Pin placement changes  
Ongoing ‘late’ pin loosening was still being seen at around three weeks post-operatively 
(Figure 4.8a). Most commonly, but not exclusively, this was seen at the most proximal pin. 
Notably, on two occasions there appeared to be a radiographically pathognomonic ring 
sequestrum associated with some pin tracts (Figure 4.8b). Typically these have a 
“characteristic radiographic finding of a band of sclerotic bone adjacent to the pin tract, 
which is surrounded by an irregular radiolucent zone of bone destruction” (Nguyen et al. 
1986). In human bone, thermal necrosis leads to a wide sclerotic zone of dead bone with a 
narrow lucent halo, suggested to be associated with increased osteoclastic activity, whereas 
the infected necrotic sclerotic zone is smaller and the lucent region consists of granulation 
tissue (Nguyen et al. 1986).  
a 	b  
Figure 4.8: a) Radiograph showing osteolysis and lucency around the proximal pins. b) Radiograph 
showing a distal femoral fragment with marked remodeling around the distal pin tracts. The upper pin 
tract has a sclerotic region with a surrounding lucent zone suggestive of a ring sequestrum.    
 
Although infection is also required, a relationship between thermal necrosis and the 
aetiology of this type of radiographic phenomena is widely reported (Augustin et al. 2007; 
Matthews et al. 1984). A broadly accepted risk factor for pin loosening and infection is 
thermal necrosis of bone and heat damage to soft-tissues (Matthews et al. 1984). Rabbit 
studies have shown that a temperature exposure of 70°C will cause immediate necrosis 
(Berman et al. 1984) and 47°C for greater than one minute will also lead to cortical bone 
necrosis (Eriksson et al. 1984). In human bone studies, predrilling prior to pin placement 
significantly reduced the temperature elevation (Matthews et al. 1984). Pre-drilling was 
already part of this procedure, however saline irrigation was not. Experiments with pig 
femurs have shown that applying 25°C external water cooling was more important in 
reducing drilling temperatures than drill bit size, speed, feed rates or bit design (Augustin et 
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al. 2007). The heat distribution associated with drilling has been investigated in ex-vivo 
bovine mandibles using embedded thermo-resistors. The greatest amount of heat was found 
at the superficial and not the deep region of the drilled hole, hence external coolant rather 
than a cannulated internal coolant to the drill tip is appropriate (Sener et al. 2009). From this 
point onwards, sterile saline was used to irrigate pins and drill bits whilst in use.  
The pre-drilled hole for the fixator pin was initially performed using a high-speed dental burr 
(Hand Engine No.5, Royal, UK), which reaches speeds of 20,000rpm. The thermal effects of 
drill speed in the published literature is quite mixed (Pandey & Panda 2013). Work from the 
1950s showed increased temperature when speeds increased from 125 to 2000rpm 
(Thompson 1958). A more recent study showed that sequentially increasing drill speed from 
188 to 1820rpm with a consistent drill bit diameter increased the bone temperature from 31 
to 55°C (Augustin et al. 2007). However, a cadaveric porcine mandible study showed high-
speed drilling at 2500 rpm caused a significantly smaller increase in temperature than at 
1667 or 1225rpm. This is not necessarily a simple contradiction in the literature, as they note 
the overall time the drill was in contact with the bone was less when the higher speeds were 
used, suggesting an additional influence of duration of drilling (Sharawy et al. 2002). Similar 
findings were seen in a rabbit tibial model that used concurrent coolant during osteotomy 
preparation, with thermocouple readings showing an inverse relationship of temperature and 
speed when 2,000, 30,000 and 400,000 rpm were compared (Iyer et al. 1997).  
A confounding factor in evaluating drill speed data is the interaction of the driving or 
feeding force applied to the drill bit, such that it can cut effectively and not simply rotate on 
the bone creating excessive friction and heat. In an ex vivo study with different loads applied 
to a drill press, it was clear that increased drill driving load, significantly decreased the bone 
temperature as read by thermocouples, and importantly, it was below 50°C (Bachus et al. 
2000). Others have shown a 10 fold increase in drill speed did not increase the temperature 
measured in the bone, however an increase in force applied to the drill did decrease the 
temperatures measured (Matthews & Hirsch 1972). On balance therefore, I changed from the 
dental burr to a spiral push drill (Rolson, UK). These drills do not rotate as quickly as a burr 
and require the application of axial load to rotate the drill bit, which was not as intuitive with 
the high-speed dental burr. Although not directly measurable, it is likely there was an 
improvement in the driving force applied and hopefully an improved cutting efficiency and 
reduced heat generation. To ensure good cutting efficiency the drill bits were regularly 
replaced with new ones.  
As noted, high pin insertion speeds have been shown to generate more heat (Thompson  
1958) and current recommendations are that they should be driven with power at low,  
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<150rpm speeds	(Egger 1992; Lewis et al. 2001). In my model, pins were advanced by hand 
in a small chuck (162A Pin Vice, 0-0.040, Starrett, USA), as a low speed high torque driver 
at the micro scale was not available.  
Pin site care to reduce pin tract infection and loosening is a debated topic in human and 
veterinary clinical fixator management. Antiseptic cleaning, specialised dressings and 
prophylactic antibiotics have all been suggested to reduce pin tract infections and associated 
loosening (Kazmers et al. 2016). However, a relatively recent Cochrane review of all 
available evidence was unable to give a clear indication of what pin care measures should be 
taken (Lethaby et al. 1996). Many of these ideas were not feasible in relation to this study 
due to the risks and welfare impact by regular handing and cleaning of the fixator pin tract 
sites, particularly when the evidence base is not strong.  
A final option would have been to adopt a pin coating such as hydroxyapatite to improve the 
pin-bone interface	(Magyar et al. 1997; Saithna 2010). However, this would have been cost-
prohibitive and technically problematic with such small pin threads and was not pursued. 
Additionally, although the specimens were decalcified for histology, it could have 
introduced problems with histology processing when pin removal was required.  
4.2.5 Pin size & number 
As interfacial strains greater than 2% are thought to induce osteoclastic, chondrogenic and 
fibrous tissue formation, and hence pin loosening, a reduction in strain should be beneficial 
(Palmer et al. 1992). Further mitigation of late pin loosening was therefore sought via two 
alternative techniques. Firstly, the number of pins in the proximal segment was increased to 
increase the construct stiffness (Bouvy et al. 1993) and reduce the load at each individual 
pin-bone interface (Moss & Tejwani 2007). Two pins per fragment is the minimum to 
prevent rotational instability and beyond four per segment, there are no further changes in 
frame stiffness (Palmer et al. 1992). Unfortunately, there was limited space available on the 
rat femur for pin placement and instrument access and therefore a 2:3 configuration was 
adopted, with three proximal pins (Figure 4.9a). Although no pin loosening was seen (n=3), 
the additional pin made the fixator placement more challenging.  
The alternative method investigated was to increase the pin diameter. The fixator construct 
in these osteotomies is not load sharing initially and therefore all limb loads will be 
transferred between the pins and the bone at their interfaces. A parametric analysis based on 
finite element models was able to show that these loads could be reduced by ensuring full 
pin insertion, decreased pin working length and by increasing the resistance of the pin to 
bending (Huiskes et al. 1985). I could not reduce the pin working length due to issues of 
	 142	
soft-tissue interference and therefore increasing the pin diameter was chosen. The resistance 
to bending of a cylindrical structure is dictated by the following equation; 3πd4 E/64L3, where 
d is the pin diameter and L is the pin working length (distance from the edge of the bone to 
the fixator block) and E is the modulus of elasticity (Huiskes 1986). To that end, a small 
increase in pin diameter will give a large increase in bending resistance (to the forth power), 
which should reduce the loads and strains at the pin-bone interface. A threaded 1.4mm 
trochar tipped 316LVM stainless steel Kirschner wires, with a 3 point 45 degree trochar 
(Veterinary Instrumentation, UK), was chosen (Figure 4.9b), and the pre-drill hole was 
increased to 1.0mm. The core diameter from cutting a thread into this size pin was 1.155mm, 
ensuring radial preload generation. The 1.4mm diameter pin was also deemed around the 
maximum size appropriate relative to the size of the femur, as it was approximate 30% of the 
bone diameter. The use of hand tools and placement of trochar tipped threaded 1.4mm pins 
resulting in no radiographic or clinical evidence of pin loosening throughout the study period 
of five weeks  (n=6) (Figure 4.9 c) 
a		 b	 	
c	  
Figure 4.9: a) (i) Photograph of the 3:2 proximal pin fixator next to the standard 2:2 fixator. (ii) 
Radiograph taken five weeks post surgery using the 3:2 fixator system with 1.25mm diameter pins. b) 
Photograph showing the 1.25mm sharp trochar pin (i) next to the 1.4mm sharp trochar pin (ii). c) 
Radiograph taken five weeks post-operatively showing no evidence of pin loosening with the 1.4mm 
fixator pins.   
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4.2.6 Surgical summary 
All procedures on live animals were performed under general anesthesia using aseptic 
techniques, in accordance with U.K. Government Home Office regulations. The procedure is 
summarised in figure 4.10. Briefly, the left hindlimb was disinfected and draped. A lateral 
femoral approach was made, with a 2cm skin incision followed by incising the external 
fascia along the cranial edge of the biceps femoris. The biceps femoris was bluntly separated 
from the tensor fascia lata along their adjacent planes and then elevated along the 
craniolateral aspect of the femur using a freer elevator. The distal extreme of the greater 
trochanter was used as a landmark for consistent positioning of the jig-guide over the 
craniolateral femur, which was then held in place using a precision micro-ratchet forceps 
(Kyon, Switzerland). The most proximal hole was loaded with a drill insert-sleeve. A 1.0mm 
HSS drill bit, was loaded into a spiral push drill (Rolson, UK) and used to drill both cortices 
whilst sterile saline coolant was applied. A 0.8mm temporary stabilising pin was then 
inserted (Figure 4.11a), and the distal hole was drilled, followed by the placement of a short 
(23mm) 1.4mm pin, using the pin insert-sleeve in the guide jig with a miniature hand chuck 
(162A Pin Vice, 0-0.040, Starrett, USA). Pins were placed bi-cortically, ensuring that the 
entire trochar tip had passed the trans cortical edge. This was checked using a small curved 
edge Mosquito haemostat and is of importance as bicortical pin placement significantly 
improves pin holding power (Oliphant et al. 2013). The remaining pins were placed as 
described, such that there was a short pin (23mm) next to a long pin (28mm) in the proximal 
pair and the distal pair, to facilitate the instrumentation. The cranial femoral skin was 
retracted caudally over the pins and a small pin tract was made using a no. 11 scalpel blade 
to allow the pin to pass through the skin. A custom precision fork-shaped spacer (Figure 
4.11c) was placed to ensure a fixed distance between the cis cortex and connecting blocks of 
9mm.  
The fixator was then attached and the pin locking grub screws tightened. A mid-diaphyseal 
femoral osteotomy with no periosteal stripping was made using a diamond tipped handsaw, 
whilst applying sterile saline coolant/lubricant. The distal fixator block had its grub screws 
loosened and then the block was slid distally to distract the osteotomy gap. A precision 
spacer of the desired osteotomy size (Figure 4.11b) was placed within the osteotomy and 
then the osteotomy was closed down onto it and the distal block grub screws re-tightened. 
The biceps femoris was closed over the osteotomy with a single horizontal mattress suture 
(1.5M PDS II, Ethicon, UK), and the skin was closed with intradermal continuous suture 
(1.5M Monocryl, Ethicon, UK). Activity was unrestricted post surgery. In chapter 5, 1.0mm, 
1.5mm and 2.0mm gaps were evaluated for their healing. 
	 144	
 
Figure 4.10: Photographs showing the temporal sequence of placement of the Stanmore micro fixator 
to achieve a 1mm osteotomy. a) Skin incision exposes boundary of the biceps femoris to tensor fascia 
lata. b) Placement of drill and pin guide jig, retained with micro-ratchet forceps. c) Proximal drill 
sleeve and drill bit, with spiral push drill. d) Proximal stabilising pin in place and distal fixator pin 
placed, with sleeves remaining. e) Checking the full trochar has penetrated the trans cortex. f) Four 
fixator pins placed – short pins proximal and distal, long pins centrally. g) Fixator pin tracts made and 
skin placed over pins. h) Fixator positioned along pins and spaced by precision spacer from bone. i) 
Cutting the mid-diaphyseal osteotomy with a diamond tipped handsaw. j) Setting the desired 
osteotomy distance using the precision titanium spacer. k) Checking the osteotomy size. l) Surgical 
incision closed with intradermal continuous suture.   
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Figure 4.11: Photographs showing the new tools developed for the procedure. a) The temporary 
stabilising pin, placed after the first drill hole is made, to prevent jig-guide movement. b) The 
precision spacer temporarily placed within the osteotomy gap. c) The pin working length spacer, 
which accommodates the skin and sat between the inner aspect of the connecting block and the outer 
aspect of the bone. 
 
4.2.7 PEEK scanning fixator blocks for microCT 
After culling and formalin fixing, the femurs were microCT scanned. To reduce beam 
hardening artifact interference associated with the titanium connecting blocks, a PEEK 
scanning fixator was also designed (Figure 4.12). This could be placed between the bone and 
the titanium fixator prior to removal of the titanium fixator for scanning. This fixator also 
had a sliding mechanism such that it could accommodate the differing gaps between the 
proximal and distal pin pairs dictated by the size of the osteotomy created at surgery. 
a  b  
Figure 4.12: a) Photograph showing the cranial surface of the scanning fixator. The ‘nut’ component 
associated with the bolt threads can be rotated to pass in between the existing fixator pins, and then be 
rotated back to allow it to compress against the pins as the M2 stainless steel hex bolts are tightened. 
b) Photograph showing the scanning fixator in place below the titanium fixator. Note the ovoid hole 
on the right hand side, which accommodated for the differing gap sizes between the proximal and 
distal pin pair.  
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4.3 CONCLUSION 
The revised jig system improved asepsis and allowed for a rapid and reliable surgical 
procedure. The 9mm pin working length and chamfered block edges significantly reduced 
soft-tissue interference. The reduced pre-drill size relative to pin size and utilisation of a 
cutting trochar tip improved initial pin stability. Using a spiral twist drill, applying irrigation 
and the increased pin diameter reduced late pin loosening attributed to osteolysis. Due to 
ethical consideration and 3Rs, it was not appropriate to evaluate these differences 
individually as the aim was to reduce pin loosening, rather than determine which change was 
most influential. The PEEK scanning fixators successfully reduced the microCT beam-
hardening artifact.  
Overall, the revisions made here improved the fixator system, increased its repeatability and 
reduced complications. In chapter 5 the redesigned fixator was used to determine the 
preferred gap size to impair healing for subsequent evaluation of endogenous mobilisation of 
stem and progenitor cells in chapter 6.  
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CHAPTER 5: Evaluation of Gap Size & Tissue Formation 
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5.1 INTRODUCTION: Goldilocks scenario  
The influence of mechanical stability on fracture healing has been extensively investigated 
(Betts & Müller 2014). Numerous animal models have altered fracture rigidity to study the 
mechanisms underlying fracture healing, be it intramembranous ossification, endochondral 
ossification, or extreme nonunion models	 (Garcia et al. 2013; Mills & Simpson 2012). 
Previous work using the prototype Stanmore micro fixator has shown guaranteed union by 
five weeks with a 0.5mm osteotomy gap and non-union with a 3.0mm osteotomy (Harrison 
et al. 2003). This model demonstrated the influence of a critical sized defect, which is 
defined as the “minimum amount of bone loss that will not heal by new bone formation over 
an animal’s lifetime” (Schmitz & Hollinger 1986). Key’s hypothesis proposed that a 
segment 1.5x the diaphyseal diameter would lead to non-union (Key 1934). Toombs 
evaluated this in cats and determined that 1.5x was an overestimation (Toombs et al. 1985), 
although there may be species differences in healing capacity. The recommended defect size 
is unknown for rodents (Mills & Simpson 2012), however, the rats used in Harrison’s study  
had an estimated diaphyseal diameter of 3-4mm and a 3mm gap resulted non-union 
(Harrison et al. 2003), implying the critical size may be smaller in rats than proposed by Key.  
To evaluate endogenous mobilisation strategies effectively in later chapters, I was looking 
for a compromised healing environment; one not so compromised that it would be 
impossible to show an effect of intervention, but likewise not so competent at healing that 
any improvement would be lost; my so called ‘Goldilocks scenario’. It is expected that this 
would be approximately 1.5mm, as 0.5mm and 3mm gave the extremes of union and non-
union, however, this needed to be proven. In this chapter, I aimed to evaluate the 
biomechanical effect of osteotomy gap size between those two extremes and to map this 
against the associated interfragmentary strain (IFS). Perren’s theory of IFS predicts that if 
IFS falls to levels where cartilage can form (<10%) then soft callus will develop, and if <2%, 
bone can form and hence ‘hard callus’ should follow. If however, the IFS was not initially or 
subsequently low enough, fracture union would fail (Perren 1979; Perren 2004). Perren’s 
theory would also predict that for a given interfragmentary movement, the bigger the gap the 
better the predicted healing due to reduced IFS.  
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Question: Could the biomechanical environment between union and non-union be 
manipulated to identify a compromised healing environment to evaluate endogenous 
mobilisation strategies for fracture healing? 
Hypothesis – increasing gap size from 1.0 to 1.5mm to 2.0mm will decrease IFS, reduce 
construct stiffness and hence improve bone formation within the gap. 
 
5.2 MATERIALS & METHODS 
5.2.1 Biomechanical assessment of interfragmentary strain & construct stiffness 
The fixator was placed as per chapter 4 (4.2.6), on the femora of cadaveric 12-14 week old 
Wistar rats (n=4). Femora with the fixator still attached were then disarticulated at the hip 
and stifle and stripped of soft-tissue attachments. An orthogonal (lateral to medially 
orientated) 0.8mm bicortical hole was drilled between the two proximal and two distal 
fixator pins. A microminiature differential variable reluctance transducer (accuracy 
0.001mm) (Lord MicroStrain, model 6101-0200) was then inserted and fixed in position 
using cyanoacrylate glue, to quantify fracture movement (Figure 5.1). Femurs were 
biomechanically tested using a materials testing machine (Zwick Roell 5T, UK). They were 
mounted in an axial loading jig with the femoral condyles centred over the lower mount and 
the upper mount was centred over the femoral head to simulate the physiological loading 
axis of the femur along its mechanical axis (Figure 5.1b). This design also effectively tested 
the entire construct of fixator and bone as a single unit, as it would be clinically.  
a  b  c  
Figure 5.1: Photographs showing the set-up for the biomechanical analysis to determine the IFS and 
stiffness of the fixator construct. a) Lateral aspect of the femur with the fixator and microdisplacement 
sensor in place b) The load was applied from the femoral head to the femoral condyles to simulate 
physiological loading along the mechanical axis. In the orthogonal projection a LORD micro 
displacement sensor was attached to provide a highly accurate measure of displacement at the level of 
the osoteotmy.  c) Zoomed out image of the test apparatus. 
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A calculated resting load for quadrupedal animals of 60% weight carriage to forelimbs and 
40% to hindlimbs (Lee et al. 1999) gave 20% per hindlimb. A maximum weight of 300g was 
seen in the in vivo study and therefore peak-walking load was assumed to be 0.6N. A single 
cycle non-destructive test was performed, with a preconditioning load of 0.5N, followed 
with loading to a maximum of 10N in compression at 5mm/min, sampling rate of 50Hz. The 
first cycle was disregarded and then four repeats were performed per gap size, per sample. 
The microsensor millivoltage output was recorded and the difference pre and at peak load 
was determined. This was then converted into a displacement according to manufacturers 
calibration equation. Fixator–bone construct stiffness was determined from the load vs. 
displacement (deformation) graphs obtained from TestXpert software (Zwick, Roell, UK). A 
linear regression line (r2) was calculated for the linear portion and r2 >0.99 was considered 
appropriate for the linear elastic region. The gradient (m) was determined based on a 
y=mx+c equation and gave the stiffness (Figure 5.2). 
 
Figure 5.2: A typical load displacement (deformation) graph. The gradient of the linear portion of the 
curve provided the construct stiffness.   
 
Three gap sizes were evaluated per specimen; 1.0mm, 1.5mm and 2.0mm. The distal fixator 
connecting block was loosened to allow insertion of the precision titanium spacer and then 
tightened again. The gap was then checked a second time prior to loading and again between 
each repeat by ‘offering-up’ the spacer to the gap. Care was taken to ensure the gap was even 
across the width of the osteotomy.  
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5.2.2 In vivo evaluation of osteotomy gap size on fracture healing 
As previously described in chapter 4 (4.2.6), the modified Stanmore micro fixator was 
placed in 12-14 week-old female wistar rats (230-300g). Three groups were assessed: 1.0mm 
(n=5), 1.5mm (n=7), and 2.0mm gap (n=6). Activity was unrestricted post surgery. 
MicroCT & radiography 
After five weeks, the left femur including the fixator was retrieved from the sacrificed rats. 
A radiolucent PEEK fixator block was connected externally to the fixator pins after careful 
removal of the skin and surrounding soft-tissues. Without disturbing the fracture callus, the 
titanium block fixator was then removed to reduce beam-hardening artifact generated from 
the interaction of the X-ray beam and the metallic implant on the microCT scans. Samples 
were fixed in 10% buffered formaldehyde for up to three days. The formalin fixed samples 
were wrapped in cling film to prevent dehydration and mounted into a sample holder for 
microCT scanning. Samples were scanned using a Bruker Skyscan 1172 microtomograph 
machine (Bruker, Belgium), at 60KV, 167uA with a 0.5mm aluminum filter. A rotation step 
of 0.5 degrees, without frame averaging, and an image pixel size of 4.89um was used. A 
single capture image was taken with the image intensification ‘scout’ prior to scanning, for 
2D radiographic assessment of the osteotomy union. Radiographic scouts were assessed for 
bone union in a randomised and blinded manner and then assigned to one of the three 
categories (Figure 5.3):  
• Non-union, where there was no mineralised tissue bridging between the ends of the 
osteotomy  
• Partial-union, where there was significant bone formation, however a radiolucent 
line remained between the proximal and distal segments 
• Union, where no gap between bone ends was visible  
a  b  c  d  
Figure 5.3: Plain radiographs showing a) 1mm osteotomy day 0. b) Non-union. c) Partial-union. d) 
Union. Images b-d were taken at five weeks post 2.0mm osteotomy. 
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MicroCT scans were reconstructed using NRecon (Bruker, Belgium) with smoothing = 2, 
ring artifact reduction = 12% and beam hardening artifact reduction = 41%. Analysis was 
performed using CTAn (Bruker, Belgium). Using the measuring tool, the centre point of the 
osteotomy was determined and the transverse slice at that point was selected as the reference 
slice. If the alignment of the osteotomy or the orientation of the osteotomy relative to the 
transverse slice section on the microCT were not identical, then analysis of the full width of 
the osteotomy could be misleading due to potential inclusion of cortical bone edges from the 
original osteotomy. To avoid this and to allow comparison between different gap sizes the 
central 60% of the osteotomy gap (Table 5.1), i.e. only new bone formation within the 
osteotomy was analysed (Figure 5.4 gives representative examples). This percentage was 
reached after trial and error. Due to the differing gap sizes between the groups and in order 
to determine a uniform measure of tissue healing, a comparison index was calculated by 
dividing the overall output parameters by the number of slices analysed.  
 
Table 5.1: The number of slices analysed and the effective osteotomy gap proportion analysed by 
microCT, to give a proportional analysis for direct comparison between groups. 
 
a b c  
Figure 5.4: Radiographic and computed tomographic images showing microCT analysis of the 60% 
osteotomy gap window for a) 1.0mm osteotomy. b) 1.5mm osteotomy. c) 2.0mm osteotomy. A 
representative transverse slice is shown from the most proximal, mid and distal region of analysis. 
 
Gap Size (mm) 
 
Number of Slices 
(slice thickness 5um) 
60% Osteotomy Gap  
Distance (mm) 
60% Osteotomy Gap 
 Slice Number 
1.0 200 0.6 120 
1.5 300 0.9 180 
2.0 400 1.2 240 
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Slices were filtered with a Gaussian blur (2d Space), square Kernel radius = 1 algorithm, 
then thresholded with a lower grey threshold of 100, upper grey threshold of 255. The callus 
was isolated using a 2D ROI shrink wrap stretching over holes <40 pixels, despeckled <150 
voxels and then 3D analysis was performed (Campbell & Sophocleous 2014) with output 
into Excel (Microsoft, USA).   
Histomorphometric analysis of callus 
After microCT analysis the bones were decalcified in a solution of 
ethylenediaminetetraacetic acid (EDTA, Sigma Aldrich, UK), at 37°C, with constant gentle 
agitation for four weeks. Decalcification was confirmed radiographically and then specimens 
were sequentially dehydrated for 24 hours at the following alcohol concentrations: 50%, 
70%, 90%, 100%, followed by de-fatting with chloroform for 48 hours and then embedded 
into wax, with the fixator pins orthogonal to the facing surface of the block (Figure 5.5a). 
Fixator blocks and pins were removed once the wax had set and a sledge microtome 
(ThermoFisher Scientific, UK) was used to make 5µm thick slices (Figure 5.5b). The 
alignment of the blocks within the microtome was altered as necessary to ensure a central 
sagittal slice through the femur. The position of a mid-sagittal section through the fracture 
gap was assessed using the fixator pin tract holes; at the mid position, the fixator pin tract 
holes for both the proximal and distal segment were in the centre of the femoral medullary 
cavity with a section of the cortical bone spaced equally from the pin holes.  
a  b  
Figure 5.5: Photographs showing the post-mortem processing after limb removal at five weeks. a) 
Bone embedded ready for removal of fixator pins and blocks. b) Block being cut in the microtome. 
 
Wax slices were mounted onto positively charged glass slides (X-tra, Leica biosystems, UK) 
and de-waxed twice in xylene, followed by two changes of 100% alcohol, prior to a 
hydration series of 90%, 70% and 50% alcohol. After hydration, samples were stained with 
haematoxylin nuclear stain for five minutes (Sigma-Aldrich, UK). Excess stain was removed 
by gentle washing with water for five minutes. Slides were counterstained in 1% eosin 
(Sigma-Aldrich, UK) for four minutes and then washed and dehydrated in increasing 
concentrations of alcohol. Slides were then cleaned in xylene and mounted under 40mm 
coverslips using Pertex Mounting Medium (CellPath plc, UK). Slides were observed under a 
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light microscope (KS-300 Zeiss, UK). All slides were imaged and saved as Tiff files. 
Histomorphometric analysis was performed on 1x and 2.5x magnified images (Figure 5.6). 
Four mid sagittal sections were made and the most central two were stained and the best was 
analysed.  
a b  
Figure 5.6: Histology images of the osteotomy gap. a) Shows a 1.5mm gap non-union. b) 1.5mm gap 
partial union. Both images are shown at x1 magnification with a central region for detailed 
histomorphometric analysis at x2.5. 
 
As higher magnification images did not allow full visualisation of the callus, at 1x 
magnification, the total area between the two innermost pin tract holes and areas of fibrous 
or cartilaginous tissue were all measured using Image J (NIH, USA) (Figure 5.7a). On the 
digitised scaled images, the area of interest was delineated using the drawing tool. The 
measure function was then used to give an area measurement based on the square pixels 
present in the delineated region. This method was chosen as the image size and megapixels 
(3.0x10^6) were consistent in all x1 magnification images and it was not possible to have a 
scaled graticule incorporated into the images due to the equipment. The areas measured 
provided a useful comparison between samples in this study, but could not be used as an 
index to compare with other studies.  
Histomorphometric analysis at 2.5x magnification was performed on the most central slice, 
using a line-intercept method with a grid scaled to the graticule and drawn using powerpoint 
(Microsoft, USA). The grid covered the entire visual field from top to bottom and was 
centered over the osteotomy; its width was equivalent to the original osteotomy (1.0, 1.5 or 
2.0mm as appropriate). Grid ‘density’ was consistent between the different group osteotomy 
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sizes, such that the 1.0mm gap had 75 intersections, 1.5mm gap had 120 intersections and 
the 2.0mm gap had 165 intersections. Grid squares were 160um in both directions for all 
groups. Intersections were then scored as bone, cartilage, fibrous tissue, vascular (identified 
by red blood cells not within matrix) or void.  
a  b  
Figure 5.7: Histology images. a) Examples of 1x area analysis of a central sagittal slice. Total callus 
area was measured between the innermost margins of the fixator pin holes on all samples to provide a 
consistent landmark. This was possible as the surgical fixator guide gave a consistent distance 
between the two innermost pins and the edge of the osteotomy. The blue outline delineates a central 
region of cartilaginous tissue. b) 2.5x image, with a grid width equal to the original gap size, in this 
case 1mm. Intersection points were then scored for the tissue formed.  
 
5.2.3 Statistical analysis 
Due to the relatively small group sizes (n<9), non-parametric tests were performed to 
compare groups including Mann-Whitney U (MWU) and Kruskal-Wallis (KW) as 
appropriate. Significance was set at p<0.05 and tests were analysed with SPSS version 24 
(IBM, Chicago, USA). Fisher exact test was performed to look for differences between 
radiographic fracture union (GraphPad Prism v6.00, USA). 
5.3 RESULTS 
5.3.1 Mechanical analysis 
The mean±SD stiffness of the four femoral-ESF constructs for the 1.0, 1.5 and 2.0mm gaps 
were 32.6±5.4, 32.5±2.4, and 32.4±8.3 N/mm; the gap size over the ranges tested had no 
impact on the construct stiffness (p=0.779), however gap size did significantly reduce the 
IFS in the gap (p=0.013), with 1.0 gap having a significantly higher IFS than the 2.0mm gap 
(p=0.029). The mean±SD % IFS for the 1.0, 1.5 and 2.0mm gaps were 11.2±1.3, 8.4±1.5 and 
6.1±1.2% respectively. The results for the individual femurs are summarized in table 5.2 and 
figure 5.8 and figure 5.9. The trends were consistent between femurs, however there were 
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differences in the absolute values, potentially relating to the position of the fixator or the size 
of the femur.  
 
Table 5.2: Summary stiffness (N/mm) and strain (percentage change) of different femurs with 
different gap sizes. All values are the mean ± standard deviation 
Femur 1  Femur 2 Femur 3  Femur 4 Group mean±SD 
1.0mm Gap Strain (%) 12.9±0.3 11.4±0.7 9.7±0.5 10.9±0.1 11.2±1.2 
Stiffness (N/mm) 39.8±0.8 31.7±1.0 26.7±1.1 32.2±0.6 32.5±4.6 
1.5mm Gap Strain (%) 10.3±0.3 8.3±0.2 6.8±0.1 8.0±0.2 8.3±1.2 
Stiffness (N/mm) 29.4±2.7 34.9±0.9 33.7±0.1 31.8±0.2 32.5±2.4 
2.0mm Gap Strain (%) 7.9±0.1 5.7±0.4 5.5±0.1 5.3±0.3 6.0±1.1 
Stiffness (N/mm) 24.3±2.0 31.5±1.2 29.7±0.2 43.9±0.8 32.2±7.3 
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a  
b  
c  
Figure 5.8: a) Photograph of the four femurs biomechanically tested showing the position of the fixator 
(numbered femur 1-4 from left to right). b) Line graph showing the mean IFS as the gap increased for each 
femur. c) Line graphs showing the mean stiffness (N/mm) as the gap size increased for each femur. 
Notably, all trends were consistent despite the variations in fixator position and femoral length, with the 
higher IFS being measured on femur 1 and lowest on femur 3. This could relate to individual bone 
variations, or the positioning of the fixator / osteotomy on the bone, from proximal to distal, potentially 
influencing the bending forces. 
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a  
b  
Figure 5.9: a) Boxplot plot showing the percentage IFS was significantly affected by gap size. (* 
p=0.029). b) Line graph of mean±SD construct stiffness (N/mm), which was unaffected by gap size 
(p=0.779).  
 
5.3.2 Radiographic assessment 
As the gap size increased there was an increase in non-union and partial-union development 
and a concomitant decrease in union rates, with the non-union rate more than doubling 
(Table 5.3). Fisher exact contingency tables comparison of union vs non-union combined 
with partial union did not show a significant effect of gap size (GraphPad Prism v6.00, USA). 
Some samples also appeared to have a tendency towards increased periosteal callus on the 
caudomedial aspect of the bone, i.e. on the opposite side to the fixator, which is probably the 
region experiencing the greatest compression and least tension.   
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Table 5.3: Radiographic assessment of degree of union from microCT scout image shown in absolute 
numbers and as a group percentage. 
 
5.3.3 MicroCT analysis of osteotomy tissue formation 
The 1.0mm gap size had approximately 50% greater callus volume per slice (0.069um3) vs 
the 2mm gap (0.029um3), and a higher bone volume per slice (0.035um3 vs 0.026um3) 
(Figure 5.10). Assessment of trabecular thickness was largely similar between groups, 
although the spacing between the regions of woven bone (trabecular spacing per splice) was 
greater in the smaller 1.0mm gap with its overall higher total bone volumes. The 1.5 and 
2.0mm gaps had similar trabecular spacing, indicating the bone structure was similar but 
reduced in volume within the bigger gap. The measured trabecular thickness was 
significantly higher (p=0.048) in the smaller 1.0 gap than the larger 1.5mm gap 
(0.055±0.01um and 0.044±0.01um), however it increased again when the gap size increased 
to 2.0mm (0.057±0.02um). Tissue surface area per slice, giving a relative index of callus size, 
was also significantly higher (p=0.03) in the in the smallest 1.0mm gap (0.41±0.22um^2) 
than the largest 2.0mm (0.14±0.12um^2) (Figure 5.11a). Although bone volume per slice 
clearly showed a decreasing trend, significance was not shown (p=0.082) between the 1.0 
and 2.0mm gaps. A post-hoc sample size calculation (power = 0.8 and p=0.05) indicated that 
14 animals per group were needed to determine a significant difference in bone formation 
(microCT BV) between the smallest and the largest gap. Full microCT results are in table 5.4. 
The relationship between IFS and the microCT bone and tissue volumes formed within the 
callus is shown in figure 5.12. 
Gap$Size$(mm)$ Non/Union$ Par3al$Union$ Union$
1.0$ 1/5$(20%)$ 1/5$(20%)$ 3/5$(60%)$
1.5$ 3/7$$(43%)$ 2/7$$(29%)$ 2/7$(29%)$
2.0$ 3/6$(50%)$ 2/6$(33%)$ 1/6$(17%)$
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a  
b  
Figure 5.10: a) Boxplot showing a sequential reduction in overall callus size (TV per slice). b) 
Boxplot a reduction in mineralised callus (BV per slice) as the osteotomy gap increased in size.  
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a  
b  
Figure 5.11: a) Boxplot showing a significant decrease in tissue surface area (TS) per slice, in the 
2.0mm compared with the 1.0mm osteotomy. b) Boxplot showing a reduction in trabecular thickness 
between the 1.0 and 1.5mm osteotomies (* = p<0.05).  
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Table 5.4: Callus morphometry of the central 60% of the osteotomy gap obtained from microCT for 
the different gap sizes. All values are the mean±SD. 
 
 
Figure 5.12: Bar chart showing bone volume per slice (BV um^3) overlaid with a line graph of IFS 
(%), vs gap size showing the relationship between the reducing IFS and reducing bone formation 
within the osteotomy gap. All values are the mean±SD. 
 
5.3.4 Histomorphometric analysis of osteotomy healing 
At the x1 magnification scale, there was a trend for the absolute overall callus area to be 
larger despite the smaller gap in the 1.0mm vs the 2.0mm gap (Table 5.5 and Figure 5.13). 
Only combined absolute fibrous-cartilage tissue area was significantly different between 
1.0mm Gap 1.5mm Gap  2.0mm Gap 
TV per slice (um^3) 0.07±0.04 0.05±0.03 0.03±0.03 
BV per slice (um^3) 0.04±0.02 0.02±0.02 0.02±0.02 
BV/TV (%)  54.25±9.38 53.79±20.82 66.39±15.37 
TS per slice (um^2)  0.41±0.23 0.35±0.25 0.14±0.12 
BS per slice (um^2) 2.09±1.62 1.81±1.22 0.90±0.94 
Tb.Th (um) 0.06±0.01 0.04±0.01 0.06±0.02 
Tb.Sp (um) 0.12±0.05 0.07±0.03 0.07±0.05 
Tb.N (1/um) 9.88±0.87 14.10±9.32 13.42±8.26 
Total porosity (%) 45.75±9.38 46.22±20.82 33.61±15.37 
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groups (p=0.006), specifically being significantly higher in the 1.5mm group than the 1.0mm 
group (p=0.01) (Figure 5.13c). 
 
Table 5.5: Histomorphometric characteristics of the tissue in between the two innermost fixator pin 
tract holes at x1 magnification. Absolute measurements are in square pixels. All values are the 
mean±SD.  
 
a 	b	 	
c  
Figure 5.13:  Shows the histomorphometric assessment of tissue formation between the two innermost pins 
at x1 magnification. a) Bar chart showing histomorphometric assessment of the actual area composition, 
measured in square pixels. Values are mean±SEM. b) Bar chart showing the calculated percentage area 
composition of the tissue in between the two innermost fixator pin tract holes. Values are the mean±SEM. 
c) Boxplot showing the area of combined fibrous and cartilage in the callus region as total area measured in 
square pixels at x1 magnification. 
TISSUE AREA 1.0mm Gap 1.5mm Gap 2.0mm Gap 
Total callus 324682±99071+ 351681±89789+ 264502±88196+
Bone 288311±111808+307513±98801+ 223095±100484+
Cartilage 36371±30633+ 36839±28385+ 16621±15003+
Fibrous 0±0+ 7329±19390+ 23786±29598+
% TISSUE 
Bone 86.8±13.0+ 85.9±9.1+ 82.1±12.9+
Cartilage & fibrous combined 13.1±13.0+ 14.1±9.1+ 17.9±12.9+
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However, trends reflecting the microCT data were seen at the higher magnification of 2.5x. 
As the gap size increased the % bone within the callus decreased and fibrous tissue increased. 
Cartilage tissue was highest in the mid sized gap, which may have related to the degree of 
endochondral ossification present in that gap size; i.e. more cartilage as less bone has formed, 
however, fibrous tissue was still lower than the biggest gaps. None of these trends were 
statistically significant (Table 5.6 and Figure 5.14). Summary images of the healing are 
presented in Figures 5.15-5.18. 
 
Table 5.6: Histomorphometric analysis of tissues formed within the osteotomy gap from line-intercept 
analysis at x2.5 magnification, expressed as the mean±SD percentage of total area.   
% TISSUE 1.0mm Gap 1.5mm Gap 2.0mm Gap 
Bone 45.6±33.0( 39.1±23.9( 23.2±26.6(
Cartilage 36.7±22.1( 43.1±24.6( 37.2±17.9(
Fibrous 14.7±30.6( 15.3±37.4( 36.1±40.8(
Vascular 3.0±1.9( 2.4±2.0( 3.5±3.4(
Combined bone & cartilage 82.3±29.0( 82.3±36.4( 60.4±37.7(
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a b  
c  d  
Figure 5.14: Histomorphometric analysis of tissues formed within the osteotomy gap from line-
intercept analysis, at x2.5 magnification. a) Boxplot showing percentage bone formed within the 
osteotomy gaps. b) Boxplot showing percentage cartilage formed within the osteotomy gaps. c) 
Boxplot showing percentage fibrous tissue formed within the osteotomy gaps. d) Bar chart showing 
mean±SEM of all tissues formed within the different gap sizes. As the osteotomy gap increased in 
size, there was a reduction in bone. The percentage cartilage present remained similar, increasing 
slightly in the mid sized gap, however the increasing gap size was related to progressive increase in 
fibrous tissue.  
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a  
b  
c  
Figure 5.15: Representative imaging including microCT and histology. a) 1.0mm gap with complete 
union. b) 1.5mm gap with partial union. c) 2.0mm gap with non-union (atrophic). 
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Figure 5.16: Histology images of an atrophic non-union seen in a 1.5mm osteotomy gap. Images are 
shown at x10 and x40 magnification. MC = marrow cavity, CoB = cortical bone.  
 
 
Figure 5.17: Histology images of delayed healing in a 1.5mm osteotomy gap. Images are shown at 
x10 and x20 magnification. CoB = cortical bone. WB = woven bone, Ca = cartilage.  
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Figure 5.18: Histology images of healed 1.0mm osteotomy gap. Images are shown at x10 and x40 
magnification. WB = woven bone. 
 
5.4 DISCUSSION 
5.4.1 Interfragmentary strain theory 
Based on Stefan Perren’s IFS theory (Perren 1979), my hypothesis for this chapter was that 
increasing the gap size, would decrease IFS and improve fracture healing. This hypothesis 
was not supported based on day 0 assessment of IFS.   
Interfragmentary movement has been duplicitously described as both a stimulator and 
inhibitor of fracture healing. The IFS hypothesis predicts that the strain tolerance of a tissue 
is the maximum strain that the tissue can tolerate and continue to function. Above this 
threshold the tissue cannot function or indeed fails (Perren 1979). Perren went on to describe 
the strain range in context of healing fracture; for bone formation the IFS had to be below 
2%. Cartilage can tolerate 2-10% IFS and hence endochondral ossification and secondary 
bone union should develop. Only granulation tissue can tolerate higher strains of up to 100%. 
However, I think it is far too simplistic to assume the IFS will be uniform throughout a 
fracture gap. Inevitably, there will be different ‘micro-environments’, which will permit 
different stages of bone healing relating to individual and regional IFS. This is corroborated 
in FE models which utilise homogenised tissue characteristics and have shown heterogeneity 
of strain within a uniform osteotomy (DiGioia et al. 1986). Therefore, the assessment of a 
global gap IFS may not elaborate the whole picture. A further confounder is the decreasing 
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gap size with ongoing healing, which predicts an increase in the IFS beyond the limits of 
bone formation (Elliott et al. 2016). Clearly this theoretical situation is surmounted, 
potentially by sequential tissue formation within the gap, widening of the bone diameter by 
periosteal callus formation and processes such as spiral osteoblast alignment (Claes et al. 
1998). Claes et al. used an FE model to correlate histological data to mechanical strain, cell 
differentiation and hydrostatic pressure and determined that intramembranous ossification 
will develop with strains <5%, whereas endochondral ossification can develop in strains 
<15% (Claes et al. 1999); more in line with my experimental findings. Other large animal 
studies with known gap sizes and interfragmentary movements have also shown good bone 
healing with IFS >2-10% (Claes et al. 1995; Kenwright & Goodship 1989). Claes et al. 
showed that a high initial IFS, above the Perren 10% threshold, resulted in increased callus 
formation, however, a larger gap had less bone formation for the same initial strain (Claes et 
al 1997). 
When a fracture occurs, a well established sequence of events follows (Elliott et al. 2016) 
with initial deposition of a strain toleratant tissue, such as granulation tissue, which does 
little to reduce strain. Most bone healing occurs in an environment of relative stability and 
therefore the initial IFS at day 0 after fracture will be higher than 2%. Perren suggests that 
the apparent osteonecrosis and bone lysis at the opposing fracture ends increases the gap and 
thus reduces the IFS. My study confirmed a reduction in IFS as the gap increased, however 
this did not appear to potentiate healing. Perhaps the bone loss described by Perren is a 
pathological process associated with de-vascularisation of the fracture ends and not intended 
as a ‘strain-modifying’ process to aid healing. Simultaneous to this increase in gap size, 
connective tissues, which are sequentially less strain tolerant, differentiate and form a wide 
tissue cuff or ‘callus’, stiffening the gap and further increasing fracture stability and reducing 
IFS (Perren 2015). When I looked at the bone surface (BS) and tissue surface (TS) measures 
on microCT, there was a trend for a smaller callus as the strain reduced, which could fit the 
idea of a bigger callus cuff being required when there is a higher IFS. Perren’s theory has 
been expanded upon by Carter and Blenman who suggest that it is not only the amount of 
strain, but the way the strain is applied, be it in compression, tension, shear, and further that 
the degree of vascularisation has influence (Carter et al. 1988). Their finite element model 
also accounted for eccentric callus formation with an asymmetric cartilage deposition, which 
I noted in some of my samples. They suggested this was due to varying hydrostatic forces 
with a more ‘compressive microenvironment’ producing more cartilage and a ‘tensile’ 
environment resulting in more fibrous tissue deposition. This is consistent with the types of 
loading patterns that will be developed within the osteotomy of the rat femur, with its 
eccentric mechanical axis and the use of a unilateral external fixator. Some of my samples 
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also showed eccentricity of callus shape and structure. Prendergast suggested a further model 
with two biophysical stimuli; fluid velocity and shear strain components playing a role in the 
solid and liquid phases (Prendergast et al. 1997). However, despite the development of 
various models, they all only approximate in vivo findings in the extremes.  
There is greater consensus with regards to rigid fracture fixation, that allows direct osteonal 
healing (McKibbin 1978). This is peculiar to a particular surgical method of fracture fixation, 
typically using plates and screws with fracture compression. This mechanical environment 
effectively creates an IFS <2% permitting physiological bone turnover, whereby osteonal 
remodeling occurs across the fracture line (contact healing), or where there are small gaps 
<1mm, woven bone is directly deposited and then later remodeled by lamellar bone (gap 
healing) (Marsell & Einhorn 2011).  
5.4.2 Modulating interfragmentary strain - dynamisation 
As an accessible mechanical device, the external fixator can be altered during fracture 
healing to influence its rigidity and the subsequent micro-movement and IFS experienced at 
the fracture site. Goodship et al. applied various loads to a fixator system at differing 
frequencies and phases of fracture healing and showed that application of increased 
micromotion early in fracture healing increased fracture stiffness and bone mineral density 
(Goodship et al. 1998). This phenomenon became known as active dynamisation, but this 
effect can also be achieved without motors, through the normal loads applied during weight 
bearing if the fixator rigidity is altered, termed passive dynamisation. In human fractures 
stabilised by a unilateral fixator, cyclic movements even occur with a locked unilateral 
fixator when walking (Richardson et al. 1995). In my model, dynamisation could be 
achieved by initially having a longer pin working length and subsequent sliding the 
connecting blocks closer to the limb to stiffen the construct, or by the use of a telescopic 
connecting bar to engineer the stain environment as the fracture heals.  
5.4.3 Non-unions 
It is orthopaedic dogma that non-unions are described as vascular or avascular based on their 
radiographic morphology. Hypertrophic non-unions for instance, are widely accepted to 
occur due to excessive fracture micromotion. The hypertrophy develops through florid 
intramembranous ossification, which originates from the periosteum of the fracture ends 
when there is a large interfragmentary motion (Harrison et al. 2003). The view that atrophic 
non-unions have reduced vascularisation is probably, at least in part mistaken, as human 
samples of clinical atrophic non-unions showed no difference in vascularisation than those 
that had healed (Reed et al. 2002). Interestingly, when evaluated in an experimental model, 
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there was a temporal difference in vascularisation, with vessels being seen later in non-
unions, although the same total vascularisation was ultimately achieved in both groups (Reed 
et al. 2003). Perhaps the early lack of vascularisation is at a critical stage for cell migration, 
including stem cells, and thus ultimately prevents the correct cellular chain reaction for 
healing, despite a suitable IFS. It is worth considering that simply quantifying the numbers 
of blood vessels may not be sufficiently sophisticated to answer fully these questions and the 
actual oxygen tension readings may be more informative. Gender and possibly the associated 
impact of differing hormones may also have influence, as rat critical sized defects of the 
same size (5mm) gave delayed union in male rats and non-union in female rats (Mehta et al. 
2010). However, it is also worth noting that the male bones were bigger and hence the 
proportional gap size was smaller.  
My study showed over a doubling of non-union rates and halving of bone volume, with an 
increase in fibrous tissue within the osteotomy as IFS changed from 12% to 6%. The 
explanation is difficult, but these findings are recapitulated elsewhere with increasing gaps 
leading to reduced healing (Harrison et al. 2003; Mehta et al. 2010; Claes et al. 2003). 
Perren’s theory predicts for a given interfragmentary movement, the bigger the gap, the 
better the predicted healing due to reduced IFS. However, large gaps and critical sized 
defects, even when fixed very rigidly, do not heal. This implies that if Perren’s theory is in 
part correct, there must be thresholds or non mechanical factors that influence the outcome. 
The expectation from Perren’s theory would be any fracture with an IFS under 10% should 
be able to undergo endochondral ossification and heal. This chapter showed that within the 
immediate fracture environment, were IFS ranged between 12-6%, the groups with the IFS 
>10% had improved healing than those <10%. This may also suggest that the purported die 
back phenomenon of bone to reduce IFS (Perren 2004; Perren 1979) may not be the reason, 
as reduced IFS from increased gap size appeared to negatively influence healing. My 
findings are corroborated elsewhere (Claes et al. 1997).   
Perhaps critical sized defects do no heal due to the biological hurdles these large gaps create 
for fracture healing, or critical sized gap may have their own biomechanical rules for healing, 
which are distinct from the smaller gaps. Claes et al, showed that bigger gaps had reduced 
fracture healing in a sheep metatarsal model, however the stability of the fixation also 
influenced healing, with more rigid fixation producing less callus in small gaps, but this was 
not recapitulated in larger gaps (Claes et al. 1997). It is also possible that the fixation rigidity 
will affect the micromotion and hence the IFS seen. For the same fixation, a bigger gap will 
make the environment more mechanically elastic, or flexible due to the change in implant 
working length. Whether these defects require increased micromotion (Goodship et al. 1998), 
or a stiffer reduced IFS remains to be clearly determined. 
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5.4.4 Cellular responses to the mechanical environment 
When considering a tissue’s response to its mechanical environment, it is remiss not to 
acknowledge that the cell is at the heart of this response. In vitro experiments have 
demonstrated that different cells also have different strain tolerances. Fibroblasts respond to 
uniaxial stretching and the line of magnitude influences their alignment and response. 
Surprisingly, fibroblasts but not their synthesised tissues, appear less tolerant than 
osteoblasts to larger strains, whereas chondrocytes respond to a strain range of 1-3% 
(Jagodzinski & Krettek 2007). Osteoblasts in culture have also been shown to align along 
axes of strains, up to a maximum of 6% (Neidlinger-Wilke et al. 2001). When considering 
fracture healing and the recruitment of stem and progenitor cells to facilitate de novo tissue 
formation, the mechanical environment will exhibit its effects on stem cells, and that will in 
turn be part of the signaling for differentiation. Bone marrow mesenchymal stem cell 
differentiation is influenced by a combination of biological cues and the strain environment, 
with experiments showing chondrocyte (Angele et al. 2003) and osteoblast (Mauney et al. 
2004) differentiation being influenced by strain. Undifferentiated stem cells plated on 
variably compliant polyacrylamide gels show sensitivity to their local matrix mechanical 
environment. Importantly, naïve MSCs with no lineage specific markers, are differently 
affected by the stiffness of the mechanical environment in which they inhabit, with stiffer 
environments driving osteogenic differentiation and softer environments favouring neuro or 
myogenic pathways. After several weeks of exposure to a particular mechanical environment, 
the mechanical influence becomes dominant over growth factor driven differentiation 
(Engler et al. 2006). The initial IFS therefore, and subsequent IFS over the duration of 
fracture healing will influence the tissue formation through its mechanical conditioning of 
the recruited stem cells. However, the exact interplay between mechanics at the micro and 
macro levels are not currently defined (Ghiasi et al. 2017). It is also possible that woven 
bone may behave differently to lamellar cortical bone, as cultured osteoblasts have a 
physiological strain range between 1-5% and cartilage callus forms when stains are 5-10%, 
and hence Perren’s IFS theory may need to be further reconsidered in light of the tolerance 
of healing woven bone rather than remodeled bone (Elliott et al. 2016).  
There are two arms to successful fracture healing; the mechanical and the biological. A 
purported key factor for the mechanical aspect is stability (presumed to be the correct IFS), 
and for the biological is blood supply (Rhinelander 1974). Ovine studies have shown that 
increased fracture gaps with the same IFS had reduced vascularisation and hence diminished 
ability to heal (Claes et al. 2003). However, other studies quantifying blood vessels have 
shown no difference between atrophic non-unions, hypertrophic non-unions and healing 
fractures (Reed et al. 2002), although blood vessels appear at a later stage and therefore early 
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vascularisation may be key (Reed et al. 2003). The histology from my study also showed a 
consistent level of vascularisation between different gap sizes and despite their subsequent 
healing fates. The histologic analysis was performed at five weeks and therefore it is 
conceivable with an increasing gap size, the time required for vascular development could be 
longer and perhaps critical blood vessel density was not reached at a sufficiently early time 
frame. This is speculation, however, this study either points to Perren’s hypothesis of 
thresholds for tissue formation as incorrect if they are soley based on initial IFS at day 0, or 
there are other ‘rules’ or considerations at play, such as progressive changes in IFS as the 
fracture heals. Additionally, insufficient IFS has been reported to retard healing, with a 
postulated level of insufficient IFS of 1% (Elliott et al. 2016). Other complicating factors 
such as increasing animal age (Strube et al. 2008) or sex have influenced fracture healing in 
some studies, although the large difference in bodyweight between female and male rats was 
not controlled for (Mehta et al. 2010). My study had a tightly controlled age range and hence 
weight, and all were female Wistar rats. 
5.4.5 Tissue formation 
In terms of tissue formation analysis, this study made a direct comparison between the 
different gap sizes by analysing the same central proportion of the osteotomy. With 
consistent scan slice thickness of 5um, a universal measure of bone volume/slice was 
possible and allowed a direct comparison. It is acknowledged that this would not therefore 
analyse any intramembranous ossification that may have arisen directly adjacent to the 
periosteum at the cortical fracture ends (Harrison et al. 2003), but was focused on 
endochondral ossification of cartilage to woven bone within the osteotomy gap itself. This 
was intentional to ensure a consistent healing region within the osteotomy was analysed, 
such that there was no influence of ‘capturing’ the native ends of the osteotomy with their 
high bone volume distorting analysis. Histology on the other hand, covered a larger area for 
analysis and still corroborated the trends seen in the microCT. The histomorphometric 
analyses did not generally reach statistical significance, however, considering that histology 
represents analysis of the callus in only a single sagittal slice, it is not surprising that trends 
found with microCT volumetric analysis are harder to show histologically. Nonetheless, 
histology is an extremely useful partner to microCT data as it allows for soft-tissue 
distinction and cellular process evaluation as required.  
My 1x analysis measured the gap plus the bone in between the two innermost pins. I would 
have therefore predicted an increasing overall area as the gap size increases, assuming all 
gaps healed in a similar manner. The increase from 1.0mm to 1.5mm did show an absolute 
increase, but then a decrease at 2.0mm indicating bone loss, consistent with the atrophic non-
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union morphology seen in 50% of those samples. When appraising the ‘non bone’ within 
this region, specifically fibrous and cartilaginous tissue, the 1.5mm gap had significantly 
more, suggestive that the fracture gap enlargement from 1.0mm to 1.5mm is significantly 
filled by soft-callus type tissue; fibrocartilage. There is then, an absolute reduction in tissue 
in the 2.0mm gap simply because the callus is much smaller, as it tends towards atrophy.  
The 2.5x images allowed assessment of tissue composition within the original osteotomy. 
The 1.0mm gap with its higher IFS of 12% had the most bone tissue, some cartilage and no 
fibrous tissue. As the gap size increased to 1.5mm and to 2.0mm, there was a sequential 
reduction in bone and an increase in cartilage and fibrous tissue. The 1.5mm gap with an 8% 
IFS, had greater cartilage than fibrous tissue, whereas 6% IFS 2.0mm gap had little bone and 
less cartilage than the 1.5mm gap, with the highest proportion of fibrous tissue. These 
changes should be considered in context of a callus, which is reducing in size as the gap 
enlarges. It is noteworthy that the trabecular thickness was unchanged across the groups 
although more spaced out in the 1.0mm gap compared with 1.5 and 2.0mm. This indicates 
the woven bone structure is the same and the changes are simply related to the amount 
present and potentially its arrangement. 
5.4.6 Biomechanical testing 
The second part of my hypothesis was that the stiffness would be affected by the gap size 
and I found that the construct stiffness was unaffected by the increasing gap size. Beyond the 
variable activity of individuals and any weight differences, there would have been no 
difference in the loading of the osteotomy and therefore the IFS was entirely varied by gap 
size alone. The uniform consistent stiffness is probably due to the double connecting bar 
making the construct relatively stiff, compared to any influence of increasing the working 
length of the bar between the connecting blocks as the gap size increased. To that end, this is 
an excellent model to evaluate the effect of gap and IFS alone as there is not a secondary 
influence of construct stiffness.  
The test set-up was clinically relevant as loading was applied from the femoral head to the 
femoral condyles as it would be physiologically (Barak et al. 2008). The mechanical axis is 
therefore eccentric, creating an inherent bending force with compression on the medial 
aspect and tension on the lateral. The unilateral fixator is then at right angles to this being 
placed cranial to caudal and hence allows a second orthogonal bending moment. Although 
the exact type of loading, be it torsion, bending in one or other direction, or a composite, is 
difficult to determine, it should accurately mirror the in vivo situation and is therefore 
informative to the in vivo findings. Making use of a microstrain displacement sensor 
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positioned as close as possible to the proximal and distal ends of the osteotomy would 
significantly reduce artefactual whole construct displacement variation, which would have 
been present if determining such small displacements from the materials testing machine 
displacement sensor.  
5.4.7 Conclusion 
Despite the clear trends across the groups, and some showing statistical significance, I find it 
interesting that in every group there was a large variation in the individual’s fracture healing 
potential, with non-union seen in 1.0mm gaps and union in 2.0mm gaps. The rats were out-
bred strains and therefore genetic variation could have played a role. Otherwise they were all 
females of the same age, had identical procedures and treatment, and lived in the same 
environment. Do these variations relate to their inherent activity levels affecting osteotomy 
healing (Goodship & Kenwright 1985), or is this a biological innateness, or both? Mice have 
been shown to have significantly different levels of activity post external fixator surgery and 
the more mobile animals produced a bigger callus containing more cartilage (Connolly et al. 
2006). Clinical findings also corroborate, with insufficient as well excessive activity both 
negatively influencing fracture healing (Gaston & Simpson 2007). It is also clear from in-
bred mouse studies that there are genetic differences in skeletal stem cell regulation, 
influencing the temporal patterns of chondrogenic and osteogenic lineage development and 
this will affect the rate of fracture healing (Jepsen et al. 2008). Moving to in-bred rat strains 
may be sensible in future studies, however the variation in healing seen in my study is 
reflected in human fracture healing. In clinical fracture healing, comorbidities such as 
diabetes mellitus, thyroid disorders, malnutrition, age, prescribed medications such as 
NSAIDs, steroids, smoking and alcoholism can all influence healing (Gaston & Simpson 
2007) and therefore the variation seen experimentally may have relevance to the clinical 
situation.  
In conclusion, the construct stiffness was unaffected by the increasing gap size with the 
Stanmore micro external fixator, and increasing gap size resulted in decreased IFS as 
measured on day 0. On balance the most appropriate sized gap to use as an impaired fracture 
model for proceeding chapter was the 1.5mm gap.   
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CHAPTER 6: Modulation of Fracture Healing by Growth 
Factor & AMD3100 Administration 		
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6.1 INTRODUCTION 
Bone marrow stromal stem cells, subsequently termed MSCs, have both in vitro and in vivo 
potential to produce all tissues required to form a bone organ (Hankenson et al 2011; Owen 
& Friedenstein 1988; Bianco et al. 2013). Peripheral blood circulating cells that are plastic 
adherent and can form colonies with osteogenic potential, have been found in mice, rabbits, 
guinea pigs and humans in low numbers of around 1 in 106-8 (Kuznetsov et al. 2001; Zvaifler 
et al. 2000).  
Pitchford et al. showed significant mobilisation of EPCs in addition to MSCs, most notably 
when VEGF was combined with AMD3100 (Pitchford et al. 2009). The potential role of 
EPCs in fracture healing is logical as vascularisation is essential for bone formation and 
fracture healing (Keramaris et al. 2008; Hankenson et al 2011; Rhinelander 1968). EPCs 
have also been shown to be increased in the peripheral circulation after fracture in humans 
(Ma et al. 2012) and in models of distraction osteogenesis and fracture healing, with peaks 
early in the healing process (three days), although they remained elevated throughout (Lee et 
al. 2010). This has led to interest in isolating, culturing and transplanting EPCs to aid healing, 
in particular for cardiovascular disease	 (Chong et al. 2016; Ward et al. 2007). In fracture 
healing experiments, locally transplanted cultured EPCs have increased healing in a rat 
critical sized defect model, with significant increases in bone volume, trabecular number, 
trabecular thickness and trabecular spacing (Li et al. 2011). Isolated EPC populations have 
been shown to differentiate into endothelial cells and contribute to neovascularisation 
directly (Ward et al. 2007), however EPCs may also improve healing through provision of 
trophic stimulation to resident cells. Beyond the mobilisation work of Pitchford for EPCs, 
there is further evidence of a role of SDF1/CXCR4 with EPCs (Kawakami et al. 2015), 
where CXCR4 conditional knock-out sourced EPCs had reduced migration and colony 
forming ability in vitro, and the mice had reduced fracture healing in vivo.  
The recruitment, migration and homing of cells to a fracture is essential for inflammation, 
blood vessel formation, chondrogensis, osteogenesis and therefore fracture healing. However, 
a significant number of bone defects and fractures do not heal (Rodriguez-Merchan et al. 
2004), leading to delayed or non-union. Clinically we look for radiographic union, however, 
other higher resolution modalities such as histology or microCT are available in the research 
setting. In rodent studies, there is no clear definition for delayed or non-unions and a variety 
of different outcome points have been used, however, reduction in fracture movement, i.e. 
stability from healing is expected to reach 0% at around four weeks (Garcia et al. 2013). 
Experimental studies have looked towards a consensus definition and based on the somewhat 
arbitrary ratio of eight weeks for human long bone fractures to heal and a non-union 
	 178	
definition of six months, a three-fold time span was suggested. A rat non-union is hence 
defined as incomplete healing by 15 weeks, assuming five weeks for normal healing duration, 
and the same ratio gives a non-union definition of 12 weeks in mice (Garcia et al. 2013). 
However, there is known variation in the ‘expected healing time’ based upon numerous 
criteria including the individual, the fracture configuration/location, and the method of 
treatment. No gold-standard definition exists for human non-unions.  
The NHS reports a non-union rate of 10% and treatment can be difficult with a cost of up to 
£80,000 per patient (Mills & Simpson 2013). Some of these failures are related to 
comorbidities (Gaston & Simpson 2007) such as diabetes mellitus, which has shown a direct 
influence on osteotomy healing in rats through reduced fracture SDF1 expression (Arakura 
et al. 2017). Another key group of fractures with impaired healing are the osteoporosis 
related fragility fractures, and again the SDF1-CXCR4 axis appears implicated with 
reductions of CXCR4 on T regulatory cells seen in ovariectomised mouse models (Fan et al. 
2015).  Delayed-unions, which are defined as “a fracture in which healing has not occurred 
in the expected time and where the outcome remains uncertain” (Harwood et al. 2010), are 
also problematic. Protracted healing and potential secondary interventions have an 
associated morbidity, with impact on full return to function for the patient.   
Based on the most comprehensive evaluation of endogenous stem and progenitor 
mobilisation in mice (Pitchford et al. 2009), in chapter 3 I showed it was possible to increase 
the circulating levels of MSCs and EPCs in rats using AMD3100 combined with VEGF. 
This protocol was suggested to be the most effective combination of growth factor together 
with AMD3100 in order to mobilise MSCs and EPCs, however, despite significant increases 
in CFUs, the numbers of stem/progenitor cells isolated was still quite low; at 3/ml blood for 
PBMSCs and PBEPCs. This may have been an artefact of in vitro culture and the processing 
required to remove red blood cells, or perhaps associated with the older rats used. Further, 
this measure represented the circulating pool of cells at the predicted peak elution time point, 
one hour post administration of AMD3100 (Broxmeyer et al. 2005). When evaluating the 
potential of endogenous mobilisation for fracture healing in vivo, a single time point 
measurement may be misleading and the duration and character of the cell elution profile in 
the circulatory system may be more important. Cell culture based assessments also have their 
limitations, as the very act of in vitro cell culture induces cellular change, including their cell 
surface characteristics (Bara et al. 2014). Finally, it is impossible to determine the potential 
synergistic or otherwise interactions of different mobilised cells populations, including those 
not measured in chapter 3, in fracture healing. Therefore, the best means to assess whether 
there is a translational potential in this therapy is to conduct an in vivo fracture model study. 
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As MSCs and EPCs can both impact on fracture healing (Kawakami et al. 2015; Lee et al. 
2010), the protocol described by Pitchford et al. where VEGF was used in combination with 
AMD3100 (Pitchford et al. 2009) to increase the circulating levels of EPCs and MSCs was 
of particular interest. However, although chapter 3 did show in vitro proof of concept with 
VEGF AMD3100 combination, all combinations tested in Pitchford’s work (Pitchford et al. 
2009) were evaluated in this in vivo fracture model chapter. In addition, two further 
treatment strategies that have been tested to improve fracture healing in mice were evaluated. 
One was an ‘Einhorn style’ intramedullary pin stabilised femoral fracture, with which they 
gave AMD3100 alone for three consecutive days and showed greater total callus volume at 
21 days (Toupadakis et al. 2013). The other created a tibial fracture by 3-point bending, 
supported by a splint and treated with IGF1 with AMD3100 (Kumar & Ponnazhagan 2012), 
and showed significantly increased bone mineral density at eight weeks. It is important to 
note that both these models had a poorly controlled mechanical environment with which to 
evaluate a biological augmentation, and these fractures were not inherently compromised in 
their healing, and hence unlikely to develop a delayed or non-union. This therefore led me to 
my question and hypothesis:  
Question: In a standardised biomechanical environment, could compromised fracture 
healing be improved through endogenous mobilisation of stem and progenitor cells?  
Hypotheses: Administration of AMD3100 based mobilising protocols, which have been 
previously shown to increase the number of circulating MSCs and EPCs, will increase 
bone formation within the osteotomy and improve fracture union.   
 
6.2 MATERIALS & METHODS 
My work in chapter 5 confirmed impaired fracture healing with a 1.5mm osteotomy. In this 
chapter I evaluated bone formation within an osteotomy gap of 1.5mm when treated with 
different mobilisation strategies. The groups included: 
• PBS + AMD3100 (n=5) (PBS-AMD) 
• VEGF + AMD3100 (n=8) (VEGF-AMD) 
• IGF1 + AMD3100 (n=6) (IGF1-AMD) 
• GCSF + AMD3100 (n=5) (GCSF-AMD) 
• (1.5mm gap control osteotomy with no treatment from chapter 5) (n=7)
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6.2.1 Preparation of growth factors & AMD3100 
Growth factors and AMD3100 were prepared as described in chapter 3 (3.2.2.1). The dose 
was 5mg/kg i.p. based on the peak mobilising concentration in mice (Broxmeyer et al. 2005). 
Rat Vascular Endothelial Growth Factor 165 (VEGF) (PeproTech, USA, 400-31) was 
prepared by dissolving the lyophilized product in sterile water to make a 0.1mg/ml stock 
solution. A working solution was prepared by adding 1ml of stock solution to 4mls of sterile 
PBS + 0.1% BSA (Sigma-Aldrich A9418), to achieve 100ug/ml injectable solution which was 
aliquoted and stored at -20°C until needed. Recombinant human Insulin-like Growth Factor-1 
(IGF1) (PeproTech, USA, 100-11) and murine Granulocyte colony stimulating factor (GCSF) 
(PeproTech, USA 250-05) were prepared in the same manner. Finally, PBS + 0.1% BSA, 
‘sham growth factor’, to determine the effects of AMD3100 alone was also prepared. The 
growth factor dose was 100ug/kg i.p. based on previous studies (Pitchford et al. 2009; Kumar 
& Ponnazhagan 2012; Toupadakis et al. 2013; Fu et al. 2012). 
6.2.2 Surgery & mobilisation protocol 
Surgery was performed as described in the previous chapter 4 (4.2.6). Twenty-four hours post 
surgery, rats were given a single i.p. injection of either VEGF, IGF1, GCSF, or PBS once 
daily for four days. On day five, they were given a single injection of AMD3100. All i.p. 
injections including AMD3100 and sham PBS were administered at a volume of 0.5mls/100g 
bodyweight based on the day 0 pre-surgical weight (Figure 6.1). All procedures were carried 
out at the Royal Veterinary College, North Mymms, in accordance with the Animals 
Scientific Procedures Act 1986. Home Office licences were held by those taking part in any 
surgical procedure. 
 
Figure 6.1: Diagram depicting the sequence of events for endogenous mobilisation of stem cells into 
the peripheral circulation after osteotomy surgery. 
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6.2.3 MicroCT & radiography 
After five weeks, the rats were sacrificed and the left femur including the fixator was 
retrieved. Femurs were fixed (PBS-AMD n=5, VEGF-AMD n=8, IGF1-AMD n=6, GCSF-
AMD n=5) and microCT scanned using the same settings and as described in previous 
chapter 5 (5.2.2.1). All groups had a 1.5mm osteotomy and the central 60% of the osteotomy 
gap was assessed (0.9mm = 180 slices at 5um thick). The reconstruction protocol and 
radiographic evaluation was performed as per chapter 5 (5.2.2.1).  
6.2.4 Histomorphometric analysis of callus 
Histology slides were prepared and analysed as described in chapter 5 (5.2.2.2), with four 
sections taken at the mid-sagittal region and the best two were stained, and one was evaluated. 
Briefly, histomorphometric analyses were performed at 1x and 2.5x magnification. The 1x 
images were analysed with imageJ (NIH, USA), to give an area measure of the different 
delineated tissue regions based on the square pixel number. At 2.5x magnification, tissues 
were semi-quantified with a 1.5mm scaled width line-intercept grid, with 120 intersections; 
grid squares were 160um in both directions. The grid was centered over the osteotomy and 
was scaled to be the same width as the original osteotomy (1.5mm). Intersections were then 
scored as percentage bone, cartilage, fibrous tissue, vascular (identified by red blood cells not 
present in matrix) or void. 
6.2.5 Statistical analysis 
Due to the relatively small group sizes (n<9), non-parametric tests were performed to 
compare groups including Mann-Whitney U (MWU) and Kruskal-Wallis (KW) as 
appropriate. Assessment of data spread was made with a Levene’s test for equality of 
variance. Significance was set at p<0.05 and tests were analysed with SPSS version 24 (IBM, 
Chicago, USA). Fisher exact test was performed to look for difference between radiographic 
fracture union (GraphPad Prism v6.00, USA). 
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6.3 RESULTS 
6.3.1 Surgical procedure 
No adverse effects were seen with the growth factor or AMD3100 administration. 
6.3.2 Radiographic evaluation 
 
Table 6.1: Radiographic assessment of degree of union from microCT scout images, shown as absolute 
numbers and percentages. 
 
There was a trend for an increase in union and reduction in non-union in the treated groups 
except for GCSF-AMD. The PBS-AMD group showed the largest positive effect (Table 6.1), 
however no significant differences from the control group were shown using Fisher’s exact 
test.  
6.3.3 MicroCT analysis of osteotomy tissue formation 
MicroCT analysis PBS-AMD 
Rats treated with PBS-AMD (n=5) had double the bone volume (BV) within the osteotomy 
(8.9±2.2 um^3, p=0.01), compared with the untreated control (4.3±3.1um^3) (Figure 6.2a). 
Not only was the BV increased, but the overall callus volume (TV) was greater than the 
controls (15.3±3.6 vs 9.2±6.1 um^3). The percentage bone volume was not significantly 
increased however, owing to a relative proportional increase in mineralised (BV) and non-
mineralised callus tissue. Additionally, the bone structure was different to the controls with 
the PBS-AMD group having a significant increase in trabecular thickness (P=0.03); 
0.061±0.002um compared with 0.042±0.003um (Figure 6.2b). There was also a trend for 
increasing tissue volume and trabecular number when compared with the empty gap control 
group. Notably, the data appeared less spread, however significance was not shown. 
 
 
Group& Non)union& Par-al)union& Union&
1.5mm&Control& 3/7$$(43%)$ 2/7$$(29%)$ 2/7$(29%)$
PBS&AMD& 1/5$(20%)$ 0/5$(0%)$ 4/5$(80%)$
VEGF&AMD& 2/8$(25%)$ 2/8$(25%)$ 4/8$(50%)$
GCSF&AMD& 3/5$(60%)$ 0/0$(0%)$ 2/5$(40%)$
IGF1&AMD& 2/6$(33%)$ 1/6$(17%)$ 3/6$(50%)$
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a 			
b  
Fig 6.2: Boxplots comparing microCT measures of the control untreated group (1.5 Control) and the 
AMD3100 without additional growth factors (PBS-AMD). a) The bone volume (BV um^3) was 
significantly increased in the AMD3100 group (* p=0.01) b) Trabecular thickness was also 
significantly increased (Tb.Th um) (* p=0.003). 
 
MicroCT analysis VEGF-AMD 
The VEGF-AMD group (n=8) did not show any significant differences from the control 
group (n=7). The trends were consistent with the PBS-AMD group however, with mean bone 
volume for VEGF-AMD being higher than control (5.2±1.7um^3) (Figure 6.3a), as was 
trabecular thickness (0.05±0.01um) (Figure 6.3b). The overall data spread was significantly 
reduced in the VEGF-AMD3100 group when looking at tissue volume (TV um^3, p=0.036) 
and trabecular number (Tb.N, 1/um, p=0.048).  
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a 	
b	  
Fig 6.3. Boxplots comparing microCT measures of the control untreated group (1.5 Control) and the 
VEGF-AMD treated group. a) VEGF-AMD increased bone volume (BV um^3). b) Trabecular 
thickness (Tb.Th um) was also increased, but significance was not shown. 
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MicroCT analysis GCSF-AMD 
Interestingly, treatment with GCSF-AMD resulted in a significant increase in percentage BV 
63.1±7.3% vs 53.8±20.8% (p=0.048), however the actual volume of the callus (TV 4.3±4.7 vs 
9.2±6.1um^3) and bone volume (BV, 2.5±2.6 vs 4.3±3.1um^3) was smaller compared with 
controls (Figure 6.4a). However, trabecular thickness was significantly higher 0.069±0.03 vs 
0.042±0.008um (p=0.048) (Figure 6.4b) and total porosity was significantly lower 36.9±7.3% 
vs 46.2±20.8% (p=0.048) (Figure 6.4c). This suggests that although GCSF-AMD group had 
less overall total woven bone, the bone formed was less porous and the size of each bone 
forming region was greater than in controls. Only trabecular thickness (Tb.Th um) showed a 
significant reduction in data spread in the treatment group (p=0.041). 
 
a  b   
c  
Figure 6.4. Boxplots comparing microCT measures of the control untreated group (1.5 Control) and the 
GCSF-AMD group. a) The bone volume (BV um^3) was reduced in the GCSF-AMD group. b) 
Trabecular thickness was increased (0.069±0.03um^3), as seen in other treatment groups (* p=0.048). 
c) Total porosity was significantly reduced to 36.9±7.3% (* p=0.048). 
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MicroCT analysis IGF1-AMD 
Rats treated with IGF1-AMD (n=6) also had an increase in bone volume (5.1±4.2um^3), 
compared with controls (Figure 6.5a). Percentage bone volume was significantly increased 
(p=0.035), and the overall callus size was the same as controls (TV 9.1±7.6 vs controls 
9.2±6.1um^3). There was also a significant increase in trabecular thickness 0.062±0.008um 
(p=0.01) (Figure 6.5b). Total porosity was significantly lower when treated with IGF1-AMD 
compared with controls; 40.8±5.6% vs 46.2±20.8% (p=0.035) (Figure 6.5c). There was also a 
trend for increased trabecular number when compared with the control group. The spread of 
data was not significantly different.  
a  b  
c  
Figure 6.5: Boxplots comparing microCT measures of the control untreated group (1.5 Control) and the 
IGF1-AMD group.  a) The bone volume (BV um^3) was increased in the AMD3100 group. b) 
Trabecular thickness was significantly increased (Tb.Th um) (* p=0.01). c) Total porosity (%) was 
significantly reduced (* p=0.035). 
 
When comparing between all groups, there were significant differences in bone volume (BV) 
(p=0.033) (Figure 6.6), trabecular thickness (Tb.Th) (p=0.003) (Figure 6.7), total porosity (%) 
(p=0.043) (Figure 6.8), and percentage bone volume (TV/BV) (p=0.043) (Table 6.2). All 
treated groups had greater bone formation than control, other than GCSF-AMD, which had a 
	 187	
negative impact on healing. However only PBS-AMD reached statistical significance for 
increased overall bone volume (BV) (Figure 6.6), and IGF1-AMD for % bone (TV/BV) 
within the callus. All groups had significant increases in trabecular thickness other than 
VEGF-AMD. 
 
Figure 6.6: The mean±SEM tissue volume (TV) and bone volume (BV) within the osteotomy measured 
using microCT. * represents significant (p<0.05) differences compared with 1.5mm control. 
**,***,****,*****,****** indicate significant differences (p<0.05) between paired groups. 
 
There were variations not only in the overall amount of new bone formed within the 
osteotomy, but also the bone structure. All treatment groups other than GCSF-AMD showed 
an increased trabecular separation of the woven bone (Figure 6.7), implying a different, more 
porous structure to the control group. All groups, including GCSF-AMD with its impaired 
overall bone formation, had increased trabecular thickness (Figure 6.7). Hence all treatment 
groups had a similarly increased thickness of the bone microstructure, despite variation in 
total bone formed.  
Total porosity of the woven bone was reduced compared with control in GCSF-AMD, IGF1-
AMD and GCSF-AMD (Figure 6.8). All groups had reduced trabecular number compared 
with control, although it was only significantly reduced when comparing between PBS-AMD 
and VEGF-AMD, consistent with the aforementioned trabecular separation findings. 
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Trabecular number showed a trend for being reduced compared with control, although non 
significant. Some groups showed a difference in mean surface area (Figure 6.9), with GCSF-
AMD, having the lowest tissue (TS) and bone surface areas (BS) indicative of a smaller or 
more atrophic callus; BS was significantly reduced compared with PBS-AMD (p=0.016) and 
VEGF-AMD (p=0.019) treatment groups. Direct comparisons between all groups for 
microCT analyses are made in figures 6.6 through 6.9, and table 6.2. Representative 3D 
reconstructions of each group with a reveal to see through to the centre of the callus is shown 
in figure 6.10. 
 
Figure 6.7: The mean±SEM trabecular thickness (Tb.Th) and separation distance (Tb.Sp) of bone 
formed within the osteotomy measured using microCT. * represents significant (p<0.05) differences 
compared with 1.5mm control. ** and *** indicate significant differences (p<0.05) between different 
groups. 
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Figure 6.8: The mean±SEM trabecular number (Tb.N) and percentage total porosity of bone formed 
within the osteotomy measured using microCT. * represents significant (p<0.05) differences compared 
with 1.5mm control. ** and *** indicate significant differences (p<0.05) between different groups. 
 
 
Figure 6.9: The mean±SEM tissue surface area (TS) and mean bone surface area (BS) of tissue 
formed within the osteotomy measured using microCT. * and ** indicate significant differences 
(p<0.05) between different groups. 
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Figure 6.10:  MicroCT 3D reconstructions of mid femoral regions, with a mid-sagittal reveal (top row). 
The bottom row shows a 3D reconstruction of the central 60% of the original osteotomy region (180 
slices) within the osteotomy that was analysed for quantitative morphometry. All groups other than 
GCSF-AMD showed increased mineralised callus formation when compared with the untreated control 
osteotomy group.  
 
 
Table 6.2: Quantitative morphometry indices evaluated from the microCT analysis of bone formation 
within the central 60% volume of the osteotomies. All values are the mean±SD. 
 
1.5mm Control PBS-AMD VEGF-AMD GCSF-AMD IGF1-AMD 
TV (um^3) 9.23±6.14 15.28±3.61 10.03±3.22 4.33±4.72 9.08±7.57 
BV (um^3) 4.31±3.08 8.91±2.16 5.22±1.71 2.50±2.60 5.11±4.21 
TV/BV (%) 53.79±20.82 58.51±6.06 52.52±5.85 63.07±7.29 59.24±5.58 
TS (um^2) 62.83±45.55 60.32±14.75 63.56±19.88 34.24±27.19 39.77±30.77 
BS (um^2) 326.15±220.05 450.92±121.44 355.52±130.15 133.83±147.25 269.57±232.90 
Tb.Th (um) 0.04±0.01 0.06±0.00 0.05±0.01 0.07±0.03 0.06±0.01 
Tb.Sp (um) 0.07±0.03 0.09±0.03 0.08±0.02 0.06±0.02 0.08±0.03 
Tb.N (1/um) 14.09±9.32 9.57±1.01 10.99±1.08 10.49±4.88 9.71±1.30 
Total Porosity (%) 46.21±20.82 41.49±6.06 47.48±5.85 36.93±7.29 40.76±5.58 
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6.3.4 Histomorphometric analysis of osteotomy healing 
At the x1 magnification scale, there was a trend for a smaller callus area at the mid-sagittal 
region, being significantly smaller for VEGF-AMD group only (p=0.029) (Figure 6.11), and 
overall tissue composition is shown in figure 6.12 and table 6.3. 
 
Figure 6.11: Boxplot showing the absolute measured area (square pixels) between the two innermost 
fixator pin tract holes, measured at 1x magnification. * represents significance p<0.05. 
 
 
Figure 6.12: Mean±SEM absolute measured area (square pixels) of different tissue types between the 
two innermost fixator pin tract holes, measured at 1x magnification. * represents significance p<0.05. 
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Table 6.3: Mean±SD tissue area measured (square pixels), showing histomorphometric characteristics 
of the tissue in between the two innermost fixator pin tract holes at x1 magnification.  
 
The 2.5x histomorphologic analysis did not show any significant results, however clear trends 
were seen which corroborated the microCT data (Figures 6.13-6.17). The percentage cartilage 
(p=0.053) and percentage fibrous tissue (p=0.059) trended towards significance (KK test). 
Levene’s test for equality of variances did not show a significantly reduced data spread 
between the control group and PBS-AMD, or GCSF-AMD or IGF1-AMD, however, there 
was a difference between control and VEGF-AMD for bone (p=0.032) and fibrous tissue 
(p=0.026), showing a reduction in variation. 
 
Fig 6.13: Boxplot showing the % bone formed within the osteotomy from 2.5x magnification 
histomorphometry.  
 
TISSUE AREA (square pixels) 1.5mm Control PBS-AMD VEGF-AMD GCSF-AMD IGF1-AMD 
Total callus 351681±89789) 341085±64261) 257928±64144) 298808±128985) 273779±91089)
Bone 307513±98801) 311770±46801) 232199±59324) 251017±113340) 247786±102675)
Cartilage 36839±28385) 29315±26005) 24226±14988) 26596±7566) 19796±13590)
Fibrous 7329±19390) 0±0) 1504±2799) 21195±44140) 6198±10069)
TISSUE AREA (%) 
Bone 85.9±90.9) 91.9±5.5) 90.0±4.3) 89.5±4.1) 90.4±8.8)
Cartilage & fibrous combined 14.1±9.1) 8.1±5.5) 10.0±4.3) 10.5±4.1) 9.6±8.8)
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Figure 6.14: Boxplot showing the % cartilage formed within the osteotomy from 2.5x magnification 
histomorphometry. 
 
a   
b 
Figure 6.15: Boxplot showing the % fibrous tissue formed within the osteotomy from 2.5x 
magnification histomorphometry 
 
 
	 194	
 
Figure 6.16: Boxplot, showing the % vascular tissue formed within the osteotomy from 2.5x 
magnification histomorphometry. 
 
 
Figure 6.17: Mean±SEM percentage tissue formed within the osteotomy from 2.5x magnification 
histomorphometry. 
 
Trends for increased bone formation were associated with decreased cartilage, whilst the 
worse performing groups had an increase in fibrous tissue with decreased bone and cartilage 
formation (Figure 6.17 and Table 6.4). The level of vascularisation of the tissues was not 
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significantly different, however, animals in the GCSF-AMD group had the lowest levels of 
vascularisation, whilst groups with more bone formation had higher levels of vascularisation 
(Figure 6.16). Notably, PBS-AMD, which had the highest levels of bone and vascular tissue, 
had reduced cartilage and no fibrous tissue (Figure 6.17). However, in other groups cartilage 
formation was increased, suggesting conversion to bone by endochondral ossification. The 
next highest bone formation was seen in VEGF-AMD, which also showed a low level of 
fibrous tissue and higher level of vascular tissue on histomorphometric analysis. 
Representative images of the histology are shown for 1.5mm control (Figure 6.18), PBS-
AMD (Figure 6.19), VEGF-AMD (Figure 6.20), GCSF-AMD (Figure 6.21 and 6.22), and 
IGF1-AMD (Figure 6.23). 
 
Table 6.4: Histomorphometric percentage area of tissue formed within the original osteotomy gap as 
evaluated at x2.5 magnification. All data expressed as mean±SD.  
% Tissue 1.5mm Control PBS-AMD VEGF-AMD GCSF-AMD IGF1-AMD 
Bone 39.1±23.9' 58.1±17.1' 55.1±7.8' 32.8±26.1' 50.0±34.7'
Cartilage 43.1±24.6' 35.9±16.5' 40.9±9.8' 25.0±14.3' 20.7±11.6'
Fibrous 15.3±37.4' 0.0±0.0' 0.3±0.8' 39.6±37.5' 26.7±42.2'
Vascular 2.4±2.0' 6.0±2.8' 3.9±3.9' 2.6±2.5' 2.8±2.8'
Combined bone & cartilage 82.3±36.4' 94±2.8' 96±3.7' 57.9±38.8' 70.8±40.3'
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1.5mm Control example 
 
Figure 6.18: Histology images taken from a mid-sagittal 5um slice stained with H and E, from a 1.5 
Control example, at x1, x2.5 and x20 magnification from top to bottom. A microCT reconstruction 
with a mid-sagittal reveal of the same sample is also shown. CoB = cortical bone. 
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PBS-AMD example 
 
Figure 6.19: Histology images taken from a mid-sagittal 5um slice stained with H and E, from a PBS-
AMD example, at x1, x2.5 and x10 magnification, from top to bottom. A microCT reconstruction with 
a mid-sagittal reveal of the same sample is also shown.  
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VEGF-AMD example 
 
Figure 6.20: Histology images taken from a mid-sagittal 5um slice stained with H and E, from a 
VEGF-AMD example, at x1, x2.5 and x5 magnification, from top to bottom. A microCT 
reconstruction with a mid-sagittal reveal of the same sample is also shown. 
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GCSF-AMD example 
 
 
Figure 6.21: Histology images taken from a mid-sagittal 5um slice stained with H and E, from a GCSF-
AMD example (GCSF-AMD 3), at x1, x2.5 and x5 magnification, from top to bottom. A microCT 
reconstruction with a mid-sagittal reveal of the same sample is also shown. 
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Figure 6.22: Histology images taken from a mid-sagittal 5um slice stained with H and E, from GCSF-
AMD 5, at x5, x10 and x20 magnification from top to bottom, showing the marked cellularity and lack 
of hypertrophic chondrocytes. 
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IGF1-AMD example 
 
Figure 6.23: Histology images taken from a mid-sagittal 5um slice stained with H and E, from a IGF1-
AMD example (IGF1-AMD 5), at x1, x2.5 and x10 magnification, from top to bottom. A microCT 
reconstruction with a mid-sagittal reveal of the same sample is also shown. 
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6.4 DISCUSSION 
6.4.1 Overview of results 
Blood circulating skeletal progenitors were first described by Paget in 1863 (Chesney & 
Bucala 1997) and have been evaluated in more detail since (Kuznetsov et al. 2001; Zvaifler 
et al. 2000). Patients with fractures have increased numbers of circulating osteoprogenitor 
stem cells (Alm et al. 2010) and EPCs (Ma et al. 2012) and parabiotic mouse studies support 
the mobilisation of progenitors to a fracture site (Kumagai et al. 2008). It is assumed that 
stem cells are mobilised from the bone marrow, however they could also be from other 
stem/progenitor niches, such as the periosteum or muscle (Knight & Hankenson 2013). The 
exact mechanism of contribution of the blood mobilised EPCs and MSCs to fracture healing 
is not clear however. They may have contributed to blood vessel or skeletal tissue formation 
directly or they may have provided immunomodulatory and trophic influence on tissue 
resident cells. In any case, it is clear that antagonising the SFD1-CXCR4 axis, which 
regulates stem/progenitor cell niches and facilitates mobilisation, was able to increase 
fracture healing and is worth further study.  
There is evidence for the influence of SDF1-CXCR4 on fracture healing from a range of 
species. In human distraction osteogenesis procedures using Ilizarov fixators, circulating 
SFD1 levels were increased two to three days after initial osteotomy and remained elevated 
during the distraction period (Lee et al. 2010). A mouse ulna stress fracture model also 
demonstrated increases in fracture site SDF1 at four days (Kidd et al. 2010), suggesting an 
importance in early fracture healing, probably in recruitment of MSCs and EPCs. Increased 
SDF1 mRNA expression in the periosteum of healing bone indicates a likely role in early 
intramembranous bone formation, and fracture healing could be reduced with SDF1 blocking 
antibodies or by genetic reduction of SDF1 expression (Kitaori et al. 2009). 
There is also evidence for a role of SDF1 in endochondral ossification, with increased SDF1 
expression in pre-hypertrophic and hypertrophic chondrocytes of rib fractures. SDF1 double 
knock-out mice have shorter humeri, and in particular, a reduced hypertrophic zone (Murata 
et al. 2012) indicating a role of SDF1 in hypertrophic cartilage derived bone formation. 
Expression of SFD1 has been localised to the callus and in particular hypertrophic and 
immature cartilage near pre–existing cortical bone. Notably, SDF1 was expressed in areas 
where hydroxyprobe binding was high, indicating a role of hypoxia (Toupadakis et al. 2012). 
An upstream influence of hypoxia inducible factor 1alpha subunit (HIF1α) is suggested to 
drive SDF1 expression in fractures (Yellowley 2013). Under hypoxic conditions the 
breakdown of HIF1α is reduced (Hirota & Semenza 2006) and elevating concentrations of 
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HIF1α increases SDF1 expression and hence increases stem/progenitor recruitment (Ceradini 
et al. 2004). As fracture sites are known to be hypoxic (Heppenstall et al. 1975; Brighton & 
Krebs 1972), and reduced oxygen tension at endosteal surfaces is thought to increase SDF1 
expression in the bone marrow (Eliasson & Jönsson 2010), it is plausible that the hypoxic 
fracture environment could be an instigator of raised SDF1 expression. The resultant SDF1 
chemotaxis gradient is then surmised to drive trafficking and homing of stem and 
progenitors to the site of injury (Yellowley 2013).  
Otsuru et al., using a bone marrow transplanted parabiotic mouse model with GFP labeled 
marrow, showed the role of CD45 negative osteoprogenitors being mobilised into the 
peripheral blood due to tissue injury, and under the influence of SDF1, the cells migrated to 
bone forming sites and became osteoblasts (Otsuru et al. 2008). Bioluminescence studies 
showed that MSCs expressing luciferase migrated to a tibial fracture site, and by sorting 
them for CXCR4, they showed its role in directed migration (Granero-Moltó et al. 2017). 
Not only did they show migration, they also demonstrated a positive effect of the trafficked 
MSCs with increased cartilage and bone content associated with callus morphology changes. 
The healing callus was typically bigger with increased cartilage in the treated group, 
however, this was at significantly earlier time points than in my study. Histologically, there 
were increased chondrocytes and notably increased hypertrophic chondrocytes, indicating 
increased endochondral ossification with MSC transplantation. Using Lac Z-tagged MSCs, 
the transplanted cells were seen along the margins of the woven bone as osteoblasts, but 
were not seen in the periosteal callus. A potential role for the MSCs in periosteal callus 
formation was suggested by their expression of BMP-2 driving paracrine bone formation.  
My study was the first to evaluate the potential effects of CXCR4 antagonism on fracture 
healing in rats. Critically, my study evaluated the potential to rescue a compromised healing 
environment, rather than simply augmenting uncomplicated healing. In answer to my 
question and hypothesis for this chapter; it was possible to improve compromised fracture 
healing using endogenous stem and progenitor mobilisation. All strategies tested other than 
GCSF-AMD improved fracture healing, with an increase in radiographic union and decrease 
in non-union compared with controls. AMD3100 alone gave significant increases in bone 
formation as measured on microCT, with a bigger (proportionally mineralised) callus 
compared to controls. IGF1-AMD showed a relatively more mineralised callus with a 
significant increase in % bone, and VEGF-AMD showed a trend for increased bone 
formation over the control. Intriguingly, the intragroup spectrum of healing, from non-union 
to union, as seen in the controls, was also seen in the treated groups, with no strategies 
providing a homogenous result. If it is reasonable to conclude that individuals have variation 
in healing potential, as noted in the previous chapter, and mechanical loading from 
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individual activity will influence healing, it is not surprising that my work in this chapter 
showed a similar heterogeneity. It is feasible that increasing the pool of available stem cells 
for fracture healing is likely to be more beneficial in those with inherently better biological 
healing (Jepsen et al. 2008). In any case, the treatment does appear to benefit most 
individuals by moving them further along the healing scale. Ideally, a standardisation or 
even quantification of physical activity, and or inbred strains would be useful to clarify the 
causes of the heterogeneity.  
In my study, microCT was the only modality to show significant increases in healing with 
certain mobilisation strategies. MicroCT also provides information on the hard callus 
microstructure and quantitative morphometry gives different indices of the microstructure, 
including trabecular thickness, separation and number, many of which are predictive of 
mechanical strength (Bouxsein et al. 2010). My scans were performed at 5um and currently 
<10um is recommended to achieve sufficient resolution to calculate these indices (Casanova 
et al. 2014). This high-resolution 3D imaging showed interesting variations not only in the 
overall amount of new bone formed but also in its structure. The trabecular thickness and the 
space between trabeculae (trabecular separation), provides commentary on the nature of the 
woven bone formed within the osteotomy. All treatment groups other than GCSF-AMD had 
increased trabecular separation with increased trabecular thickness, implying the woven 
bone formed was more porous, but the individual struts were thicker. Perhaps this represents 
a more advanced or more rapidly developed stage of endochondral ossification. In any case, 
AMD3100 alone had significantly more bone formed than control, and IGF1-AMD 
significantly increased the % bone content of the callus.  
6.4.2 PBS-AMD group 
The most effective treatment group was AMD3100 alone (PBS-AMD group). This group 
had the highest bone formation on microCT and histomorphometry. The efficacy of 
AMD3100 used alone has been shown previously in a mouse femoral fracture model, 
whereby AMD3100 was given for three days after fracture. At 24 days the callus was 
significantly larger, however by 84 days it was significantly smaller than controls 
(Toupadakis et al. 2013). A single injection of AMD3100 has also been shown to improve 
intramedullary trabecular bone regeneration after ablation at three weeks (McNulty et al. 
2012). My work also showed structural change in the bone compared with control, with 
thicker trabeculae and increased trabecular spacing of the woven bone. This would likely 
correlate with increased mechanical strength. AMD3100 alone also had the highest 
percentage vascular tissue with the lowest fibrous and highest bone composition 
histologically, consistent with bone formation requiring vascular invasion to reduce the 
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hypoxia to a level necessary for bone to be synthesised (Einhorn & Gerstenfeld 2014; Stegen 
et al. 2015). 
Toupadakis et al. showed using flow cytometry that AMD3100 alone was successful at 
mobilising haematopoietic stem cells, EPCs and MSCs (Toupadakis et al. 2013). Pitchford’s 
work on the other hand, measured CFUs for EPCs, MSC and haematopoietic stem cells, and 
showed that VEGF combined with AMD3100 was more effective than AMD3100 alone in 
terms of mobilising MSCs and EPCs (Pitchford et al. 2009). Pitchford did not show MSC 
mobilisation with AMD3100 alone, whereas others have (Toupadakis et al. 2013; McNulty 
et al. 2012). Clearly there is some contradiction in the literature when cells are isolated in 
terms of isolation and culture techniques, surface markers evaluated, and hence these types 
of studies have limited merit when translating to a bone healing therapy. A critical limitation 
is that these studies only inform you about the populations you choose to look for and by the 
criteria you propose. As my study showed significantly increased bone formation with 
AMD3100, it seems whatever the combination and number of cells it mobilised, there was a 
beneficial effect.  
6.4.3 Osteotomy influence – a role of endogenous growth factors?  
When AMD3100 was used alone, exogenous growth factors were not co-administered 
precluding their direct humoral influence on bone formation, or their potential role as a bone 
marrow stem cell modulator. From the results seen with AMD3100 alone, this would imply 
that the exogenous growth factors are not necessary in an in vivo system of fracture healing. 
Again, the shortcomings of previous single time-point studies evaluating a selected 
population(s) (Pitchford et al. 2009; Kumar & Ponnazhagan 2012) shows that in vivo 
evaluation is necessary to evaluate a translational therapy.  
A key difference between some in vitro mobilisation studies (Pitchford et al. 2009), the in 
vitro studies I completed in chapter 3, and the work in this chapter, is the presence and 
influence of the osteotomy. It is well know that fractures release increased levels of growth 
factors (Devescovi et al. 2008; Lieberman et al. 2002). In vivo work has demonstrated a 
range of growth factors associated with the fracture site (Simpson et al. 2006), including 
platelet derived growth factor, fibroblast growth factor, transforming growth factor, bone 
morphogenic proteins (BMP)s, and notably for my work, VEGF and IGF1. Clinically, VEGF 
is increased in human patients with long bone fractures within the first couple of weeks, 
lasting up to six months post trauma (Sarahrudi et al. 2009). Experimentally, VEGF mRNA 
transcripts are increased in a rat femoral drill hole model with temporal patterns of splice 
variants of VEGF. In this model, VEGF was detected from one day after fracture and 
remained high for 11 days before slowly declining. The timing between fracture and surgical 
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stabilisation with internal fixation also influences the levels of VEGF seen, with longer 
delays and more instability associated with higher levels of VEGF (Dong et al 2014).  
When VEGF is exogenously administered in combination with AMD3100, the expectation is 
VEGF has a priming effect on the bone marrow. This effect is mediated not through up-
regulation of MSCs or EPCs in the bone marrow, nor by altering CXCR4 expression, but by 
reducing the ability of haematopoietic stem cells to migrate to SDF1 by activating their cell 
cycling through VEGF receptor 1. It is then presumed that the reduced haematopoietic 
migration allows for increased MSC and EPC migration (Pitchford et al. 2009). As 
AMD3100 was given five days after osteotomy in my protocol, it is conceivable that 
endogenous VEGF was present and potentially priming the bone marrow niche in the 
AMD3100 only group. 
IGF1 is produced by bone matrix, osteoblasts and chondrocytes (Lieberman et al. 2002), and 
IGF1 has been shown to be increased in both human and rodent fractures (Andrew et al. 
1993; Edwall et al. 2009). In rodent studies, IGF1 was expressed by chondrocytes and 
osteoblasts, and was elevated by the initial measurement (day four) and had peaked at day 
eight (Edwall et al. 2009). Research from humans also showed no expression of IGF mRNA 
in the earliest stages of fracture haematoma. IGF1 was detected in some chondrocytes but 
only once osteoblasts appeared (Andrew et al. 1993). As IGF1 does not increase as early as 
VEGF, it is difficult to know if it was likely to have been present when the AMD3100 
injection was given. It is possible that IGF1 would have been present to some extent, which 
may have further influenced the effect of AMD3100 on mobilisation and healing. Indeed, it 
may have been the proportions of different growth factors and their temporal relationships 
when combined with AMD3100 that facilitated the promotion of bone formation.  
6.4.4 IGF1-AMD group 
IGF1-AMD gave a significantly improved % bone formed as detected using microCT, with a 
callus volume similar to the controls. Kumar et al. showed IGF1-AMD mobilised slightly 
more CFU-f/ml than VEGF-AMD. However their study was quite limited as they only 
counted the CFU-Fs and looked at bi-differentiation from the IGF1-AMD group only 
(Kumar & Ponnazhagan 2012). Pitchford et al. did not evaluate IGF1 in combination with 
AMD3100, however their work comprehensively evaluated mobilisation of MSCs, EPCs and 
hematopoietic progenitor cells, and further they looked at cell surface markers for lineage 
assessment, in addition to differentiation testing (Pitchford et al. 2009). Kumar however, 
took the IGF1-AMD protocol further by evaluating its therapeutic potential to mobilise 
MSCs in a mouse fracture model. Using DXA, they showed a significant increase in fracture 
site bone mineral density, similar to my increased % bone formation, however, their results 
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showed IGF1 alone also gave a moderate improvement in bone density, whereas AMD3100 
alone did not (Kumar & Ponnazhagan 2012).  
IGF1 has a critical role in bone development and maintenance and hence can influence 
fracture healing. Growth hormone drives IGF1 synthesis from the liver and is essential for 
longitudinal bone growth at the physes with peaks at puberty (Spencer et al. 1991), and 
growth hormone has been shown to increase mechanical fracture strength in rats (Bak et al. 
2009). IGF1 is thought to act through paracrine and autocrine mechanisms on bone cell 
differentiation (Hock et al. 1988; Mochizuki et al. 1992) and low levels of IGF1 are 
associated with reduced bone density. Osteoblast maturation and function is a complex 
process, but a role of IGF1 in promoting osteoblastogenesis and reducing bone cell apoptosis 
through β-catenin Wnt signaling is suggested (Kawai & Rosen 2012). IGF1 has also been 
shown to increase osteogenesis through regulation of marrow derived osteoblasts, and can 
also drive osteogenic differentiation of human MSCs (Levi et al. 2010).  
Although it is difficult to distinguish the inherent effects of IGF1 on bone itself as apposed to 
the mobilising effects of IGF1 combined with AMD3100, Kumar et al. comprehensively 
demonstrated that although IGF1 did improve fracture healing, probably through humoral 
signaling mechanisms, the combination was by far more influential and stem cell 
mobilisation was thought to underlie the enhanced healing (Kumar & Ponnazhagan 2012). 
They determined that MSCs cultured in IGF1 had increased phospho-Akt, phospho-Erk1/2 
and phospho-smad2/3 activity and hence upregulated bone forming pathways. To determine 
the effects of IGF1-AMD on stem cell function further, they isolated mononuclear cells from 
IGF1 with AMD3100 treated mice, and compared them to an AMD3100 treatment group. 
CFU formation, osteogenic and adipogenic differentiation were evaluated and there was 
increased staining indicative of increased differentiation potential in the IGF1 with 
AMD3100 group. They also showed increased proliferation and migration in vitro. They 
speculated that the increase in CFUs indicates the IGF1 had a priming effect on the bone 
marrow, increasing the number of available MSCs in the bone marrow to be mobilised, and 
hence the AMD3100 treatment combined with IGF1 was more efficacious at increasing a 
pool of more potent MSCs (Kumar & Ponnazhagan 2012). Although my study showed 
significant increases in % bone formation using microCT, the histomorphometry revealed 
relatively high levels of fibrous tissue within the callus. This outcome may be due to 2/5 
animals in this group developing an atrophic non-union, whereas the other 3/5 had 
radiographic union.  
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6.4.5 GCSF-AMD group 
GCSF was one of the first cytokines identified and was rapidly adopted into clinical 
medicine as a means to boost neutrophil populations in chemotherapy patients. Later, its 
ability to mobilise haematopoietic stem cells from the bone marrow into the peripheral 
circulation was exploited for stem cell transplantation (Bendall & Bradstock 2014). The 
mobilisation of stem cells by GCSF involves increased production of CD34+ cells within the 
bone marrow and proteolytic cleavage of VCAM-1 (Lapidot & Petit 2002), and SDF1 
(Lévesque et al. 2003). In terms of mobilisation, Pitchford et al. showed GCSF combined 
with AMD3100 to be as effective as AMD3100 alone for mobilising MSCs, poorer than 
AMD3100 alone for EPCs and extremely potent at mobilising haematopoietic progenitor 
cells. The haematopoietic stem cells mobilised by GCSF were identified in the G0/G1 cell 
cycle phase, whereas bone marrow niche haematopoietic stem cells are actively cycling and 
probably unable to migrate (Pitchford et al. 2009). The question therefore, is whether it is a 
reduction in EPCs, or a flooding of HSCs that resulted in the impaired healing in my study? 
Pitchford et al. also showed that GCSF-AMD combinations gave maximal neutrophil 
mobilisation and this could potentially influence the inflammatory environment at the 
fracture site. A comparison of CD34+ cells to a total mononuclear cell fraction transplanted 
into a fracture gap showed the mononuclear mixed population had poorer healing, possibly 
due to increased inflammation (Fukui et al. 2015), and hence increased neutrophil migration 
and inflammation may have had a role. Additionally, if MSCs are important for bone 
regeneration, it would not be unexpected that their suppressed mobilisation with GCSF-
AMD did not improve fracture healing.  
Haematopoietic precursors mobilised preferentially by GCSF-AMD may have also provided 
precursors to osteoclasts (Fujikawa et al. 1996) and hence the reduction in bone volume and 
increased atrophic type non-unions (3/6) seen in this group. Histomorphometry showed a 
reduction in hypertrophic cartilage and bone formation, with a large increase in fibrous tissue. 
The GCSF-AMD samples also did not show as much chondrocyte hypertrophy as the other 
treated samples and as chondrocyte hypertrophy is a critical step to allow calcification, 
vascularisation and osteoblast differentiation (Babarina et al. 2001), it is therefore not 
surprising there was reduced bone formation. It is also possible that GCSF had direct 
humoral effects that were negative to bone healing, as GCSF has no beneficial effect on 
osteoblasts and only moderate effect on human endothelial cells (Liu et al. 2016). It is also 
known that long term clinical administration of GCSF results in osteopenia with associated 
vertebral fractures, and experimental evidence shows just five days of treatment reduces the 
number of osteoblasts present (Semerad 2005). Further evaluation of short-term treatment 
with GCSF in mice showed decreases in endosteal and trabecular osteoblasts, and osteoblast 
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turnover in the marrow was accelerated by inducing osteoblast apoptosis (Christopher & 
Link 2008). They also showed that osteoprotegerin was decreased and RANKL remained 
unchanged suggesting a possible mechanism for increased osteoclast activity from GCSF 
administration.  
Studies using CD34+ cells in part contradict the work of this thesis (Kuroda et al. 2014). 
Human peripheral blood CD34+ cells have been systemically transplanted into non-healing 
femoral fractures of immunocompromised rats and fracture healing was significantly 
improved (Matsumoto et al. 2006). However, this and any similar studies are reliant upon 
transplantation rather than endogenous mobilisation and therefore only reflect a subset of the 
cells mobilised by GCSF-AMD. It should also be considered that CD34 is seen on both 
haematopoietic progenitors and some EPCs, and therefore the EPC fraction may be 
conferring the reported benefit seen (Atesok et al. 2010; Giles et al. 2017; Lee et al. 2008). 
Notably, when a mixed mononuclear population rather than a CD34+ selected population 
was transplanted into a fracture gap, the healing was reduced, associated with increased 
inflammation (Fukui et al. 2015).  
6.4.6 VEGF-AMD group 
Hypoxia and subsequent vascularisation of tissues within the fracture site plays a crucial role 
in progressive fracture healing and VEGF is a potent angiogenesis promoter, with a clear 
role in endochondral and intramembranous bone formation (Street et al. 2002; Gerber et al. 
1999). Local delivery of VEGF in rabbit mandibular defects showed increased density of 
bone formation, but no difference in the quantity. Vascular development was sustained for 
longer periods and the consensus was VEGF will have a direct influence on healing, through 
improved vascularisation, particularly when it is compromised at the outset (Kleinheinz et al. 
2005). Blocking VEGF with soluble receptors decreases angiogenesis, bone formation and 
callus mineralisation, whereas exogenous VEGF enhances vascularisation, ossification and 
callus formation in mouse femoral and rabbit radial defects (Street et al. 2002). Therefore, 
exogenous VEGF administration is likely to have both direct and indirect effects on bone 
formation. VEGF can act indirectly through its receptors on endothelial cells, influencing the 
development of a new vascular network, which then allows bone orientated stem and 
progenitors to migrate into the fracture callus and differentiate into osteoblasts (Stegen et al. 
2015).  
VEGF can also stimulate endothelial cells to produce cytokines that promote differentiation 
of progenitors down an osteoblastic lineage (Bouletreau et al. 2002). It has also been shown 
that osteoblasts not only synthesise VEGF but are activated by it, affecting differentiation, 
proliferation and migration (Street et al. 2002; Midy & Plouët 1994; Deckers et al. 2000; 
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Mayr-Wohlfart et al. 2002). Histomorphometric assessment of vascularisation was not the 
objective of this chapter, but notably the most efficacious group in terms of bone formation 
(PBS-AMD) also had the highest number of blood vessels, although, significant differences 
were not detected between groups. VEGF-AMD had the second highest percentage 
vascularised tissue, but the significance of that is difficult to know from this work. 
Immunohistochemistry analysis would be an option to quantify blood vessel formation in 
more detail by staining for endothelial markers. 
The other question that remains is what was the contribution of mobilised EPCs? Pitchford et 
al. showed the highest mobilisation of EPCs when VEGF combined with AMD3100 (240 
CFUs/ml), however even AMD3100 alone mobilised significant numbers (130 CFUs/ml) 
over and above no treatment (10 CFUs/ml), as did GCSF combined with AMD3100 (90 
CFUs/ml) (Pitchford et al. 2009). This profiling does not explain the variations in healing 
between the groups, as VEGF-AMD was not the best performing group, however, how these 
cells may have contributed to the complex process of fracture healing may not be 
immediately represented by their number.  
There is evidence that culturing and transplanting EPCs can improve fracture healing 
(Matsumoto et al. 2008), with rat models showing significantly increased torsional stiffness 
and bone formation (Li et al. 2011; Atesok et al. 2010), however, there are issues in the 
literature with the different culture techniques, criteria for definition and even cell types such 
as early vs late EPCs (Mund & Case 2011; Patel et al. 2016; Minami et al. 2015). Early 
EPCs have been shown to be more effective than late in one study for improving fracture 
healing (Giles et al. 2017). Despite this, CD31 positively expressing cells have been shown 
to be reduced in older fracture patients, and experimentally, CD31+ cells improved fracture 
healing in a rat model (Sass et al. 2017).  
6.4.7 Conclusion 
This chapter suggests a beneficial effect of CXCR4 antagonism using AMD3100, supporting 
the hypothesis. The exact interaction between AMD3100 alone and when combined with 
growth factors is less clear and indeed, as seen with GCSF, potentially negative.   
The nature of the disturbance to the SDF1-CXCR4 axis is important. Short duration 
blockade may mobilise more stem and progenitor cells and hence increase the total pool 
available to the fracture site. However, the homing to the fracture site also relies upon the 
very interaction being antagonised. The short half-life of AMD3100 (De Clercq 2009) 
should be beneficial and hence the ‘pulse’ in the early inflammatory phase of fracture 
healing should have a greater mobilising effect at stem cell niches, rather than significantly 
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impairing the recruitment of cells to the fracture site, which occurs over days to weeks. 
However, longer term blockade throughout the period of fracture healing will significantly 
reduce callus cartilage, callus size and bone formation, with reduced expression of genes 
associated with endochondral ossification (Toupadakis et al. 2012). It is likely that continued 
antagonism of the CXCR4 receptor prevents migrating stem and progenitor cells from 
homing to the fracture site. 
In this chapter, I have shown that AMD3100 treatment can influence fracture healing and 
pre-treatment with growth factors or not, also impacts on the outcome. GCSF-AMD had a 
negative effect and should be avoided, potentially due to increased inflammation and 
reduced endochondral ossification at the fracture site (Fukui et al. 2015). Notably, there was 
no panacea here, as all groups had at least one non-union, however, there were clear and 
significant improvements in fracture healing in a challenged healing environment. In 
contradiction to in vitro mobilisation studies, AMD3100 was highly effective on its own, 
which may be in part due to endogenous growth factors being physiologically present at the 
fracture site, or indeed the actions of the pharmacological antagonism provide sufficient 
mobilisation of the required cell populations. For clinical translation, this would be 
beneficial as it is already licensed for use in humans and it avoids the cost and potential risks 
of oncogenesis associated with some growth factors. 
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CHAPTER 7: Main Discussion 
 
	 213	
7.1 Hypothesis & aim 
Failed fracture union remains a significant clinical issue. A regenerative medicine approach 
to improve fracture healing typically involves isolating a source of stem cells with delivery 
back to the body at a later stage. However, issues remain over the time, effectiveness, costs, 
disease transmission and donor site morbidity. An alternative is to increase circulating 
stem/progenitor cell populations endogenously through non-invasive mobilisation and thus 
increase the cells available to home to, and improve the healing of fractures. The aim of my 
thesis was to improve fracture healing through endogenous mobilisation of stem and 
progenitor cells. The main hypothesis was “antagonism of the CXCR4-SDF1 axis will 
mobilise stem and progenitor cells into the circulation of rats, and by increasing the 
available pool of cells early in fracture healing, will improve fracture union”. Over the 
course of my thesis I was able to prove my hypothesis. 
7.2 Proof of concept: endogenous mobilisation  
As MSCs and EPCs have critical roles in fracture healing and have improved fracture 
healing when transplanted (Kadiyala et al. 1997; Bruder et al. 1998; Ward et al. 2007; 
Kuroda et al. 2014), it was important to establish a mobilisation protocol that increased the 
availability of these cells. Pitchford et al. published the most comprehensive evaluation of 
peripheral mobilisation of different stem/progenitor populations. They established that 
VEGF combined with AMD3100 was the most effective protocol to mobilise MSC and 
EPCs into the peripheral circulation, compared with AMD3100 alone or when combined 
with GCSF. Their landmark study was in mice, whereas a rat model was my preferred test 
system due to their size; the larger rat allowed for a consistent and reproducible fracture that 
could be stabilised by an external fixator, to give a predictable mechanical environment for 
testing my hypothesis. At the time, AMD3100 and VEGF had not been evaluated in rats and 
therefore an initial proof of concept was required. Although SDF1 and CXCR4 expression 
had been confirmed in the rat and had also been associated with fractures, mobilisation data 
was only available in mice (Pitchford et al. 2009; Toupadakis et al. 2013; Kumar & 
Ponnazhagan 2012; McNulty et al. 2012). One rat mobilisation study had been published 
where Tacrolimus (an immunosuppressive drug) and AMD3100 were used and improved the 
healing of skin wounds. They associated this improvement with an increase in circulating 
“Lin-, c-Kit, CD34+, CD133+ cells and Lin- Triple positive” stem cells (Lin et al. 2014), but 
not MSCs.  
Chapter 3 provided ‘proof of concept’ of endogenous mobilisation of stem and progenitor 
cells using VEGF combined with AMD3100 in a rat model. My hypothesis, based on the 
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work of Pitchford et al. was that VEGF combined with AMD3100 would significantly 
increase circulating MSCs and EPCs as measured by CFU-F and EPC CFUs in culture. 
Although I did show a significant increase in CFUs, the actual numbers of CFUs/ml were 
low with 3/ml for PBMSCs and PBEPCs, compared with Pitchford’s work which had greater 
mobilisation of 15 MSC CFUs and 230 EPCs CFUs/ml (Pitchford et al. 2009). Although in 
chapter 2 the techniques to isolated and evaluate bone marrow MSCs worked well, the 
poorer yields for the PBMSCs may indicate a need for further studies where the dose, time 
and frequency of AMD3100 administration is optimised in order to release a higher number 
of stem cells. However, the low yields that I obtained may simply reflect a difference in the 
mobilisation potential in old rats compared with very young mice, which then lead to a low 
initial seeding density and slow growth (He et al. 2006). Perhaps rats mobilise differently 
compared to mice due to species variations in the CXCR4 receptor, although the receptor is 
generally well conserved, with 90% homology between mouse and human (Pawig et al 
2015). Difficulty in isolating peripheral blood MSCs have however, been reported 
previously (Kassis et al. 2006). It also remains unknown at what time point these cells 
should be mobilised in the fracture healing process.  
In chapter 2 I isolated rat bone marrow MSCs and evaluated their cell surface markers, and 
showed them to be CD34- CD45- CD90+ CD29+, in line with other studies on rats (Fafián-
Labora et al. 2015; Fu et al. 2012; Dezawa et al. 2004). These cells could tri-differentiate and 
were used as my benchmark comparison for mobilised peripheral blood MSCs (PBMSCs). 
As a comparison for evaluating peripheral blood EPCs (PBEPCs), I looked to HUVECs, 
identified by their ‘cobblestone’ morphology, expression of CD31 and VEGFR2, and in vitro 
tube formation. Unexpectedly, the PBMSCs differed from bone marrow MSCs, with a 
comparatively reduced CD90/CD29 and increased CD45 expression. These cells had 
negligible adipogenic potential, but proved to be potent osteogenic progenitors and therefore 
may positively contribute to fracture healing. Unfortunately, due to the protracted culture 
times and low yields, it was not possible to evaluate chondrogenic potential, hence whether 
these cells were bi-potent or ‘osteo-exclusive’ remains unknown. Since I completed Chapters 
2 and 3, another group has used AMD3100 in rats preconditioned with the hypoxia-
mimicking agent, cobalt chloride. In line with my experience, they mobilised MSCs that 
were preferentially osteogenic, with reduced adipogenicity and equal chondrogenic potential 
to bone marrow MSCs. Interestingly, their highest levels of CFUs mobilised was similarly 
low at 3.8/ml (Liu et al. 2018). This suggests that mobilisation using AMD3100 may 
preferentially mobilise a subpopulation, or a later lineage population of MSCs. Although 
most literature cites MSCs as having tri-lineage potential, classical bone marrow stem cell 
work identified clonal populations frequently do not have full tri-differentiation, whilst 
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interestingly, the osteogenic lineage is always present (Pittenger et al. 1999). Others 
elaborated upon these findings showing a sequential loss of lineages for MSCs with 
osteogenic differentiation remaining (Muraglia et al. 2000). This affirms my suggestion that 
mobilised PBMSCs could be ‘later’ lineage determined cells. Future work could evaluate 
this lineage selection of mobilised compared with bone marrow isolated stem cells by 
looking at mRNA transcripts; ‘stemness’ could be evaluated using Rex1, Oct4, Sox2 and 
Nanog (Fafián-Labora et al. 2015), and lineage association by SOX9 (chondrogenic), Runx2, 
Osterix (osteogenic) and PPARγ (adipogenic) (Kubo et al. 2009). Should further work be 
undertaken to evaluate cell populations, I suggest evaluating mobilisation in young rats in 
case of improved yields, although in terms of translation, older rats are probably more 
appropriate. When considering other relevant test groups, as a potential translational therapy 
for fragility fractures, it would be worth evaluating the mobilisation response and impact on 
healing in an osteoporotic model, such as ovariectomised osteopenic rats.  
The mobilised PBEPCs were morphologically distinct from the PBMSCs and similar 
looking to HUVECs, however, they did not fully match the HUVECs in terms of cell surface 
markers or tube formation. Again, I did achieve proof of concept that VEGF with AMD3100 
mobilised several cell populations in rats, this time with adipogenic differentiation potential 
and no osteogenic potential. Exactly what they are and their potential contribution to fracture 
healing remains unclear and again was hampered by the extremely low yields and slow 
culture dynamics. It is arguable that rat endothelial cells, and potentially small vessel 
endothelial cells may have been a better comparator than HUVECs, however the vast 
majority of in vitro angiogenesis assays and gold standard endothelial cell characteristics are 
based on HUVECs (Staton et al. 2009). As endothelial cells vary by the location of isolation, 
vessel size, and whether from an artery or vein (Staton et al. 2009), future studies looking to 
evaluate EPC mobilisation in rats, may be better compared to a rat endothelial cell culture. In 
order to elucidate the mechanisms further in this model system, I would suggest moving to 
young rats. Ex-breeders were logically chosen at the outset as their increased size should 
give higher blood volumes and they better mimic a potential translational population. 
However younger animals are likely to have bigger niche populations and higher 
mobilisation levels (Fafián-Labora et al. 2015; Sethe et al. 2006; Kuznetsov et al. 2001), 
allowing further evaluation and potentially chondrogenic differentiation assessment. Another 
consideration is the influence of in vitro cell culture on the cells being isolated, in particular 
affecting their cell surface characteristics (Bara et al. 2014).  
Finally, I noted that mobilisation appeared to be dependent on the individual. Some cultures 
did not mobilise, some had low levels and others had much higher levels of CFUs/ml. This 
could again relate to the varying ages of ‘ex-breeders’ or to different inherent biological 
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kinetics. To that end, I hypothesise that mobilisation may only induce a factorial increase of 
circulating stem/progenitors from the animal’s inherent baseline. This was not possible to 
evaluate using the techniques employed in chapters 2 and 3, as sufficient blood volume was 
only achieved through terminal cardiac venipuncture. Sequential bleeds with the individual 
as its own control would be very informative, but the very act of taking blood could have 
impact on endogenous cell populations, through transient hypoxia or similar mechanisms. A 
large animal model whereby a larger volume, but a smaller proportion of the circulating 
blood volume could be isolated may be a route forward to answer that question.  
Due to the difficulties associated with the in vitro stem/progenitor cultures, I did not evaluate 
other potential growth factor combinations with AMD3100 for circulating MSCs/EPCs. To 
some extent, the nature of the CFU analysis in chapter 3 is limited as there will be an elution 
profile and other cell populations and differing levels of stem/progenitors will be mobilised 
over a period of time (Broxmeyer et al. 2005). Other cell populations may also be important, 
or indeed, the particular combinations or temporal contributions could be critical to outcome. 
Other groups have evaluated IGF1 combined with AMD3100 in mice with a CFU-F count, 
but lacked an in-depth analysis of the cells mobilised (Kumar & Ponnazhagan 2012), with no 
account of EPCs or other cell types. They identified 26 CFU-F/ml, compared with 20 
CFU/ml for VEGF with AMD3100, and 2.5CFU/ml for AMD3100 alone. However, in their 
published images, the colony looks very immature. I saw similar ‘colonies’, however, many 
didn’t continue to grow and divide, bringing into question whether they should be classified 
as bona fide CFU-Fs; in my study, they were not. Critically, without any evaluation, it is 
impossible to know what those cells were. Quantification of stem cell mobilisation in 
another mouse study using AMD3100 alone reported significant increases in stem cells 
mobilised, but they actually just counted plastic adherent cells (Toupadakis et al. 2013). 
Contamination with fibroblasts and other cells would be possible and this does not fulfill the 
in vitro requirement of MSCs to be self-replicating/expandable (Dominici et al. 2006). Their 
evaluation of numbers of cells based on flow cytometry showing an increase was more 
convincing however (Toupadakis et al. 2013). To that end, with the limited scope of such 
studies in mind, but with some evidence of feasibility, it was sensible to evaluate these other 
two AMD3100/growth factor combinations in a fracture healing scenario. In chapter 6 I 
evaluated VEGF with AMD3100 in a fracture model, but also evaluated the other reported 
protocols to permit a direct comparison.   
7.3 Fracture model 
Chapters 4 and 5 were focused on improving the fidelity of the fracture model and 
determining the ideal test fracture gap to evaluate endogenous mobilisation. My aim was to 
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use a gap size together with a fixator that produced delayed healing. My rationale for this 
approach was that a full non-union model may be too aggressive to show any positive effects 
of mobilisation, and a model with a smaller gap size may not have been able to decipher the 
effects of mobilisation due to the fast healing rate. If my work is to be translated into clinical 
models then the main benefit would be to enhance bone formation in fractures which have a 
higher potential for delayed healing. As fracture healing is influence by both biological and 
mechanical factors (Betts & Müller 2014), I needed the mechanical test scenario to be 
reliable, repeatable and standardised, in order to evaluate a biological intervention such as 
endogenous mobilisation. Chapter 4 focused on redevelopment of an existing rat micro 
fixator system and the model was successfully improved by applying clinical principles of 
external fixator application and design. The modifications included development of a 
autoclave-stable drill and pin jig-guide, drilling at low speeds with irrigation, pin 
redevelopment to increase radial pre-load with a self-cutting thread design and altering the 
block profile to reduce soft-tissue interference. 
Chapter 5 was designed to identify the ideal test situation for endogenous mobilisation and to 
understand the impact of changing the size of the gap on construct stiffness and 
interfragmentary strain (IFS). The hypothesis was that “increasing gap size from 1.0 to 
1.5mm to 2.0mm will decrease IFS, reduce construct stiffness and hence improve bone 
formation within the gap”. The Stanmore micro fixator is a visibly rigid design compared 
with the commercially available AO rodent external fixator and has been shown to be 
significantly stiffer at 4.7 times the axial stiffness (Osagie-Clouard et al. 2018). Fitted with a 
double carbon-fiber connecting bar and using titanium connecting blocks with 1.4mm 
diameter pins, it was likely to provide a relatively rigid fixation. Interestingly, increasing the 
fracture gap, which increases the working length of the carbon-fiber bars did not have any 
effect on construct stiffness, indicative of the relatively rigid fixator design. Therefore, the 
increasing gap size in this test scenario only tested the influence of the gap size, as construct 
rigidity remained consistent. Based on Stefan Perren’s theory of IFS (Perren 1979), my 
hypothesis for this chapter was that increasing the gap size, would decrease IFS and improve 
fracture healing. Based on the IFS at day 0, I could not support the hypothesis, with a 
doubling of non-union rates and halving of bone volume associated with a reciprocal 
increase in fibrous tissue, as IFS decreased from 12% to 6%. In contrast, IFS theory would 
predict a non-union in the 1mm group (12% IFS measured), and endochondral based healing 
in the 1.5 and 2.0mm group (Perren 1979), however the influence of subsequent tissue 
development within the gap on the IFS remain unclear. The trends for reduced healing was 
clear, with a significantly smaller surface area of callus in the 2mm vs 1mm gap, although 
statistical significance was not reached for bone volume. A post-hoc sample size calculation, 
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with a power of 0.8 and p=0.05, indicated that 14 animals per group would have been 
required. For future biomechanical studies using this fixator system, this sample size should 
be kept in mind. Others have also shown increasing gap size associated with decreased 
healing, however, I was able to corroborate that to the IFS using a micro-miniature 
differential variable reluctance transducer (accuracy 0.001mm). This made the 
measurements more accurate than those based on the materials testing machines 
displacement measures. The results of chapter 5 are important as despite the commonplace 
role of rodents in fracture healing research, most studies have evaluated the influence of IFS 
with large animal models in vivo (Claes et al. 1997; Claes et al. 1999; Claes et al. 2003) or 
using FE models only (Steiner et al. 2014; Wehner et al. 2014; Comiskey et al. 2010). 
The work in chapter 5 lead to the selection of the 1.5mm osteotomy gap as a ‘half-way house’ 
in terms of a spectrum from healed to non-union, in a five week time frame, for the 
evaluation of mobilisation in chapter 6. Whether a bigger gap, such as 3mm with guaranteed 
non-union would have been able to show a benefit more clearly remains unknown; a smaller 
gap may equally have been unable to demonstrate enhancement. Ultimately, the 1.5mm gap 
was chosen as compromised healing is translationally appropriate, but without losing the 
opportunity to demonstrate an effect of endogenous mobilisation.  
Osteotomy healing was evaluated with microCT and histology. MicroCT allowed 3D 
volumetric assessment of bone and soft-tissue, but without the ability to resolve cellular 
processes and different soft-tissue types. The two together were therefore synergistic, as the 
single histological section only provided information on the centre of the callus and wasn’t 
truly global, but provided cellular detail. Due to time and cost considerations, a pragmatic 
decision was taken not to evaluate the mechanical stability of fracture healing in chapters 5 
and 6. With the equipment I had available, it was not possible to perform accurate non-
destructive mechanical testing, which would have rendered samples unavailable for microCT 
and histology. To a certain extent, the histology and microCT findings indicate the likely 
strength (Bouxsein et al. 2010), however smaller differences in bone formation may not be 
mechanically significant when tested. Should resources have permitted, mechanical testing 
would have been a useful addition. 
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7.3.1 Variation in healing 
Despite a mechanically standardised fixator, repeatable surgical procedure, consistent age 
and strain of rats (albeit none were inbred), the results reported in chapters 5 and 6 showed a 
large variation in fracture healing, although the in-group incidence of complete healing and 
non-union fitted trends. Based on chapter 5’s mechanical evaluation, this was unlikely to 
relate to an issue of the initial fracture stability provided by the fixator, and likewise the final 
imaging confirmed no pin tract lucency affecting stability. Potentially, the rats inherent 
activity levels may have affected osteotomy healing through variable passive dynamisation 
(Goodship & Kenwright 1985; Richardson et al. 1995). Mouse studies have shown 
significantly different levels of activity post external fixator surgery and this had an impact 
on callus size with more mobile animals producing a bigger callus (Connolly et al. 2006). It 
may be worth quantifying movement post surgery in the future and technology such as 
micro-pedometers could be considered. The rats I used were out-bred strains and therefore 
genetic variation could have also played a role. In-bred mouse studies have shown genetic 
differences in skeletal stem cell regulation affecting the rate of fracture healing (Jepsen et al. 
2008). Moving to in-bred rat strains may be sensible in future studies, however, the variation 
in healing seen in my study is reflected in human fracture healing and therefore the 
experimental variation may mirror the clinical situation. If individuals have variation in their 
ability to heal (Jepsen et al. 2008), and variable activity may have mechanically influenced 
healing, it was likely that chapter 6 also showed a similar heterogeneity. However, if there is 
individual variation in the biological potential to heal, it is feasible that mobilisation may be 
more effective in those with inherently better biological potential, as they may have a bigger 
or more responsive pool of stem cells.  
7.3.2 Endogenous mobilisation in a fracture model 
The hypothesis for chapter 6 was developed and based on the results of previous chapters. 
Chapter 6 was the first study that gave a comparison of different mobilisation strategies to 
improve fracture healing and notably they were tested in a compromised healing model. My 
hypothesis in chapter 6 was “administration of mobilising protocols including 
AMD3100…would increase bone formation within the osteotomy and improve fracture 
union”. In answer, it was possible to improve compromised fracture healing using 
endogenous stem and progenitor mobilisation. All strategies tested other than GCSF-AMD 
improved fracture healing, with an increase in radiographic union and decrease in non-union 
compared with controls. AMD3100 alone gave significant increases in bone formation as 
measured on microCT, and in fact, the entire callus was larger. This was similar to the 
findings of Toupadakis et al., who gave AMD3100 only, but a three-day dose, rather than a 
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single dose. They also showed a bigger callus at 21 days, but by 84 days (which is much 
longer in duration than my study), the AMD3100 treated group had a significantly more 
remodeled and smaller callus (Toupadakis et al. 2013). Whether or not my group would have 
progressed in the same manner remains unknown. This also highlights an unresolved 
question of timing of dosing and frequency; studies on the elution and pharmacokinetics of 
AMD3100 suggest that serial administration will induce a peak mobilisation at one hour post 
treatment to the same level each time, suggesting that there isn’t a receptor/system 
desensitisation (Broxmeyer et al. 2005). Repeated dosing over several days may therefore 
increase the circulating pool several times and further potentiate its effects, however, 
consideration of the effect of CXCR4 blockade at the recipient fracture site needs thought as 
protracted treatment with AMD3100 throughout fracture healing or during distraction 
osteogenesis reduces healing (Toupadakis et al. 2012; Xu et al. 2017). For translation, the 
safety and patient tolerance is important. Animal safety trials showed AMD3100 caused 
sedation, spasms, and dyspnea in rats, and diarrhea or tachycardia in dogs (Hendrix et al 
2000). In humans, therapeutic dosing of volunteers was well tolerated with only some 
transient gastrointestinal signs and headaches reported in 50%. However, repeat 
administration of AMD3100 at guideline doses in humans was not reported to cause 
significant side effects (Hendrix et al 2000; Broxmeyer 2005). It is reasonable to surmise 
that without a chemotactic gradient, cells such as haematopoietic stem cells will be 
mobilised but then return to their niche once the AMD3100 has been eliminated from the 
body.  
Chapter 6 also showed a significant increase in bone within the osteotomy when treated with 
IGF1 and AMD3100, but the callus size was the same as the controls. This finding indicates 
enhanced bone formation, and Kumar et al. also showed increased bone mineral density 
when a mouse fracture was treated with IGF1 combined with AMD3100 (Kumar & 
Ponnazhagan 2012). In contrast, VEGF-AMD only showed a trend for increased bone 
formation over the control.  
GCSF with AMD3100 inhibited bone formation 
GSCF-AMD significantly reduced fracture healing, which has not been previously shown.  
Interestingly, the percentage bone was greater within the callus and the bone formed had 
increased trabecular thickness and reduced porosity. All treatment groups including GCSF-
AMD had increased trabecular thickness indicating thicker woven bone formation. The 
callus formed however, was smaller with the GCSF-AMD group, but the bone that was 
present was more structurally dense. As I suggested in chapter 6, the reduced bone volume 
may relate to the less mature chondrocytes seen histologically, indicative of delayed 
endochondral ossification, which may in turn be due to excessive inflammation from 
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mobilised inflammatory cells, or indeed increased haematopoietic lineage osteoclast 
precursors, leading to bone reduction rather than deposition. Histologically, GCSF-AMD 
had the lowest level of bone, cartilage and vascular tissue, and the highest level of fibrous 
tissue, suggesting a pattern of reduced endochondral ossification, reduced blood supply and 
replacement with fibrous tissue instead.  
Pitchford et al. (2009) showed that GCSF-AMD induced mild mobilisation of MSCs and 
EPCs, but was principally a very effective mobiliser of haematopoietic stem cells and 
neutrophils. It is possible that the increased influx of neutrophils may have affected the 
progression of early inflammation at the fracture site, which would normally move towards 
an environment of healing, but may have been protracted in this situation. CD34+ cells, 
which are a particularly well-represented population when mobilisation is performed with 
GSCF ± AMD3100, and was one of the criteria markers used by Pitchford et al. to define 
their haematopoietic stem cells, are considered a population enriched in endothelial 
progenitors and haematopoietic stem cells. Transplantation of these cells, which are typically 
isolated from humans and introduced into immunocompromised rodent fracture models, has 
shown improved healing in several studies (Kuroda et al. 2014; Matsumoto et al. 2008). 
However, this sub-selected CD34+ population although a significant part of the cells 
mobilised by GCSF-AMD3100, are a subset and this may explain the differences in healing 
seen when this subset is transplanted, compared with mobilised populations that include 
CD34+ cells. This has been somewhat borne out by studies showing a mixed GCSF 
mobilised mononuclear cell fraction being less efficacious than a sub-selected CD34+ 
population (Fukui et al. 2015), and excessive inflammation associated with the MNC 
population was suggested to be mediating the reduced fracture healing. Corroborating my 
experience with AMD3100 combined with GCSF, another group used this combination as an 
endogenous mobilising therapy in myocardial infarcts and showed no improvement (Rüder 
et al. 2014). One study however, has showed improved fracture healing with GCSF 
treatment alone, given on five consecutive days. Interestingly, their study lasted 200 days 
and significant differences were not seen until at least 20-30 days, with a reduction in the 
osteotomy gap distance. Bone volume was significantly increased from around 30 days, but 
all rats went on to non-union (Herrmann et al 2018). Their cell elution measures which were 
taken at several time points, showed significantly increased levels of mobilised CD34+ at 
day 1 through to day 11, which is in agreement with the effect of GCSF which does not 
induce a rapid peak mobilisation, unlike AMD3100 (Liles et al. 2005; Broxmeyer et al. 
2005).  
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Timing 
Pitchford et al. (2009) showed the influence of the growth factors on mobilisation was time 
dependent. When growth factor and AMD3100 are administered simultaneously, they did 
not have the same synergistic mobilising effect as when the growth factor was administered 
for several days prior to CXCR4 antagonism. This suggests that the growth factors are 
having bone marrow mediated effects that takes time to develop, which was demonstrated to 
have influence on cell cycle activation, preventing a cycling cell from being able to undergo 
chemotaxis. Although there is evidence of almost immediate stem cell migration to a fracture 
site (Dimitriou et al. 2005), and suggests that endogenous mobilisation was most likely to be 
effective in the early inflammatory phase, homing of parabiotic stem cells has been shown to 
peak at 7-14 days (Kumagai et al. 2008). Therefore, it may be worth considering later time 
frames for treatment as well. Studies have also shown that bone marrow has increased MSCs 
when a non-union develops (Tawonsawatruk et al. 2014) and hence there may be efficacy of 
mobilisation for atrophic non-union treatment, although re-initiating the early inflammatory 
cascade through surgical ‘freshening’ may be required. 
7.4 AMD3100 alone 
The improved bone formation associated with administration of AMD3100 alone was 
particularly interesting as this is a licensed drug, and without the need for growth factors, the 
route to translation is vastly simplified. AMD3100 alone had the highest bone formation 
within the gap out of all groups. Although AMD3100 was not been shown to be a good 
mobiliser of MSCs and EPCS when given alone (Pitchford et al. 2009; Kumar & 
Ponnazhagan 2012), it has shown in vivo bone formation efficacy; in a mouse femoral 
fracture model when given for three consecutive days (Toupadakis et al. 2013); after a single 
injection to improve intramedullary trabecular bone regeneration post ablation (McNulty et 
al. 2012); and in calvarial defect healing (Wang et al. 2011). Chapter 6 therefore 
corroborates their findings in a different species using a compromised diaphyseal fracture 
model. The mechanism of action may relate to the combination of the physiologically raised 
growth factors and cytokines at the fracture site (Devescovi et al. 2008; Lieberman et al. 
2002) and migration of stem cells released from their niche. Other cell populations that were 
not cultured in my thesis may have been mobilised and may have had a positive influence, 
and the precise timing of their mobilisation using AMD3100 in relation to the fracture 
healing process warrants further work.  
In my thesis, I did not investigate the in vitro cell mobilising effect of administration of 
AMD3100 alone. In chapter 6, I showed that AMD3100 had a positive and unexpected effect 
on fracture healing and so at the end of my PhD, I performed a small pilot to evaluate this 
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further; exbreeder rats (n=4) were treated with AMD3100 alone. Protocols were as chapter 3, 
with blood collection, preparation and culture for PBMSC and PBEPC CFUs. Out of four 
cultures, all had a high number of plastic adherent cells, which looked as though they were 
forming early CFUs (Figure 7.1a). However over the 20±2 days culture duration, no 
convincing mature PBMSC CFUs established in ¾ and one CFU formed in ¼ cultures 
(Figure 7.1b). This would suggest that PBMSC mobilisation, at least as measured at that 
time point, was not the underlying mechanism of improved healing. On the other hand, ¾ 
PBEPC cultures developed multiple ‘late EPCs’ (Figure 7.2a-c) with a mean of 14.6±7.0 
CFUs/ml. This compares with the data from chapter 3 of 0.3±0.3 CFU/ml non-mobilised 
controls and 2.9±3.3 CFU/ml in the VEGF-AMD treated group (Figure 7.3). The increase 
was not statistically different between the controls (p=0.144) or between VEGF-AMD 
(p=0.414) and AMD3100 treated alone, most likely due to the small n-number and the wide 
data variation (Figure 7.3), generated by one individual not showing any cell mobilisation. 
Post hoc sample size calculation suggests n=8-10 was required.  
a  b  
Figure 7.1: Light microscope images taken at x10 magnification of MSC culture of AMD3100 
mobilised P0 cells at 20 days. a) Typical conformation of the high numbers of plastic adherent cells 
seen after culture of blood. These cells did not produce typical CFU-Fs in ¾ cultures. b) Only one 
culture developed a more typical CFU-F P0 MSC morphology. 
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a  b  c
 
Figure 7.2: Light microscope images of PBEPC culture of AMD3100 mobilised P0 cells at 20 days. a) 
Circumscribed colony of cobblestone shaped cells, at x5 magnification. b) More advanced CFU at x20 
magnification. c) PBEPCs forming luminal type structures at x20 magnification.    
 
 
Figure 7.3: Boxplot showing the PBEPC CFUs/ml blood cultured, compared between rats that were 
not pre-treated with mobilising agents, those that had four days of VEGF followed by a single dose of 
AMD3100, and those that only had a single dose of AMD3100.   
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This small pilot suggested that the beneficial effects of AMD3100 alone might be from 
mobilisation of PBEPCs, which could feasibly improve vascularisation, potentiating MSC 
migration and osteoblast differentiation, facilitating healing. These cells were continued in 
primary cultured for 40 days and did not become uniformly confluent, although highly dense 
areas were seen.  
7.5 Summary conclusions from my thesis: 
• Mobilisation through antagonism of the SDF1-CXCR4 axis using VEGF with 
AMD3100 selectively mobilised a population of osteogenic precursor MSCs, and 
EPCs with adipogenic potential. 
• In a rodent femoral osteotomy model, the IFS at day 0 did not predict the course of 
fracture healing. In contrast, a reduction in IFS as the gap size increased reduced 
bone healing, with an associated IFS reduction from 12 to 6%. Ultimately, the 
1.5mm osteotomy gap stabilised by a relatively rigid linear Type Ia micro fixator 
was the preferred test scenario to evaluate endogenous mobilisation.  
• Despite a uniform initial mechanical fracture environment, there was a wide 
variation in fracture healing progression at five weeks, however group trends were 
identified. 
• CXCR4 antagonism using AMD3100 alone, or combined with VEGF or IGF1, 
improved fracture healing in a compromised healing environment. Whereas the 
haematopoietic stem cell preferentially mobilising treatment of GCSF combined 
with AMD3100 impaired fracture healing, associated with retarded endochondral 
ossification and increased fibrosis. AMD3100 alone had the biggest impact on 
fracture healing. 
• AMD3100 appeared to be an effective mobiliser of PBEPCs rather than PBMSCs, 
however the biological influence of the presence of a fracture on cell mobilisation is 
unknown. 
7.6 Summary limitations: 
• Although VEGF-AMD mobilised stem and progenitors were comprehensively 
evaluated, the slow culture dynamics and low yields prevented further evaluation of 
other properties such as chondrogenicity, expanded panels of cell surface marker 
expression, or transcriptomic analysis of the populations mobilised.  
• Cell identification was made on cultured cells and the act of cell culture can alter a 
cell’s characteristics. 
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• PBEPCs were compared with HUVECs and a rat endothelial cell culture may have 
been more informative. 
• Group sizes ranged from 5-8, which is usually sufficient for in vivo evaluation. 
There was however, a higher than expected variation in fracture healing, probably a 
result of activity, which was not controlled for. 
• Although healing was radiographically and morphologically assessed with microCT 
and histology, no mechanical testing was performed. Although microCT can indicate 
likely mechanical strength, a mechanical test in itself may have given a different 
indication of functional healing. 
7.7 Options for further work: 
• As AMD3100 alone appears to have the most promising outcome for fracture 
healing translation, there would be merit in evaluating whether multiple dosing in 
the early phase of fracture healing could further boost mobilisation and healing. 
• A large animal model to allow sequential longitudinal assessment of baseline and 
then mobilised cell population at different time points, would be able to determine 
whether the variation in mobilisation is proportionate to an individuals biological 
potential to mobilise. The volumes of blood available in a large animal model would 
better facilitate evaluation of elution characteristics of stem and progenitor 
populations longitudinally using flow cytometry on blood circulating cells, rather 
than cultured cells. 
• Comparing mobilisation between young and old, with a view to evaluating the 
mechanisms of cell mobilisation in younger animals if yields are greater, facilitated 
by improved culture dynamics.  
• To determine whether mobilisation (as measured by CFUs) is affected by the 
presence of fracture. This would have important ramifications as to whether this 
therapy can be used in a quiescent atrophic non-union, or whether it only has benefit 
in the early inflammatory/recruitment phase of healing.  
• To evaluate the effects of AMD3100 alone in guaranteed healing and guaranteed 
non-union situations with serial evaluation of healing over a longer time frame. This 
would determine if this ‘boost’ could overcome a more profound inhibition of 
healing and whether it could also accelerate normal healing.  
• To evaluate the potential of endogenous mobilisation using AMD3100 in other 
disease processes that may benefit from increasing homing of stem/progenitor cells 
such as osteoporosis and implant osseointegration.  
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7.8 Impact & clinical translation 
This study was the first to mobilise a population of osteogenic precursors endogenously into 
the peripheral circulation of rats. This was also the first study to compare different 
mobilisation strategies directly and further to do this in compromised mechanically 
controlled fracture healing environment.  
My thesis identified AMD3100 given without growth factors as the most promising option 
for translation. AMD3100 is already licensed for haematopoietic stem cell transplantation 
(usually in combination with GCSF), and therefore the route to translation is less complex, 
as toxicity and safety testing has already been completed. As there is a significant burden of 
non-union fractures and the cost of a dose of AMD3100 relatively low, this could make an 
excellent adjunct, or potential alternative to cancellous bone graft in atrophic non-union 
surgery. It could also be given as a prophylactic measure to patients in at risk fracture groups, 
such as fragility fractures, high energy comminuted fractures and open fractures. Finally, it 
may prove a non-invasive, low cost means to accelerate normal fracture healing, which 
could result in earlier implant removal such as for external fixator patients, reducing 
complications and facilitating faster return to full activity.  
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APPENDIX 
 
Publications 
VEGF with AMD3100 Endogenously Mobilizes Mesenchymal Stem Cells and Improves 
Fracture Healing. Meeson R, Sanghani-Keri A, Coathup M, Blunn GWB. Journal of 
Orthopaedic Research. J Orthop Res. 2018 Oct 22. doi: 10.1002/jor.24164 
CXCR4 antagnism with AMD3100 is more effective at avoiding delayed union and 
increasing bone formation, than when combined with GCSF, VEGF or IGF1. Meeson R, 
Sanghani-Keri A, Coathup M, Blunn GWB. Undergoing Minor Revisions.  
Conferences 
Peripheral Blood Mesenchymal Stem Cells Mobilised Post Administration Of VEGF 
and AMD3100 Undergo Osteoblastic And Not Adipogenic Differentiation. R L Meeson, 
A Sanghani Kerai, M J Coathup, G W Blunn. British Orthopaedic Research Society, 
Conference September 2017. Imperial College London. Oral Podium. 
Interfragmentary Strain Theory Does Not Predict Fracture Healing with Increasing Gap 
Size. Meeson R, Sanghani-Keri A, Coathup M, Blunn GWB, Moazen M. 8th World 
Congress of Biomechanics. The CCD, Dublin. Poster Presentation.  
Endogenous Mobilisation of Stem Cells with AMD3100 to Treat Non-Union Meeson R, 
Sanghani-Keri A, Coathup M, Blunn GWB. 26th Annual European Orthopaedic 
Research Society Meeting, Galway, Ireland, September 2018. Oral Presentation.  
CXCR4 Antagonism Endogenously Mobilises Stem and Progenitor Cells and Rescues 
Non-union Development. Meeson R, Sanghani-Keri A, Coathup M, Blunn GWB. 2018 
TERMIS World Congress, September 4-7, 2018, Kyoto International Conference Center, 
Kyoto, Japan. Oral Podium.
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